WO1992000995A1 - Cyclic cell adhesion modulation compounds - Google Patents

Cyclic cell adhesion modulation compounds Download PDF

Info

Publication number
WO1992000995A1
WO1992000995A1 PCT/US1991/004862 US9104862W WO9200995A1 WO 1992000995 A1 WO1992000995 A1 WO 1992000995A1 US 9104862 W US9104862 W US 9104862W WO 9200995 A1 WO9200995 A1 WO 9200995A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
phe
optional
residue
amino acid
Prior art date
Application number
PCT/US1991/004862
Other languages
French (fr)
Inventor
Thomas J. Lobl
Shiu-Lan Chiang
Pina M. Cardarelli
Original Assignee
Tanabe Seiyaku Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co. Ltd. filed Critical Tanabe Seiyaku Co. Ltd.
Priority to JP91513631A priority Critical patent/JPH05508860A/en
Publication of WO1992000995A1 publication Critical patent/WO1992000995A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to novel cyclic peptides and peptidomimetic compounds which are characterized by cell adhesion modulation activity.
  • the compounds have application to the study and treatment of disease conditions mediated by cell adhesion.
  • the compounds have application to the study, diagnosis, treatment or prevention of diseases and conditions such as cardiovascular disease, harmful platelet aggregation, neoplastic disease including metastasis of neoplastic growth, wound healing, inflammation and auto-immune disease or other diseases or conditions involving cell adhesion.
  • the extracellular matrix is the major component of connective tissue of all mammals.
  • the extracellular matrix provides for structural integrity, and promotes cell migration and cellular differentiation. As part of these functions, the extracellular matrix has been shown to support adhesion for various types of cells in vitro. Molecules such as collagens, fibronectin, vitronectin, laminin, von Willebrand factor, thrombospondin, bone sialoprotein, fibrinogen, and tenacin have been found to possess this property of mediating cell adhesion.
  • the above cell-adhesive molecules have been found to exhibit a structural similarity in their respective binding sites, each of which contains the amino acid sequence arginine-glycine-aspartic acid, or RGD using single letter nomenclature (infra).
  • the cell-binding site in fibronectin has been reproduced synthetically and establishes the RGD sequence as the essential structure recognized by cells in fibronectin. Changes in the peptide as small as the exchange of alanine for giycine or glutamic acid for aspartic acid which constitutes the addition of a single methyl or methylene group to the tripeptide, eliminates these activities (Pierschbacher &
  • fibronectin receptor site for fibronectin has been identified for various cells, in addition, cellular receptors that recognize RGD-containing sequences in other extracellular matrix proteins (e.g., the vitronectin receptor and the platelet gpIIb/IIIa receptor) have been identified. Such cellular receptors, responsive to RGD-containing proteinaceous compounds, have been characterized. The complete, primary structure of the fibronectin receptor has been deduced from cDNA, and physical properties have been determined (Argraves, et al., J.Biol. Chem. 1986, 261 , 12922; Argraves et al., J.Cell Biol.
  • the protein exists at the cell surface as a heterodimeric complex (although the larger polypeptide is enzymatically processed) having both polypeptide chains inserted into the membrane. Each chain extends 30-40 residues into the cytoplasmic space, and at least one of the cytoplasmic peptides appears to interact with the cytoskeleton (Horwitz et al., Nature 1986, 320, 531).
  • the larger of the two polypeptides, the ⁇ subunit contains a number of regions that are structurally similar to calmodulin and that apparently mediate the binding of calcium to the receptor. The presence of such divalent cations is required for the receptor to bind ligand.
  • the ⁇ subunlt is somewhat smaller and conformationally compact due to numerous intrachain disulfide bonds.
  • the cytoplasmic domain of the ⁇ subunit contains a potentially phosphoryiated tyrosine (Hirst et al., PNAS-USA 1986, 83, 6470; Tamkun et al., Cell 1986, 46, 271).
  • RGD-directed receptors as well as other "orphan" receptors the ligand for which is unknown, have also been characterized.
  • This putative RGD commonality of the ligand matrix proteins has revealed a superfamily of cell surface receptor proteins that share a high degree of structural similarity and probably also functional similarity.
  • the members of this superfamily of cell surface proteins collectively are known as the integrins.
  • the integrins are ⁇ , ⁇ heterodimeric cell surface proteins which can be grouped on the basis of the identity of their ⁇ subunit. Each integrin can interact with single or multiple ligands.
  • the ⁇ subunit, as disclosed above for the fibronectin receptor is compact due to a high degree of cross-linking.
  • the first group of integrins, ⁇ 1 molecules includes the very late activation antigen (VLA) proteins, which themselves include the fibronectin receptor (VLA-5), collagen receptor (VLA-2), laminin receptor, and a receptor (VLA-4) which binds to the vascular cell adhesion molecule-1 (VCAM-1) on cytokine activated endothelial cells.
  • VLA-5 fibronectin receptor
  • VLA-2 collagen receptor
  • VLA-2 a receptor
  • VLA-4 which binds to the vascular cell adhesion molecule-1 (VCAM-1) on cytokine activated endothelial cells.
  • the second group ( ⁇ 2 subfamily) includes the lymphocyte associated antigen-1 (LFA-1), macrophage antigen-1 (MAC-1), and p150,95.
  • the third group ( ⁇ 3 subfamily) includes the vitronectin receptor, the platelet glycoprotein gpIIb/IIIa. To date, seven ⁇ chains have been described.
  • the RGD-directed receptor present on platelets that binds fibronectin, vitronectin, fibrinogen, and von Willebrand factor has also been purified.
  • the receptor is thus not specific to one extracellular matrix protein, as is the fibronectin receptor. It has been proposed that this lack of specificity is correlated to the lack of conformational specificity in the ligands. Other work has suggested that specificity can be achieved with relatively short, conformationally restricted synthetic peptides containing the RGD sequence.
  • the present invention relates to compounds having activity as cell adhesion modulators.
  • Some of the compounds contain the amino acid sequence arginineglycine-aspartic acid (Arg-Gly-Asp or RGD).
  • Others contain non-RGD sequences, including but not limited to the RCD sequence and "reverse orientation" forms of amino acid residues.
  • the compounds in one aspect, sufficiently mimic extracellular matrix ligands or other cell adhesion ligands so as to bind to cell surface receptors.
  • Such receptors include integrin receptors, in general, including the fibronectin, collagen, laminin, LFA-1, MAC-1, p150,95, vitronectin and gpIIb/IIIa receptors.
  • novel compounds have been found to modulate cell adhesion by competing, for example, with ligands containing the appropriate amino acid sequence and by binding to ligand-directed receptors on cell surfaces.
  • the cell adhesive protein such as (but not limited to) fibronectin, is sufficiently inhibited from binding to the cell's receptor so as to prevent or reduce cell adhesion.
  • Other uses include enhancing cell adhesion by using the compounds to attach cells to a surface, or by other promotion of cell adhesion.
  • the useful compounds herein described function as cell-adhesion modulators.
  • One object of the present invention is to provide novel compounds which act to modulate cell adhesion. Another object of the present invention is to provide novel RGD-containing compounds which are capable of binding to a cellular receptor. Another object of the present invention is to provide novel non-RGD-containing compounds which contain one or more "reverse orientation" amino acid residues and which are capable of binding to a cellular receptor.
  • Another object of the present invention is to provide novel non-glycine containing, e.g., RCD-containing, compounds which are capable of binding to a cellular receptor.
  • Another object of the present invention is to provide new uses for known peptides containing the sequence RGD as cell adhesion modulators.
  • Another object of the present invention is to provide a novel method for modulating cell adhesion using novel compounds.
  • Another object of the present invention is to provide compounds having extraordinarily high potencies in modulating cell adhesion to integrin receptors, including specifically inhibition of cell adhesion to the fibronectin receptor.
  • the present invention includes compounds having an IC 50 of less than about 500 ⁇ M as established in a U937 fibronectin adhesion assay; and in another regard, the invention includes compounds having an IC 50 of less than about 100 ⁇ M in such assay.
  • the invention also includes methods for obtaining (either in vitro or in vivo) such fibronectin receptor adhesion inhibition, and integrin receptor adhesion inhibition.
  • the compounds of the present invention accomplish strong inhibition, at low concentrations, with an IC 50 of less than about 500 ⁇ M, or alternatively less than about 100 ⁇ M.
  • Another object of the present invention is to provide compounds having high potencies in modulating leukocyte adhesion to endothelial cells.
  • the present invention includes compounds having an IC 50 , of less than about 200 ⁇ M as established in a Jurkat-endothelial cell adhesion assay; and in another regard, the invention includes compounds having an IC 50 of less than about 10 ⁇ M in such assay.
  • the invention also includes methods for obtaining (either in vitro or in vivo) such leukocyte receptor adhesion inhibition.
  • the compounds of the present invention accomplish strong inhibition using disclosed compounds, at low concentrations, with an IC 50 of less than about 200 ⁇ M, or alternatively less than about 10 ⁇ M.
  • Another object of the present invention is to provide novel compounds, formulations, and methods which may be used in the study, diagnosis, treatment or prevention of diseases and conditions which relate to cell adhesion, including but not limited to rheumatoid arthritis, asthma, allergies, adult respiratory distress syndrome (ARDS), cardiovascular disease, thrombosis or harmful platelet aggregation, reocclusion following thrombolysis, allograft rejection, neoplastic disease including metastasis of neoplastic growth, wound healing, Type I diabetes, inflammatory and immunoinfiammatory conditions including ophthalmic inflammatory conditions and inflammatory bowel disease (e.g., ulcerative colitis and regional enteritis), and autoimmune diseases.
  • diseases and conditions which relate to cell adhesion, including but not limited to rheumatoid arthritis, asthma, allergies, adult respiratory distress syndrome (ARDS), cardiovascular disease, thrombosis or harmful platelet aggregation, reocclusion following thrombolysis, allograft rejection, neoplastic
  • Another object is to provide derivative compounds, such as, but not limited to, antibodies and anti-idiotype antibodies to the compounds disclosed and claimed in order to study, diagnose, treat or prevent diseases and conditions which relate to cell adhesion, including but not limited to rheumatoid arthritis, asthma, allergies, ARDS, cardiovascular disease, thrombosis or harmful platelet aggregation, neoplastic disease including metastasis of neoplastic growth, wound healing, Type I diabetes, inflammatory conditions and autoimmune diseases.
  • derivative compounds such as, but not limited to, antibodies and anti-idiotype antibodies to the compounds disclosed and claimed in order to study, diagnose, treat or prevent diseases and conditions which relate to cell adhesion, including but not limited to rheumatoid arthritis, asthma, allergies, ARDS, cardiovascular disease, thrombosis or harmful platelet aggregation, neoplastic disease including metastasis of neoplastic growth, wound healing, Type I diabetes, inflammatory conditions and autoimmune diseases.
  • FIGURES 1a and 1b are diagrams representing chemical reactions for the manufacture of amide-linked cyclic peptides.
  • FIGURE 2 shows the results of an assay demonstrating cell adhesion inhibition by the representative cyclic polypeptide
  • the compounds of the present invention are those having the property of modulating cell adhesion.
  • ARDS adult respiratory distress syndrome
  • the attachment of inappropriate cells to the lung lining induces an inflammatory response.
  • Preliminary in vitro results show that such detrimental attachment, in which the leukocyte adheres to endothelial cells or the lung extracellular matrix, is mediated by RGD-containing protein and integrin receptors on the leukocyte.
  • peptides or other compounds with a binding affinity to integrin receptors are desirable as competitive antagonists and should be useful in treating ARDS and asthma.
  • a peptide or other compound with suitable affinity for RGD receptors should likewise have anti-metastasis utility. Harmful blood clotting is also caused by inappropriate cell adhesion, particularly cell adhesion to the extracellular matrix.
  • the attachment, spreading and aggregation of platelets on extracellular matrices are central events in thrombus formation. These events can be regulated by the family of platelet adhesive glycoproteins, fibrinogen, fibronectin, and von Willebrand factor. Fibrinogen functions as a cofactor for platelet aggregation, while fibronectin supports platelet attachment and spreading reactions.
  • Von Willebrand factor is important in platelet attachment to and spreading on subendothelial matrices. Plow et al., PNAS-USA 1985, 82, 8057.
  • a peptide or other compound which would function as an antagonist and bind to cell receptors which recognize the matrix glycoprotein RGD site would be beneficial as a thrombotic.
  • cell adhesion modulation compounds of the present invention are represented in part by amino acid sequence formulas wherein the individual amino acids are represented by their standard three-letter or alternatively one-letter abbreviations as follows:
  • l- or d-enantiomers may suitably be utilized, although the l-enantiomer is preferred for amino acids having the normal (non-reversed) peptide bond orientation, and the d-enantiomer is preferred for amino acids having a reversed orientation (see discussion below).
  • BS Bovine serum albumin
  • FN Fibronectin (HCA): Hydrocinnamic acid
  • ICAM-1 Intercellular adhesion molecule 1
  • IC 50 Inhibitory concentration, concentration at which adhesion is inhibited to 50% of control level
  • VLA Very late activation antigens
  • the first class of compounds of the invention is represented by the formula:
  • L 1 and L 2 are each, or are together, a residue of an amino acid, an amino acid analog or an amino acid mimetic having a functional group suitable for the formation of a cyclizing bridge between L 1 and L 2 ;
  • Z is a cyclizing moiety or bond between L 1 and L 2 ; 1 is optional and, where present, is selected from Leu, Tyr, Phe, Ile, Pro, 3-thioPro, TC, TCA, DTC, MTC, TTC, Gly, Ala, Val, norLeu, norVal, ⁇ -Ala, Trp, d-Nal, l-Nal, Sar and (Ada)-Ala;
  • Arg 2 is selected from Arg, homoArg, nitroArg, norArg, p-aminomethyl-Phe, N-alkylArg, N,N-dialkylArg, N,N'-dialkylArg, and N,N,N'-trialkylArg wherein the alkyl has one to four carbons (such as N-methylArg, N,N'-dimethylArg, and N,N-dimethylArg);
  • 4 is selected from Asp, Glu, and the lower alkyl, aralkyl, aryl esters, OFm esters, O-cyclohexyl esters, O-benzyl esters, of the foregoing two amino acids;
  • 5 is optional and, where present, is selected from Ser, Thr, Tyr, monohalo-Tyr, dihalo-Tyr, Trp, Ala, Val, Phe, o-, m-, and p-halo-Phe, p-nitro-Phe, Leu, and
  • n 2, 3 or 4;
  • X 1 and Y 1 are each optional and, where present, are independently selected from 1 to 4 d- or l-amino acids and amino acid analogs (such as AMBA, AnC, AnB, and ⁇ -amino-lower alkyl carboxylic acids);
  • X 2 is an optional N ⁇ -substituent selected from R' (including hydrogen) and R'CO-;
  • Y 2 is an optional carboxyl-terminal substituent selected from -OR' (including hydroxyl), -NR' 2 (including -NH 2 and NHR'), -NHNH 2 and -SR'; and wherein each R' is individually a pharmaceutically suitable substituent group, preferably one selected from hydrogen, from linear and branched, unsubstituted and substituted C 1 -C 8 lower alkyIs, C 2 -C 8 alkenyls,
  • C 2 -C 8 alkynyls C 6 -C 14 aryls, C 7 -C 14 alkaryls, C 7 -C 14 cycloalkaryls and C 3 -C 14 cycloalkyls, and, in the case of -NR' 2 , from cyclized groups forming (in an attachment with the nitrogen atom) a 5-8 membered heterocyclic ring optionally containing oxygen, nitrogen or sulfur as a further ring heteroatom.
  • a bridge is formed via the cyclizing moiety Z between L 1 and L 2 such that the compound is cyclized.
  • each of L 1 and L 2 is chosen so as to provide a functional group suitable for the formation of a cyclizing bridge.
  • preferred functional groups include thiol, amino and carboxyl groups and their residues.
  • Such a functional group may be provided by the side-chain, or by the terminal ⁇ - amino (in L 1 ) or terminal carboxyl (in L 2 ) group, of a natural amino acid residue or an analog thereof (including a homolog or stereoisomer thereof; see e.g.
  • amino acid mimetic i.e., an organic residue which includes a suitable cyclizing functional group and which is covalently linked through a peptide (i.e., amide) bond to the amino terminus (in the case of
  • the bridging residues L 1 and L 2 are, in one embodiment, each preferably selected from Cys, Pen, homoC, and, for L 1 , additionally Mpr and PMP.
  • Each of these residues provides a side chain sulfhydryl group particularly suitable as a reactive precursor functional group for the formation of a cyclizing bridge between L 1 and L 2 .
  • the cyclic bridge may be formed via oxidative coupling (loss of hydrogens) to form a disulfide bond between the side chain sulfur groups (in which the cyclizing moiety Z is a simple bond between the two sulfur atoms). This may also be depicted generally for compounds wherein, for example, both L 1 and L 2 are Cys residues as follows:
  • L 1 and L 2 be Cys or Mpr.
  • the cyclizing bridge may also be formed via a hydrocarbon moiety, for example a (poly)methylene bridge moiety of the form -(CH 2 ) n - where n is an integer of from 1 to 8, preferably 1 to about 4.
  • n is an integer of from 1 to 8, preferably 1 to about 4.
  • One type of such bridge is represented below, wherein a cyclic compound with three methylene residues (representing Z) between two cysteine side-chain sulfur atoms (representing L 1 and L 2 ) is depicted:
  • n as defined above, may also conveniently be used to link, for example, side chain amino (as in Lys) or carbonyl (as in Glu or Asp) residues, respectively, on L 1 and L 2 to yield structures exemplified by
  • cyclizing moiety Z includes a portion with such a hydrocarbon form, it may be branched and may, where of a size appropriate to form a stable structure (particularly, where Z comprises two or more methylene moieties) also include one or more heteroatom-containing substituents including hydroxyl, amino, nitro, alkoxyl and halo substituents. Such substituents may be used to affect the solubility and/or biodistribution characteristics of the subject compounds.
  • Aromatic or cycloalkyl hydrocarbon-containing bridge groups may also be utilized in the Z position, as for example diketo or diamino structures such as or
  • the cyclizing bridge between L 1 and L 2 may also be formed via a monosulfide
  • L 1 can be formed from a residue of ⁇ , ⁇ -dehydroalanine, and L 2 from a residue of cysteine, which may be reacted to yield a lanthionine-like thioether linkage.
  • L 1 can be formed from a residue of ⁇ , ⁇ -dehydroalanine
  • L 2 from a residue of cysteine, which may be reacted to yield a lanthionine-like thioether linkage.
  • L 1 and L 2 may be chosen from other amino acids or analogs or amino acid mimetics which provide functional groups suitable for the formation of a side chain or as the amino- or carboxyl-terminus of an amino acid or analog residue.
  • L 2 may be selected from Asp, Glu, or other amino acids or analogs which provide a suitable side chain carboxyl group for cyclic linkage, through formation of an amide bond in a condensation reaction, with an amino group (e.g., an N ⁇ -amino group, or a side chain amino group as on, for example, Lys or Orn) on L 1 , provided, however, that the structure
  • an amino acid residue L 2 may provide a carboxyl group from its carboxyl terminus for amide linkage with either a side chain amino or ⁇ -amino group on an amino acid residue or analog L 1 ; or the direction of the amide linkage may be reversed where L 1 provides a side chain carboxyl group and
  • L 2 provides a side chain amino group.
  • Such structures may be exemplified as follows:
  • Analogs of amino acid residues may also be utilized for L 1 and/or L 2 , as for example homologs (wherein a side chain is lengthened or shortened while still providing a carboxyl, amino or other reactive precursor functional group for cyclization), d-enantiomers of amino acids, analogs having variant side chains with appropriate functional groups (as for example ⁇ -cyanoalanine, canavanine, djenkolic acid, l-azaserine or gamma-methyleneglutamic acid), or other amino acid analogs (see for example the table of amino acid analogs and mimetic compounds given above).
  • homologs wherein a side chain is lengthened or shortened while still providing a carboxyl, amino or other reactive precursor functional group for cyclization
  • d-enantiomers of amino acids analogs having variant side chains with appropriate functional groups (as for example ⁇ -cyanoalanine, canavanine, djenkolic acid, l-azaserine or gamma-methylene
  • Amino acid mimetic structures that are capable of being covalently bonded through an amide bond to a carboxyl and/or amino terminus of the residue sequence 1-2- 3-4-5-6, and which provide a suitable precursor functional group for cyclization
  • amino acid mimetic structures include organic species containing one or more heteroatoms including at least one functional group (preferably a reactive heteroatom-containing functional group) precursor suitable for cyclization. Examples include residues of the form
  • n ranges from 1 to about 8, and preferably from 1 to 4, as for example residues of ⁇ -alanine and gamma-aminobutyric acid.
  • n is 1
  • the amino acid glycine, rather than an ⁇ -amino acid mimetic results.
  • Such a structure may, similar to the amino acids and amino acid analogs discussed above, be utilized as L 1 (wherein the carbonyl group depicted above, formed for example from a carboxyl precursor, conveniently forms an amide (peptide-mimetic) linkage with the amino terminus of residue 2 or, if present, residue 1 , or it may be utilized as L 2 (wherein the depicted amino group may engage in an amide linkage with the carboxyl terminus of the terminal residue 4, 5 or 6).
  • linking residue L may serve as both L 1 and L 2 (and thereby include Z) in that cyclization can be achieved through formation of two amide bonds, one at each terminus of the sequence 1 -2-3-4-5-6.
  • Such structures may be exemplified by the form
  • N ⁇ -terminus and the carboxyl terminus of the sequence 1 -2-3-4-5-6 are bonded directly to, respectively, the carbonyl residue and the amino residue of the amino acid mimetic linking group depicted immediately above to form two peptidemimetic amide bonds.
  • cyclization can be achieved with such an amino acid mimetic linking moiety wherein a side chain functional group on a second linking moiety appended (as L 1 or L 2 ) to one terminus of the numbered sequence
  • 1-2-3-4-5-6 engages in bonding to the mimetic moiety, and the mimetic moiety (as L 2 or L 1 ) cyclizes the compound to the remaining terminal residue of the numbered sequence.
  • This may be exemplified by structures of the form
  • L 2 (as for example Asp) provides the side chain carbonyl group depicted in parenthesis
  • residue 1 provides the depicted N ⁇ -terminal amino group
  • Amino acid mimetic structures containing aromatic, cycloalkyl or other linking portions can also be utilized as L 1 and/or L 2 , such as structures of the form or
  • heterobifunctional (keto-amino) structures depicted above may also serve as a Z-group in linking complementary side chain functional groups on L 1 and L 2 (e.g., a side chain amino group on L 1 and a side chain carboxyl group on
  • homobifunctional structures such as those of the form
  • t is an integer of from 1 to about 8, and more preferably 1 to 3, may also serve individually as amino acid mimetic structures where a "reverse" amino acid sequence occurs within the structure 1-2-3-4-5-6 (see Structures II and III below).
  • the numbered portion of such a structure will display two carboxyl termini or two amino termini (rather than one of each type ), and L 1 and L 2 may be selected together to be a homobifunctional linking moiety such as one of those depicted above.
  • Other forms of cyclization include those wherein Z comprises a secondary amino structure (obtained, for example, upon reduction of the carbonyl portion of an amide linkage to a methylene group).
  • a secondary amino linking structure may be formed by reaction of an aldehyde functional group on L 1 (e.g., an aldehyde formed by reduction of a side chain carboxyl group on Asp or Glu) or on L 2 (e.g., an aldehyde formed from the terminal carboxyl group of L 2 ) with a suitable amino group (on, e.g., the side chain or N ⁇ - terminus of L 2 or L 1 ).
  • L 1 aldehyde functional group on L 1
  • L 2 e.g., an aldehyde formed by reduction of a side chain carboxyl group on Asp or Glu
  • L 2 e.g., an aldehyde formed from the terminal carboxyl group of L 2
  • a suitable amino group on, e.g., the side chain or N ⁇ - terminus of L 2 or L 1 .
  • Residue 1 in structure I is most preferably Leu; residue 2 is most preferably Arg; residue 3 is most preferably Gly; residue 4 is most preferably Asp; residue 5 is most preferably Ser; and residue 6 is preferably Pro or 3-thioPro.
  • residues 1 -2-3-4-5-6 are most preferred for residues 1 -2-3-4-5-6.
  • residue 4 is Glu where residue 2 is nor Arg.
  • residue 4 is Glu where residue 2 is nor Arg.
  • sequence Leu-norArg-Gly-Glu-Ser-Pro is also preferred for residues 1 -2-3-4-5-6.
  • X 1 and Y 1 are each optional in structure 1. Where present, they are preferably each independently selected so as to enhance the activity of the resultant compound and/or to preserve the compound against metabolism in, for example, the in vivo environment and thereby increase the effective half-life of the compound.
  • the use of one or more d-amino acids, most preferably at one or more terminal residue position in the compound are believed to stabilize the compound against metabolism by proteolytic or other enzymes in the body.
  • residues for position X 1 include Gly-, Phe-, Leu-, Asn-, Val-, Try-, 1- or 2-naphthylalanine, cyclohexylAla-, AMBA, AnC, AnB and ⁇ -amino-lower alkyl carboxylic acids, Aib-, Ser-Tyr-Asn-, Ala-Thr-Val-, and p-chloro-Phe-.
  • Preferred residues for position Y 1 include -Ala, -Ala-Ser, -Ala-Ser-Ser, -Ala-Ser-Ser-Lys, -Ala- Ser-Ser-Lys-Pro, -Thr, -Thr-Phe, -Aib, -p-chioro-Phe, AMBA, AnC, AnB, ⁇ -aminolower alkyl carboxylic acids, 1- or 2-naphythlalanine, and -(cyclohexylAla).
  • Such X 1 and Y 1 groups are preferred also in the corresponding positions given in the structural formulas described hereinafter.
  • substituent X 2 or Y 2 incorporating R' other than hydrogen e.g., acyl groups R'CO or amino groups of the form R'NH
  • preferred substituents include those derived from bulky compounds such as adamantaneacetic acid, adamantanecarboxylic acid, 1 - or 2-naphthylacetic acid, 2-norbornaneacetic acid, 3-noradamantanecarboxylic acid, 3-methyladamataneacetic acid, and 1- or 2-adamantylamine.
  • R' groups are those derived from acids such as
  • residue 5 in Structure 1 represent derivatives of amino acid residues wherein the side chain hydroxyl group (shown in parentheses) is optionally substituted with a group of the form R' which can be other than hydrogen as defined above.
  • R' is preferably selected from hydrogen and C 1 through C 8 lower alkyls, particularly methyl and ethyl alkyl moieties.
  • a particularly preferred compound within the scope of structure I includes:
  • the compound depicted has been shown to be active in inhibiting cell adhesion to fibronectin.
  • a "reversed” or “retro” peptide sequence as disclosed herein refers to that part of an overall sequence of covalently-bonded amino acid residues (or analogs or mimetics thereof) wherein the normal carboxyl-to amino direction of peptide bond formation in the amino acid backbone has been reversed such that, reading in the conventional left-to-right direction, the amino portion of the peptide bond (as underlined below) precedes (rather than follows) the carbonyl portion:
  • the reversed orientation peptides described herein include (a) those wherein one or more amino-terminal residues are converted to a reversed ("rev") orientation (thus yielding a second "carboxyl terminus” at the left-most portion of the molecule), and (b) those wherein one or more carboxyl-terminal residues are converted to a reversed ("rev") orientation (yielding a second "amino terminus” at the right-most portion of the molecule). It will be seen that a normal peptide (amide) bond cannot be formed at the interface between a normal orientation residue and a reverse orientation residue:
  • certain reversed peptide compounds of the invention can be formed by utilizing an appropriate amino acid mimetic moiety to link the two adjacent portions of the sequences depicted above utilizing a reversed peptide (reversed amide) bond.
  • a central residue of a diketo compound as shown by moiety 3 in Structure II below, may conveniently be utilized to link structures a(1) and a (2) with two amide bonds to achieve a peptidomimetic structure.
  • a central residue of a diamino compound as shown by moiety 3 in Structure III below, will likewise be useful to link structures b(1) and b(2) with two amide bonds to form a peptidomimetic structure.
  • such central residues are most preferably utilized at residue position 3.
  • the reversed direction of bonding in such compounds will generally, in addition, require inversion of the enantiomeric configuration of the reversed amino acid residues in order to maintain a spatial orientation of side chains that is similar to that of the non-reversed peptide.
  • the configuration of amino acids in the reversed portion of the peptides is preferably d, and the configuration of the non-reversed portion is preferably I. Opposite or mixed configurations are acceptable when appropriate to optimize a binding activity.
  • L 1 and L 2 are each, or are together, a residue of an amino acid, an amino acid derivative or an amino acid mimetic having a functional group suitable for the formation of a cyclizing bridge between L 1 and L 2 ;
  • Z is a cyclizing moiety or bond between L 1 and L 2 ; 1 is optional, and where present, is of reversed orientation and is selected from
  • 2 is of reversed orientation and is selected from Arg, nitroArg, homoArg, p-aminomethyl-Phe, norArg N-alkylArg, N,N-dialkylArg, N,N'-dialkylArg, N,N,N'-trialkylArg wherein the alkyl has one to four carbons (such as N-methyl, N,N'-dimethyl, and N,N-dimethyl); 3 is a moiety suitable for linking reversed-orientation residue 2 with residue 4, and is preferably of the form
  • q and r are independently integers of 0, 1 or 2;
  • 5 is optional and, where present, is selected from Ser, Thr, Tyr, monohalo-Tyr, dihalo-Tyr, Trp, Ala, Val, Phe, o-, m-, and p-halo-Phe, p-nitro-Phe, Leu and
  • 6 is optional and, where present, is selected from Pro, 3-thioPro, 1,1-ACC, Dhp, DTC, TCC, TC, MTC, TCA, Hyp, homoPro and Phe, o-, m-, and p-haio-Phe, p-nitro- Phe, TA, L-Nal, d-Nal, isonipecotic acid;
  • X 1 and Y 1 are each optional and, where present, are independently selected from sequences of from 1 to 4 d- or l-amino acids and amino acid analogs such as AMBA, AnC, AnB, and ⁇ -amino-lower alkyl carboxylic acids;
  • X 2 is an optional substituent selected from R' 2 N- (including R'HN- and H 2 N-), R'O- (including hydroxyl), H 2 NNH- and R'S-;
  • Y 2 is an optional carboxyl-terminal substituent selected from -OR' (including hydroxyl), -NR' 2 (including -NH 2 and -NHR"), -NHNH 2 and -SR'; and wherein each R; is individually a pharmaceutically suitable substituent group, preferably one selected from hydrogen, from linear and branched, unsubstituted and substituted C 1 -C 8 lower alkyls, C 2 -C 8 alkenyls, C 2 -C 8 alkynyl
  • linking groups in position L 1 may utilize for bonding to this carboxyl terminus an amino moiety, as for example a diamino moiety such as those in preferred structures of the form
  • linking groups including Z groups, and various combination of bonding between terminal functional groups and side chain function groups on L 1 and L 2 , will be recognized by those skilled in the art in view of the present disclosure.
  • the discussion above with respect to use of amino acid analogs and amino acid mimetic structures is applicable also here.
  • Residues L 1 , 1 , 2 and Y 1 are preferably d-amino acids.
  • Residue 1 in Structure II is most preferably absent or Sar, and is secondarily preferred to be d-forms of Leu, Tyr or Gly;
  • residue 2 is more preferably Arg (particularly d-Arg); in residue 3, q and r are most preferably zero and R' is most preferably hydrogen, with lower alkyl also being preferred; residue 4 is most preferably Asp; residue 5 is most preferably Ser; and residue 6 is most preferably 3-thioPro.
  • X 1 and Y 1 are both optional, and are selected from the same constituents as those of X 1 and Y 1 of Structure I (with appropriate utilization of reversed orientation residues in X 1 ).
  • Optional substituent X 2 is of a form suitable for bonding to, typically, a carboxyl terminus on X 1 or L 1 .
  • s is an integer of from 1 to about 5, preferably 1 to 3, and most preferably
  • a particularly preferred compound class of Structure II is:
  • R' in X 1 and Y 1 is preferably hydrogen or lower alkyl.
  • Specifically preferred compounds include:
  • Ada represents adamantyl notwithstanding the abbreviation used throughout the specification;
  • derivatives of the peptides of Structure II may be useful in the generation of antigens which, in turn, may be useful to generate antibodies.
  • These antibodies will in some cases themselves be effective in inhibiting cell adhesion or modulating immune activity by acting as receptors for matrix proteins or other ligands, or, if anti-idiotypic, by acting to block cellular receptors.
  • L 1 and L 2 are each, or are together, a residue of an amino acid, an amino acid derivative or an amino acid mimetic having a functional group suitable for the formation of a cyclizing bridge between L 1 and L 2 ;
  • Z is a cyclizing moiety between L 1 and L 2 ;
  • 1 is optional and, where present, is selected from Leu, Tyr, Phe, He, Pro, 3-thioPro, TC, TCA, DTC, MTC, TTC, Gly, Ala, Val, norLeu, norVal, ⁇ -Ala, Trp, l-Nal, d-Nal, (Ada)-Aia and Sar;
  • 2 is selected from Arg, homoArg, nitroArg, norArg, p-aminomethyl-Phe, N-alkylArg, N,N-dialkylArg, N,N'-dialkylArg, and N,N,N'-trialkylArg, wherein the alkyl has one to four carbon atoms (such as N-methyl, N,N'dimethyl, and N,N-dimethyl); 3 is a moiety suitable for linking residue 2 with reversed-orientation residue 4, and is preferably of the form
  • q and r are independently integers of 0, 1 or 2;
  • 4 is of reversed orientation and is selected from Asp, Glu, and the lower alkyl, aralkyl, aryl esters, OFm esters, O-cyclohexyl esters, O-benzyl esters, of the foregoing two amino acids;
  • 5 is optional and, where present, is of reversed orientation and is selected from Ser, Thr, Tyr, monohalo-Tyr, dihalo-Tyr, Trp, Ala, Val, Phe, o-, m-, and p-halo-Phe, p-nitro-Phe, and
  • n 2, 3 or 4;
  • 6 is optional and, where present, is of reversed orientation and is selected from Pro, 3-thioPro, 1,1-ACC, Dhp, Hyp, DTC, TCC, TC, TCA, MTC, homoPro, Phe, o-, m- and p-halo-Phe, p-nitro-Phe, TA, l-Nal, d-Nal, and isonipecotic acid;
  • X 1 and Y 1 are each optional and, where present, are independently selected from 1 to 4 d- or l-amino acids and amino acid analogs (such as AMBA, AnC, AnB, and u-amino-lower alkyl carboxylic acids);
  • X 2 is an optional N ⁇ -substituent selected from R' (including hydrogen) and R'CO-; Y 2 is an optional substituent selected from -R' (including hydrogen) and -COR'; and wherein each R' is individually a pharmaceutically suitable substituent group, preferably one selected from hydrogen, from linear and branched, unsubstituted and substituted C 1 -C 8 lower alkyls, C 2 -C 8 alkenyls, C 2 -C 8 alkynyls, C 6 -C 14 aryls, C 7 -C 14 alkaryls, C 7 -C 14 cycloalkaryls and C 3 -C 14 cycloalkyls, and, in the case of -NR' 2 , from cyclized groups forming (in an attachment with the nitrogen atom) a 5-8 membered heterocyclic ring optionally containing oxygen, nitrogen or sulfur as a further ring heteroatom.
  • L 2 may in such a case be selected from Mpr and
  • an especially preferred residue is -HN-(CH 2 ),-NH-, wherein s is an integer of from 1 to about 5, preferably 1 to 3, and most preferably 1.
  • Residues 4, 5, 6, L 2 and Y 1 in Structure III are preferably d-amino acids.
  • Residue 1 in Structure Hi is most preferably absent or Sar and is secondarily preferred to be Leu, Tyr or Gly;
  • residue 2 is most preferably Arg; in residue 3, q and r are most preferably zero and R' is most preferably hydrogen, with lower alkyl also being preferred;
  • residue 4 is most preferably d-Asp, residue 5 is most preferably d-Ser, residue 6 is most preferably d-Pro.
  • X 1 and Y 1 are both optional, and are selected from the same constituents as those of X 1 and Y 1 of Structures I and II (with appropriate consideration of reversed orientation residues in Y 1 ).
  • Optional substituent Y 2 is of a form suitable for bonding to, typically, an amino terminus of Y 1 or L 2 .
  • a particularly preferred compound of Structure III is:
  • preferred compounds are:
  • antibodies will, in some cases, themselves be effective in inhibiting cell adhesion or modulating immune activity by acting as receptors for matrix proteins or other ligands or, if anti-idiotypic, by acting to block cellular receptors.
  • the compounds of Class IV of the invention are represented by the formula:
  • L 1 and L 2 are each, or are together, a residue of an amino acid, an amino acid analog or an amino acid mimetic having a functional group suitable for the formation of a cyclizing bridge between L 1 and L 2 ;
  • X is a cyclizing moiety or bond between L 1 and L 2 ;
  • 1 is optional and, where present is selected from Leu, Sar, d-Nal, l-Nal, Tyr, Phe, lie, Pro, 3-thioPro, TTC, TCA, DTC, MTC, TC, Gly, Ala, Val, norLeu, norVal, ⁇ -Ala, Trp, and (Ada)-Ala; 2 is selected from Arg, homoArg, nitroArg, norArg, p-aminomethyl-Phe, N-alkylArg, N,N-dialkylArg, N,N'-dialkylArg, and N,N,N'-trialkylArg wherein the alkyl has one to four carbon atoms (such as N-methyl, N,N'-dimethyl, and N,N-dimethyl);
  • 5 is optional and, where present, is selected from Ser, Thr, Tyr, monohalo-Tyr, dihalo-Tyr, Trp, Ala, Val, Phe, o-, m-, and p-halo-Phe, p-nitro-Phe, Asn, Asp, Met and
  • n 2, 3 or 4;
  • 6 is optional and, where present, is selected from Pro, 3-thioPro, TA, DTC, TTC, TC, MTC, TCA, 1,1 -ACC, Dhp, Hyp, homoPro, Phe, and Thr, Tyr, Val, d-Nal, l-Nal, CHA, Ser, Asn, Glu, o, m, and p-halo-Phe, and isonipecotic acid; 7 is optional and, where present, is Pro, 3-thioPro, TA, DTC, TTC, TC, MTC, TCA,
  • X 1 and Y 1 are each optional and, where present, are independently selected from 1 to 4 d- or l-amino acids or amino acid analogs (such as AMBA, AnC, AnB, and ⁇ -amino-lower alkyl carboxylic acids).
  • X 2 is an optional N ⁇ -substituent selected from R'- (including hydrogen) and R'CO-;and Y 2 is an optional carboxyl-termlnal substituent selected from -OR' (including hydroxyl), -NR' 2 (including -NH 2 and -NHR"), -NHNH 2 and -SR'; and wherein each R' is individually a pharmaceutically suitable substituent group, preferably one selected from hydrogen, from linear and branched, unsubstituted and substituted C 1 -C 8 lower alkyls, C 2 -C 8 alkenyls, C 2 -C 8 alkynyls, C 6 -C 14 aryls, C 7 - C 14 alkaryls, C 7 -C 14 cycloalkaryls and C 3 -C 14 cycloalkyls, and, in the case of -NR' 2 , from cyclized groups forming (in an attachment with the nitrogen atom) a 5-8 membered hetero
  • residues L 1 and L 2 other than Cys, and Z groups other than simple bonds may also be usefully employed in the context of Structure IV. It will be seen in this regard that the presence of residue numbers 2 and 4 on either side of L 1 will typically require cyclization (through Z) to L 2 through a side chain or other functional group on L 1 that is not engaged in bonding to residues 2 or 4. Residue L 2 may more generally be engaged in cyclization through either a terminal (typically, carboxyl) functional group or a side chain functional group.
  • Preferred residues for position X 1 include Gly-, Phe-, Leu-, Asn-, Val-, Try, 1 - or 2-naphthylalanine, cyclohexylAla-, AMBA, AnC, AnB, u-amino lower alkylcarboxylic acids, Aib-, Ser-Tyr-Asn-, Ala-Thr-Val-, and p-chloro-Phe-.
  • Preferred residues for position Y 1 include -Ala, -Ala-Ser, -Ala-Ser-Ser, -Ala-Ser-Ser-Lys, -Ala-Ser-Ser-Lys- Pro, -Thr, -Thr-Phe, -Aib, -p-chloro-Phe, AMBA, AnC, AnB, w-amino-lower alkyl carboxylic acids, 1- or 2-naphthylalanine, and -(cyclohexylAla).
  • substituents X 2 or Y 2 incorporating R' other than hydrogen e.g., acyl groups R'CO or amino groups of the form R'NH
  • preferred substituents include those derived from bulky compounds such as adamantaneacetic acid, adamantanecarboxylic acid, 1- or 2-naphthylacetic acid, 2-norbornaneacetic acid, 3-noradamantanecarboxylic acid, 3-methyladamataneacetic acid, and 1- or 2-adamantylamine.
  • R groups are those derived from acids such as from 9-fluoreneacetic acid, 2-fiuorenecarboxylic acid, 9-fluorenecarboxylic acid, phenylacetic, hydroxycinnamic acid, quinaldic acid, cyclohexyl acetic acid, and 3-mercaptopropionic acid.
  • acids such as from 9-fluoreneacetic acid, 2-fiuorenecarboxylic acid, 9-fluorenecarboxylic acid, phenylacetic, hydroxycinnamic acid, quinaldic acid, cyclohexyl acetic acid, and 3-mercaptopropionic acid.
  • derivatives of the peptides of Structure IV may be useful in the generation of antigens which, in turn, may be useful to generate antibodies.
  • These antibodies will, in some cases, themselves be effective in inhibiting cell adhesion or modulating immune activity by acting as receptors for matrix proteins or other ligands or, if anti-idiotypic
  • backbones i.e., the peptide-bond linked portions of the cyclic compounds of the invention were generally synthesized using solid phase peptide synthesis, and then cyclized using a procedure which, where necessary, selectively removed protective groups from only the residues involved in cyclizing. In this way, the peptide sequence in the compound was not changed or lengthened, but the peptide was properly cyclized.
  • Other methods for synthesis and cyclization are known in the art and may be employed in the preparation of the cyclic compounds and formulations disclosed herein.
  • peptide sequences in the compounds of this invention may be synthesized by the solid phase peptide synthesis (for example, BOC or FMOC) method, by solution phase synthesis, or by other techniques known in the art including combinations of the foregoing methods.
  • BOC and FMOC methods which are established and widely used, are described in the following references:
  • a peptide of a desired length and sequence is produced through the stepwise addition of amino acids to a growing peptide chain which is covalently bound to a solid resin particle.
  • Automated synthesis may be employed in this method.
  • the C-terminal end of the growing peptide chain is covalently bound to a resin particle and amino acids having protected ⁇ -amino groups are added in the stepwise manner indicated above.
  • a preferred ⁇ -amino protecting group is the tert-butyloxycarbonyl (BOC) group, which is stable to the condensation conditions and yet is readily removable without destruction of the peptide bonds or racemization of chiral centers in the peptide chain.
  • the product peptide is cleaved from the resin, and any remaining protecting groups are removed by treatment under acidic conditions such as, for example, with a mixture of hydrobromic acid and trifluoroacetic acid, with trifluoromethane sulfonic acid or with liquified hydrofluoric acid.
  • acidic conditions such as, for example, with a mixture of hydrobromic acid and trifluoroacetic acid, with trifluoromethane sulfonic acid or with liquified hydrofluoric acid.
  • hydrofluoric acid was typically used.
  • Table 1 The preferred steps for solid phase peptide synthesis using the symmetric anhydride method are shown in Table 1, below.
  • the preferred steps for solid phase peptide synthesis using the active ester method are shown in Table 2, below.
  • the preferred steps using the DCC method are shown in Table 3, below.
  • peptide sequences or portions thereof may be synthesized in solution. See, e.g., M. Mutter and E. Bayer, In “The Liquid Phase Method for Peptide Synthesis”; E. Gross and J. Meienhofer, Eds.; The Peptides; Academic Press: 1980; pp. 285-332, for one example of peptide synthesis in solution.
  • General strategies for preparing cyclic compounds of the invention typically involve selective protection of side chains or termini so that cyclization may be accomplished.
  • the peptide bond linked linear backbone of the compound is wholly or partially constructed using one type of protection means on potentially reactive groups (e.g., side groups) on residues not involved in cyclization, with the residues bearing functional groups to be cyclized being protected with another type ("orthogonol protection").
  • the moieties to be cyclized are then chemically revealed without disturbing the other protective groups.
  • the revealed moieties are then appropriately activated and cyclized.
  • the remainder of the peptide bond linked portion of the compound is completed (if the partial backbone was cyclized), deprotected, cleaved from the resin (when appropriate) and purified. In this way, functional groups not intended for cyclization are not prematurely exposed and cyclization occurs in the proper location.
  • a peptide may be synthesized on a resin using FMOC protection on the side chains, or on the terminus or other portion, which will be used for cyclization.
  • Preferred steps for solid phase peptide synthesis using such FMOC orthogonal protection are set forth in Table 4 below.
  • the remainder of the potentially reactive groups of the peptide may be BOC protected.
  • the FMOC-protected side chain/termini are deprotected, without deprotection of the BOC-protected moieties. Inappropriate cyclization or other modification is thereby prevented.
  • the temporary terminus should be blocked with a protecting group stable to the deprotection and cyclization conditions for the involved cyclized functional groups. Following cyclization, the temporary terminus is then deprotected and the peptide construction is completed.
  • the volume given is for synthesis using 0.4 meq. growing peptide chain on one gram of resin.
  • the compounds after cleavage from the resin are isolated and purified by means well known in the art. For example, the cleaved compound/resin mixture is washed in turn with several portions of diethyl ether and then extracted with several portions of aqueous acetic acid. The resin may then be discarded. The aqueous acetic acid extracts are combined, concentrated, resuspended in water and lyophilized.
  • the crude compound can be purified by reversed phase high pressure liquid chromatography (HPLC), or by size exclusion chromatography, partition chromatography on polysaccharide gel media such as Sephadex G10 or G25, or counter current distribution.
  • HPLC reversed phase high pressure liquid chromatography
  • size exclusion chromatography partition chromatography on polysaccharide gel media such as Sephadex G10 or G25, or counter current distribution.
  • the composition of the final compound may be confirmed by amino acid analysis after degradation of the compound by standard means, by amino acid sequencing techniques, or by FAB-MS techniques.
  • compounds were usually purified by reverse-phase HPLC and subjected to amino acid analysis.
  • fluoride removal using ion exchange chromatography is unnecessary.
  • Salts of carboxyl groups of the product compounds may be prepared in the usual manner by contacting the compound with one or more equivalents of a desired base such as, for example, a metallic hydroxide base such as, for example, sodium hydroxide; a metal carbonate or bicarbonate base such as, for example, sodium carbonate or sodium bicarbonate; or an amine base such as, for example, triethylamine, triethanolamine, and the like.
  • a desired base such as, for example, a metallic hydroxide base such as, for example, sodium hydroxide
  • a metal carbonate or bicarbonate base such as, for example, sodium carbonate or sodium bicarbonate
  • an amine base such as, for example, triethylamine, triethanolamine, and the like.
  • Acid salts of the compounds may be prepared by contacting the polypeptide with one or more equivalents of the desired inorganic or organic acid, such as, for example, hydrochloric acid, acetic acid or citric acid.
  • Esters of carboxyl groups of the compounds may be prepared by any of the usual means known in the art for converting a carboxylic acid or precursor to an ester.
  • One preferred method for preparing esters of the present compounds when using the Merrifield synthesis technique described above, is to cleave the completed peptide sequence from the resin in the presence of the desired alcohol either under basic or acidic conditions, depending upon the resin.
  • the C-terminal end of the peptide when freed from the resin is directly esterified without isolation of the free acid.
  • C-terminal amino acid esters may be made using solution phase synthesis wherein the C-terminal residue bearing the desired ester functionality is incorporated.
  • Amides of the compounds of the present invention may also be prepared by techniques well known in the art for converting a carboxylic acid group or precursor to an amide.
  • a preferred method for amide formation at the C-terminal carboxyl group is to synthesize the peptides by solid phase methods on an appropriate resin, for example a 4-methylbenzhydrylamine or a benzhydrylamine resin, and thereafter to cleave the polypeptide from a solid support with an appropriate acid.
  • an appropriate resin for example a 4-methylbenzhydrylamine or a benzhydrylamine resin
  • N-Acyl derivatives of an amino group of the present peptides may be prepared by utilizing an N-acyl protected amino acid for the final condensation, or by acylating a protected or unprotected functional group in the compound. Acylation may be carried out using standard acylating reagents such as acyl halides, anhydrides, acyl imidazoles, and the like prior to deprotection of the residue side chains.
  • the coupling reaction is generally carried out at 0° - 25o C, deprotection at room temperature, and cleavage at a reduced temperature of -5o to 0° C (especially with HF cleavage).
  • the exact temperature for any particular reaction will, of course, be dependent upon the substrates, reagents, solvents and so forth, all being well within the skill of the practitioner. Illustrative reaction conditions for these processes may be gleaned from the examples.
  • the compounds of this invention may also be synthesized using any techniques that are known to those in the synthetic arts, for example, those described in
  • Example 1 relates general procedures as applied to two representative RGD-containing peptides, while Examples 2 and 3 give procedures for preparing disulfide linked compounds according to Structures II and III above.
  • Peptides of this class were synthesized and cyclized as the disulfide.
  • Such peptides include: and
  • t-butyloxycarbonyl protected amino acids with chiral centers were of the L-configuration.
  • Such protected amino acids included the t-butyloxycarbonyl derivatives of Ser(O-benzyl), Asp( ⁇ -cyclohexyl ester), Arg(tosyl), Cys (S-p-methylbenzyl) and Pen (S-p-methoxy benzyl).
  • the coupled peptides were cleaved from the peptide resin by treatment with distilled anhydrous HF (10 ml/g peptide resin) in the presence of anisole (1 ml/g peptide resin) and dimethyl sulfide (0.5 ml/g) as scavengers. The reaction was carried out at -5oC for one hour. After removal of the HF under reduced pressure, the resin was washed three times with diethyl ether. The peptide was extracted from the resin with 1 N acetic acid and then lyophilized.
  • the crude cyclic peptide was purified using preparative RP-HPLC (Waters Delta Prep 3000, Millipore Corporation, Millford, Mass.) according to the manufacturer's general instructions.
  • Such peptides can be generally purified using a linear gradient of increasing acetonitrile concentration in TEAP (1% triethyiamoronium phosphate, pH ⁇ 2.3) as mobile phase.
  • TEAP 1% triethyiamoronium phosphate, pH ⁇ 2.3
  • the collected fractions of pure peptide are reapplied to the HPLC column and then eluted again with 0.5% acetic acid to change the phosphate salt form of the peptide to the desired acetate form.
  • the peptides were then dissolved in water, and fluoride was removed via ion exchange chromatography as described above if necessary. Highly purified fractions were pooled and Iyophilized.
  • Solution phase BOC and FMOC methods are used in this synthesis.
  • the product from each step prior to HF cleavage is purified by silica gel chromatography.
  • the general approach is to synthesize the reversed form of the peptide and attach it to the partially protected diaminopropane moiety, followed with coupling amino acids in the normal orientation to the deprotected diaminopropane coupled to the reversed peptide segment.
  • the peptide is then deprotected with HF, the resulting crude dicysteine containing product cyclized, and the disulfide compound purified.
  • N-BOC-d-aspartic acid is protected with ⁇ -9-fluorenylmethyl ester, and the ⁇ - cyclohexyl ester is N-deprotected with 1 :1 TFA/DCM.
  • the resulting ammonium trifluoroacetatec is coupled to N-BOC-O-benzyl-d-serine (1.05 eq.) using benzotriazol-1-yloxy-tris(dimethylamino)-phosphonium hexafluorophosphate (BOP reagent, 1.2 meq.), 1 -hydroxybenzotriazole hydrate (HOBt, 0.12 meq.), and diisopropylethylamine (DIEA, 4 meq.) in DMF.
  • This dipeptide product is N-deprotected and coupled as above sequentially to N-BOC-d-proline and N-BOC-S-4-methylbenzyl-d-cystelne.
  • the OFm ester of the aspartic acid residue is deprotected with 20% piperidine/DMF and the free carboxyiate product coupled to 1-(9-fluorenylmethyl-carboxamide)-2-amlnoethane with BOP activation.
  • the product of this reaction is coupled sequentially to N- ⁇ -FMOC-N°-tosyl-1-(nor)arginine and N-BOC-S-4-methylbenzyl-1-cysteine, using 20% piperidine/DMF deprotection and activation with BOP.
  • the resulting cysteine sulfhydryl are cyclized in an iodine oxidation procedure to produce the final product depicted above.
  • Solution phase BOC and FMOC methods are used in this synthesis.
  • the product from each step prior to HF cleavage is purified by silica gel chromatography.
  • this peptide contains reversed (rev) forms of d-Cys and d-Arg.
  • the general approach is to synthesize the l-configuration segment of the peptide and then attach, through an amide bond, a residue of malonic acid mono-t-butyl ester.
  • the synthesis is then continued by coupling amino acids in the reversed orientation to the deprotected malonate.
  • the compound is then deprotected with HF, the resulting crude dicysteine-containing product cyclized and the disulfide compound purified.
  • BOC-Gly (O-benzyl) ester is N-deprotected with 1:1 trifluoroacetic acid/methylene chloride.
  • the resulting ammonium trifluoroacetate is coupled to N-BOC-S-4-methylbenzyl-1-cysteine (1.05 eq.) using benzotriazol-1-yloxy-tris(dimethylamino)-phosphonium hexafluorosphosphate (BOP reagent, 1.2 eq.), 1-hydroxybenzotriazole hydrate (HOBt, 0.12 eq.), and diisopropylethylamine (DIEA, 4 eq.) in dimethylformamide (DMF).
  • BOP reagent 1.2 eq.
  • HOBt 1-hydroxybenzotriazole hydrate
  • DIEA diisopropylethylamine
  • This dipeptide product is N-deprotected and coupled as above sequentially to the following compounds: N-BOC-l-proline, N-BOC-O-benzyl-l-serine, N-BOC-( ⁇ -cyclohexyl ester)-1-aspartic acid, and malonic acid mono-t-butyl ester.
  • the t-butyl ester of the malonate is deprotected with 1 :1 TFA/DCM and the freed carboxylate product is activated (using the BOP coupling procedure described above) and coupled to N g -tosyl-d-arginine, t-butyl ester (free N ⁇ -amine).
  • the t-butyl ester of the resulting arginine-containing product is deprotected with 1 :1 TFA/DCM and the free carboxylate product is again activated and coupled to S-4-methylbenzyl-d-cysteine with BOP reagent.
  • Example 4 is of a side chain-to-side chain amide bridge wherein the ⁇ -carboxyl group of Glu was condensed with the ⁇ -amino group of Lys.
  • Example 5 is of a side chain-to-backbone amide bridge wherein the terminal ⁇ -amino group of Gly was condensed with the ⁇ -carboxyl group of Asp. In both of these examples, the amino acid backbone was fully assembled, and then cyclized, on a resin.
  • Example 6 shows cyclization using an amide bridge as an Intermediate step.
  • the amino acid backbone is partially assembled and then cyclized using an amide bridge. After assembly of the amide bridge, the amino acid chain is completed.
  • N-BOC-O-9-fluorenylmethyl omega-esters of aspartic and glutamic acids were prepared following the procedure as generally described by R. Bolin, C.T. Wang, and A.M. Felix, Organic Preparations and Procedures Intern. 1989, 21, pp. 67-74, with certain modifications.
  • N-BOC-O ß -9-fluorenylmethyl asparate 8.31 g (25.7 mmol) of N-BOC-O ⁇ -benzylaspartate and 4.80 g (24.5 mmol) of 9-fluorenylmethanol were dissolved in 150 ml DCM. The solution was chilled in an ice bath. 30 mg (0.24 mmol) of 4-(dimethylamino)pyridine was added to the solution followed by addition of 5.31 g (25.7 mmol) DCC in portions, over 10 minutes. The resulting mixture was stirred for one hour with continued cooling. The precipitated n,n'-dicyclohexylurea was removed by filtration and the filtrate was diluted with 250 ml DCM.
  • N-BOC-O ⁇ -9-fluorenylmethyl aspartate Recrystallization from diethyl ether/petroleum ether yielded 3.53 g of N-BOC-O ⁇ -9-fluorenylmethyl aspartate, with a melting point of 135-137° C.
  • N-BOC-O-fluorenylmethyl-glutamate gamma ester.
  • GLUTAMATE 4.5 G, 13.3 mol
  • 9-fluorenyl-methanol 2.5 g, 12.5 mmol
  • 100 ml DCM 100 ml
  • the solution was stirred and chilled in an ice bath.
  • 15.5 mg (0.13 mmol) of 4-(dimethylamino)-pyridine and 2.75 g (13.3 mmol) of DCC were added, and the resulting mixture was stirred for 4 hr with continued cooling.
  • Precipitated N,N'-dicyclohexylurea was filtered off and filtrate was diluted with 200 ml DCM.
  • the solution was extracted and treated in the same manner as was for the aspartate described above.
  • N-BOC-O-fluorenylmethylglutamate (gamma ester) (2.3 g) was obtained by recrystallizing the crude residue from diethyl ether/petroleum ether (1 :10), melting point 123.5-126°C.
  • BOC-Ser(Bzl)OCH 2 -PAM resin (1.0 g, 0.75 mmol) from Applied Biosystems (Foster City, California) was used as the starting resin.
  • the following amino acids were used in the synthesis: BOC-1-Ser(benzyl), BOC-1-Lys(N ⁇ -FMOC), BOC-1-Pro, BOC-1- Asp(O-benzyl), BOC-Gly, BOC-Arg(N ⁇ -tos), and BOC-Glu(Fm). Excess amino acid (2-3 fold) was used for each coupling.
  • the peptide chain was constructed on the Beckman peptide synthesizer using BOC chemistry with the stepwise addition of each amino acid following the standardized cycle similar to that presented in Table 3, with adjustments for scale. 50% TFA in DCM, 5% DIEA in DCM, and 0.5 M of
  • DCC in DCM were used as deprotecting agent, neutralizer, and activating agent, respectively, for each coupling.
  • the amidating cyclization was carried out according to the following protocol. Filtering was performed between each step: (1) MeOH (2 ⁇ 1 min); (2) DCM (3 ⁇ 1 min); (3) 20% piperidine in DMF, wash for 1 min, and deprotection for 20 min; (4) DMF (2 ⁇ 1 min); (5) MeOH (2 ⁇ 1 min);
  • the compound was purified using a Waters Delta Prep 3000 system (Waters, Milford, MA) equipped with a C 16 column, using a linear gradient of increasing acetonitrile concentration in TEAP (pH 2.2 to 2.4) as the mobile phase.
  • the collected fractions of the pure compound were pooled and applied again to the C 18 column. This time the sample was eluted with 0.5% HOAc to convert the phosphate salt form of the peptide to the desired acetate form.
  • the pure peptide fractions were pooled, concentrated in vacuo, redissolved in water and lyophilized to give 92.9 mg of peptide, 98.7% HPLC purity, white powder.
  • the cyclic compound then was cleaved from the resin by HF and 10% anisole for 1 hr at 0°C. Following evaporation of the HF, the mixture was washed with diethyl ether (ether layer discarded) and extracted with 1 N HOAc. The aqueous extract was lyophilized to yield 1.23 g of the crude compound.
  • FIG. 1b is a diagram representing suitable procedures.
  • the chain is partially assembled using the DCC method (Table 3) with primarily BOC protection until the BOC-Lys(FMOC), representing L 1 in the eventual product compound, is added.
  • the BOC-Glu(Fm) and BOC-Lys(FMOC) are substituted for BOC-Glu(Chx) and BOC-Lys(Cl-Cbz).
  • the chain assembly is interrupted and the compound is cyclized while bound to the resin.
  • Cyclization proceeds by treating the compound with 20% piperidine in DCM to deprotect the Glu and Lys residues, followed by filtering and washing, and by then by reaction with BOP in DMF and DIEA until the compound on the resin is ninhydrin negative. The amino-terminal glycine residue is then added to the cyclized compound, and the resulting product cleaved from the resin and worked up as described generally in the foregoing examples.
  • Trifluoroacetic acid was from Halocarbon Co. (New York, New York). Triethyl-amine was from Fisher Scientific (Fair Lawn, New Jersey). Other reagents were obtained from conventional sources and of analytical grade.
  • Ail peptides were synthesized by the solid phase method with a Beckman automated peptide synthesizer (System 990, Beckman Instruments, Inc., Palo Alto,
  • the volume given is for the synthesis using 2 g of resin with the substitution of 0.8 mM/g of resin.
  • the peptide was removed from the resin by treatment with HF in the presence of 10% anisole and 5% of dimethylsulfide for 1 hr. at 0oC. Following evaporation of the HF, the peptide resin residue was washed in turn with diethyl ether (discarded ether wash) and extracted with 5% HOAc in H 2 O (50 ml ⁇ 4). The aqueous acetic acid solution was lyophilized to yield 780 mg of the crude, noncyclic peptide (Ellman test positive, Stewart and Young, Solid Phase Peptide Synthesis, 2nd ed. p. 116).
  • the compound was purified on a 25 ⁇ 2.5 cm SP Sephadex c-25 (Pharmacia LKB Biotechnology Inc., Piscataway, NJ) column. The column was first equilibrated with 10 mM NH 4 OAc buffer (pH 3.5) The compound was eluted with NH 4 OAc buffer in a linear gradient of increasing NH 4 OAc concentration with 10-300 mM (pH3.5-6.5). The fractions which contained the pure product were pooled and Iyophilized. The dried residue was redissolved in H 2 O and Iyophilized thrice to ensure the removal of the NH 4 OAc salt to yield 106 mg product (HPLC, 95% pure).
  • the peptides containing D-Nal are purified using a Waters Delta Prep 3000 system (Waters, Milford, Massachusetts) equipped with a C 18 column, using a linear gradient of increasing acetonitrile concentration in TEAP (pH 2.2 to 2.4) as the mobile phase.
  • the collected fractions of the pure peptide are then eluted again with 0.5% HOAc in the same HPLC system to exchange the phosphate salt form of the peptide to the desired acetate form.
  • BOC amino acid aldehydes used in this synthesis were prepared by the method of J-A Fehrentz and B. Castro, Synthesis 1983, 676.
  • the introduction of the pseudo CH 2 NH peptide bond was done by utilizing the reductive alkylation reaction in solid phase (Y. Sasaki and D.H. Coy, Peptides, 1987, 8, 119.
  • BOC-Glycinal Preparation of BOC-Glycinal. Synthesis of BOC-glycinal from BOC-glycine involved the steps of forming the N-methoxy-N-methyiamide of BOC-protected glycine, followed by reduction to the aldehyde compound. Since the aldehyde was highly reactive it was prepared immediately before use. 8.75 g (50 mmol) of BOC-glycine dissolved in 150 ml DCM and 6.95 ml (50 mmol) of TEA was added to the solution, and stirred.
  • the coupling of the additional amino acids after the CH 2 NH bond was continued using the standard BOC procedure in a manual apparatus.
  • the peptide was removed from the resin by treatment with HF in presence of 10% anisole and 5% dimethylsulfide for 1 hr at 0°C.
  • the residue was washed with diethyl ether, filtered, and extracted with 1 M HOAc in H 2 O (50 ml ⁇ 4).
  • the solution was Iyophilized to yield the crude noncyclic peptide (780 mg).
  • the peptide solution was titrated with l 2 -glacial acetic acid until the solution turned light brown in color, and stirred for 1-2 hr at room temperature. The excess iodine was removed by adding ascorbic acid-water solution. The peptide solution was then concentrated in vacuo. The residue was redissolved in water and Iyophilized to obtain the crude cyclic peptide.
  • cyclic compounds of the invention in which linkage (through L 1 , L 2 and Z) includes a secondary amine structure may analogously be prepared. It is most advantageous, from a synthetic standpoint, to incorporate the isostere bond linkage prior to final cyclization of the compound. In such a case, cyclization is completed as a final step (after assembly of the desired residues including the isostere bond) through formation of, typically, a peptide bond at a point within the sequence 1-2-3-4-5-6.
  • an effective amount of the active compound, including derivatives or salts thereof, or a pharmaceutical composition containing the same, as described below, is administered via any of the usual and acceptable methods known in the art, either singly or in combination with another compound or compounds of the present invention or other pharmaceutical agents such as immunosuppressants, antihistamines, corticosteroids, and the like.
  • compositions can thus be administered orally, sublingually, topically (e.g., on the skin or in the eyes), parenterally (e.g., Intramuscularly, intravenously, subcutaneously or intradermally), or by inhalation, and in the form of either solid, liquid or gaseous dosage including tablets, suspensions, and aerosols, as is discussed in more detail below.
  • parenterally e.g., Intramuscularly, intravenously, subcutaneously or intradermally
  • inhalation e.g., a solid, liquid or gaseous dosage including tablets, suspensions, and aerosols, as is discussed in more detail below.
  • the administration can be conducted in single unit dosage form with continuous therapy or in single dose therapy ad libitum.
  • Useful pharmaceutical carriers for the preparation of he pharmaceutical compositions hereof can be solids, liquids or gases; thus, the compositions can take the form of tablets, pills, capsules, powders, enterically coated or other protected formulations (such as binding on ion exchange resins or other carriers, or packaging in lipid protein vesicles or adding additional terminal amino acids), sustained release formulations, solutions (e.g., ophthalmic drops), suspensions, elixirs, aerosols, and the like.
  • Water, saline, aqueous dextrose, and glycols are preferred liquid carriers, particularly (when isotonic) for injectable solutions.
  • the carrier can be selected from various oils including those of petroleum, animal, vegetable or synthetic origin, for example, peanut oil, soybean oil, mineral oil, sesame oil, and the like.
  • suitable pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, and the like.
  • compositions may be subjected to conventional pharmaceutical expedients such as sterilization and may contain conventional pharmaceutical additives such as preservatives, stabilizing agents, wetting or emulsifying agents, salts for adjusting osmotic pressure, buffers, and the like.
  • suitable pharmaceutical carriers and their formulations are described in Martin, Remington's Pharmaceutical Sciences; 15th Ed.; Mack Publishing Co., Easton, 1975, see, e.g., pp. 1405-1412, 1461-1487.
  • Such compositions will, in general, contain an effective amount of the active compound together with a suitable amount of carrier so as to prepare the proper dosage form for proper administration to the host.
  • the therapeutic methods of the present invention are practiced when the relief of symptoms is specifically required or perhaps imminent; in another preferred embodiment, the method hereof is effectively practiced as continuous or prophylactic treatment.
  • the particular dosage of pharmaceutical composition to be administered to the subject will depend on a variety of considerations including the nature of the disease, the severity thereof, the schedule of administration, the age and physical characteristics of the subject, and so forth. Proper dosages may be established using clinical approaches familiar to the medicinal arts. It is presently believed that dosages in the range of 0.1 to 100 mg of compound per kilogram of subject body weight will be useful, and a range of 1 to 100 mg per kg generally preferred, where administration is by injection or ingestion. Topical dosages may utilize formulations containing generally as low as 0.1 mg of compound per ml of liquid carrier or excipient, with multiple daily applications being appropriate.
  • the compounds and therapeutic or pharmaceutical compositions of the invention are useful in the study or treatment of diseases or other conditions which are mediated by the binding of integrin receptors to ligands, including conditions involving inappropriate (e.g., excessive or insufficient) binding of cells to natural or other ligands.
  • Such diseases and conditions include inflammatory diseases such as rheumatoid arthritis, asthma, allergy conditions, adult respiratory distress syndrome, inflammatory bowel diseases (e.g., ulcerative colitis and regional enteritis) and ophthalmic inflammatory diseases; autoimmune diseases; thrombosis or inappropriate platelet aggregation conditions, and cardiovascular disease; prevention of occlusion following thrombolysis; neoplastic disease including metastasis conditions; as well as conditions wherein increased cell binding is desired, as in wound healing or prosthetic implantation situations as discussed in more detail above.
  • derivatives of the present compounds may be useful in the generation of antigens which, in turn, may be useful to generate antibodies.
  • the following assay established the activity of the present compounds in inhibiting cell adhesion in a representative in vitro system.
  • the assay was a competition assay in which both fibronectin and a test compound were present. Microtiter plates were first precoated with fibronectin. The test peptide was then added in increasing concentrations with cells known to contain the fibronectin receptor. The plates were then washed and stained for quantitation of attached cells.
  • the present assay directly demonstrates the anti-cell adhesion activity and modulatory activity of the present compounds. Additionally, by immobilizing the peptide on a surface, one could adhere appropriate cells to that surface. Other cell adhesion modulation activity, and utilities pertinent thereto, will be apparent to those skilled in the art.
  • the cell line U937 was purchased from American Type Tissue Culture Collection. The cells were cultured in RPMI media (J.R. Scientific Company, Woodland Hills,
  • Fibronectin was purified from human plasma according to the procedure of Engvall, E. and Ruoslahti, E., Int. J. Cancer 1977, 20, 1.
  • Microtiter plates (96-well, Falcon) were coated overnight at 4*C with 5 ⁇ g/mi fibronectin (FN) (for a total volume of 0.1 ml) or, as a control, 5 ⁇ g/ml bovine serum albumin (BSA) diluted in phosphate buffered saline (PBS, 0.01 M NaPO 4 in 0.9% NaCl at pH 7.2 to 7.4). Unbound proteins were removed from plates by washing with PBS. The plates were then coated with 100 ⁇ l of PBS containing 2.5 mg/ml BSA for one hour at 37oC. This procedure is a modification of a previously published method, Cardarelli, P.M. and M.D.
  • FN ⁇ g/mi fibronectin
  • BSA bovine serum albumin
  • a U937 culture was collected and washed two times with Hanks Balanced Salt Solution. The cells were counted and adjusted to 1.5 ⁇ 10 6 cells per ml in Duibecco's Modified Eagles Medium (DMEM) plus BSA (2.5 mg/ml) for cell attachment assay. Subject compounds were then dissolved in DMEM and BSA, and the pH was adjusted to 7.4 with 7.5% sodium bicarbonate. The compounds
  • FIG. 1 is a diagram representing the curve of cell adhesion inhibition for the compound TABLE 6
  • Asterisk (“*") following residue abbreviation designates linking residue that provides functional group for cyclization.
  • Functional group precursors are as follows: C*, side chain sulfhydryl; Pen*, side chain sulfhydryl; Mpr, 3-mercapto (sulfhydryl) group; K*, side chain amino group D*, side chain carboxyl group; G*, ⁇ -amino group; R*, ⁇ -amino group, "d” indicates the D-enantiomer.
  • FC*LRGDSPC* 2 See notes to Table 6.
  • an aspect of the present invention is to provide compounds having extraordinarily high potencies in modulating cell adhesion to integrin receptors, including specifically inhibition of cell adhesion to the fibronectin receptor.
  • the invention also includes methods for obtaining (either in vitro or in vivo) such fibronectin receptor adhesion inhibition, and integrin receptor adhesion inhibition.
  • the disclosed compounds accomplish strong inhibition at desirably low concentrations, with an IC 50 of less than about 500 ⁇ M, or alternatively less than about 100 ⁇ M.
  • another aspect of the invention is to provide such compounds, and such methods for obtaining integrin receptors adhesion inhibition, with IC 50 potency levels at least as low as about 1 ⁇ M, and alternatively at least as low as about 4 ⁇ M.
  • the following assay established the activity of the present compound in inhibiting cell-cell adhesion in a representative in vitro system.
  • This assay measures the adhesive interactions of T-cells to endothelial cell monolayers in the presence of a test compound.
  • the test compound is added in increasing concentrations with T-cells and this is added to endothelial cell monolayers.
  • the plates are incubated, washed and the percentage of attached cells is quantitated.
  • the assay directly demonstrates the anti-cell adhesion activity and modulatory activity of the present compounds.
  • Human umbilical vein endothelial cells were purchased from Cionetics (San Diego,
  • CA CA at passage number 2.
  • the cells were grown on 0.5% porcine skin gelatin precoated flasks (Sigma, St. Louis, MO) in EGM-UV media (Clonetics, San Diego, CA) supplemented with 10% fetal bovine serum. Cells were refed every 2-3 days reaching confluence by day 4 to 6. The cells were monitored for factor VIII antigen and our results showed that at passage 12, the cells were positive for this antigen. The endothelial cells were not used following passage 14-15.
  • the T-cell line Jurkat was obtained from American Type Tissue Culture Collection (Rockville, MD). The cells were cultured in RPMI media containing 10% fetal calf serum. The cells were washed twice with Hank's Balanced Salt Solution (HBSS) and resuspended in Dulbecco's Minimal Eagle's Media (DMEM) containing 2.5 mg/ml Human Serum Albumin (HSA). The Jurkat cells (1 ⁇ 10 6 cells/ml) were stained with 10 ⁇ g/ml fiuorescein diacetate (Sigma, St. Louis, MO) in HSSS containing 5% fetal calf serum. The cells were stained for 15 minutes in the dark at room temperature, washed 2 times, and resuspended in a DMEM-HSA solution.
  • HBSS Hank's Balanced Salt Solution
  • DMEM Dulbecco's Minimal Eagle's Media
  • HSA Human Serum Albumin
  • IC50 was determined by testing the peptides at 200, 40, 8, 1.6, 0.32, and 0.064 ⁇ M.
  • the plates were placed on ice for 5 minutes to allow for Jurkat cell settling and then incubated at 37o C for 20 minutes. Following this incubation, the monolayers were washed twice with PBS containing 1 mM calcium chloride and 1 mM magnesium chloride and the plates were read using a Pandex Fluorescence Concentration Analyzer (Baxter, Mundelein, IL). Fluorescence in each well was measured as arbitrary fluorescence units and percent adhesion in the absence of a peptide was adjusted to 100% and the percentage adhesion in the presence of the peptide was calculated. Monolayers were also fixed in 3% paraformaidehyde and evaluated microscopically to verify adhesion.
  • Table 8 shows the results of the cell adhesion inhibition assay using the JurkatEndothelial cells. Potency is expressed in terms of percentage inhibition at 200 ⁇ M and 10 ⁇ M concentrations of the tested peptides. Where peptides are determined to be very active, IC 50 (expressed as ⁇ M units) are also given.
  • PEPTIDE # SEQUENCE 200 uM% 10 uM% IC 50 ⁇ m
  • Another aspect of the present invention is to provide compounds having high potencies in modulating leukocyte adhesion to endothelial cells.
  • the present invention includes compounds having an IC 50 of less than about 200 ⁇ M as established in a Jurkat-Endothelial cell adhesion assay; and in another regard, the invention includes compounds having an IC 50 of less than about 10 ⁇ M in such assay.
  • the invention also includes methods for obtaining (either in vitro or in vivo) such leukocyte receptor adhesion inhibition. The disclosed compounds accomplish strong inhibition at low concentrations, with an IC 50 of less than about 200 ⁇ M, or alternatively less than about 10 ⁇ M.
  • a further aspect of the invention is to provide such compounds, and such methods for obtaining leukocyte receptors adhesion inhibition, with IC 50 potency levels at least as low as about 0.1 ⁇ M, and alternately at least as low as about 50 ⁇ M.

Abstract

Cyclized integrin receptor antagonist compounds useful in modulating cell adhesion, including adhesion related to fibronectin, as well as leukocyte adhesion to endothelial cells, are disclosed. Methods for synthesizing, testing, formulating, and using the compounds as therapeutic agents are also disclosed.

Description

CYCLIC CELL ADHESION MODULATION COMPOUNDS
BACKGROUND OF THE INVENTION
This application is a continuation-in-part application of Serial No. 07/550,330, filed July 9, 1990. 1. Field of invention
The present invention relates to novel cyclic peptides and peptidomimetic compounds which are characterized by cell adhesion modulation activity. The compounds have application to the study and treatment of disease conditions mediated by cell adhesion. Specifically, the compounds have application to the study, diagnosis, treatment or prevention of diseases and conditions such as cardiovascular disease, harmful platelet aggregation, neoplastic disease including metastasis of neoplastic growth, wound healing, inflammation and auto-immune disease or other diseases or conditions involving cell adhesion.
2. Background of the Invention The extracellular matrix is the major component of connective tissue of all mammals. The extracellular matrix provides for structural integrity, and promotes cell migration and cellular differentiation. As part of these functions, the extracellular matrix has been shown to support adhesion for various types of cells in vitro. Molecules such as collagens, fibronectin, vitronectin, laminin, von Willebrand factor, thrombospondin, bone sialoprotein, fibrinogen, and tenacin have been found to possess this property of mediating cell adhesion.
The above cell-adhesive molecules have been found to exhibit a structural similarity in their respective binding sites, each of which contains the amino acid sequence arginine-glycine-aspartic acid, or RGD using single letter nomenclature (infra). The cell-binding site in fibronectin has been reproduced synthetically and establishes the RGD sequence as the essential structure recognized by cells in fibronectin. Changes in the peptide as small as the exchange of alanine for giycine or glutamic acid for aspartic acid which constitutes the addition of a single methyl or methylene group to the tripeptide, eliminates these activities (Pierschbacher &
Ruoslahti, PNAS, 1981, 81, 5985). In turn, the cellular receptor site for fibronectin has been identified for various cells, in addition, cellular receptors that recognize RGD-containing sequences in other extracellular matrix proteins (e.g., the vitronectin receptor and the platelet gpIIb/IIIa receptor) have been identified. Such cellular receptors, responsive to RGD-containing proteinaceous compounds, have been characterized. The complete, primary structure of the fibronectin receptor has been deduced from cDNA, and physical properties have been determined (Argraves, et al., J.Biol. Chem. 1986, 261 , 12922; Argraves et al., J.Cell Biol. 1987, 105, 1183). The protein exists at the cell surface as a heterodimeric complex (although the larger polypeptide is enzymatically processed) having both polypeptide chains inserted into the membrane. Each chain extends 30-40 residues into the cytoplasmic space, and at least one of the cytoplasmic peptides appears to interact with the cytoskeleton (Horwitz et al., Nature 1986, 320, 531). The larger of the two polypeptides, the α subunit, contains a number of regions that are structurally similar to calmodulin and that apparently mediate the binding of calcium to the receptor. The presence of such divalent cations is required for the receptor to bind ligand. The β subunlt is somewhat smaller and conformationally compact due to numerous intrachain disulfide bonds. The cytoplasmic domain of the β subunit contains a potentially phosphoryiated tyrosine (Hirst et al., PNAS-USA 1986, 83, 6470; Tamkun et al., Cell 1986, 46, 271).
Other RGD-directed receptors, as well as other "orphan" receptors the ligand for which is unknown, have also been characterized. This putative RGD commonality of the ligand matrix proteins has revealed a superfamily of cell surface receptor proteins that share a high degree of structural similarity and probably also functional similarity. The members of this superfamily of cell surface proteins collectively are known as the integrins. The integrins are α, β heterodimeric cell surface proteins which can be grouped on the basis of the identity of their β subunit. Each integrin can interact with single or multiple ligands. The β subunit, as disclosed above for the fibronectin receptor, is compact due to a high degree of cross-linking. The first group of integrins, β1 molecules, includes the very late activation antigen (VLA) proteins, which themselves include the fibronectin receptor (VLA-5), collagen receptor (VLA-2), laminin receptor, and a receptor (VLA-4) which binds to the vascular cell adhesion molecule-1 (VCAM-1) on cytokine activated endothelial cells. The second group (β2 subfamily) includes the lymphocyte associated antigen-1 (LFA-1), macrophage antigen-1 (MAC-1), and p150,95. The third group (β3 subfamily) includes the vitronectin receptor, the platelet glycoprotein gpIIb/IIIa. To date, seven β chains have been described. For reviews, see Hynes, Cell 1987, 48, 549; Hemler, Immunol. Today 1988, 9, 109; Springer et al., Annu. Rev. Immunol. 1987, 5, 223; Kishimoto et al., Leukocyte Adhesion Molecules, T.A. Springer, D.C. Anderson, A.S. Rosenthal, and R. Rothlein, Eds., Springer-Verlag,
New York, 1989, pp. 7-43. The RGD-directed receptor present on platelets (gpllb/llla) that binds fibronectin, vitronectin, fibrinogen, and von Willebrand factor has also been purified. The receptor is thus not specific to one extracellular matrix protein, as is the fibronectin receptor. It has been proposed that this lack of specificity is correlated to the lack of conformational specificity in the ligands. Other work has suggested that specificity can be achieved with relatively short, conformationally restricted synthetic peptides containing the RGD sequence. For a literature summary, see: Pierschbacher et al., Nature 1984, 309, 30; Pierschbacher et al., PNAS-USA 1984, 81 , 5985; Ruoslahti et al., Cell 1986, 44, 517; Pierschbacher et al., J.Biol.Chem. 1987, 262, 17294; Hynes, Cell 1987, 48, 549; Ruoslahti, Ann. Rev. Biochem. 1988,
57, 375. It has also been proposed that the receptor affinity for its peptide ligand may be altered as the stereoconformation, or three-dimensional shape, of the peptide is restricted, typically by cyclization. Pierschbacher and Ruoslahti, PCT International Publication WO 89/05150 (1989). However, the publication states that the cyclic peptide of the invention (see Figure 2 and Example V) was ineffective in inhibiting attachment to fibronectin.
A limited number of compounds containing sequences of natural amino acids or derivatives other than RGD may also possess the capability for affecting cell adhesion. These non-RGD-containing peptides are not well characterized. See. Graf, J. et al., Cell 1987, 48, 989; Kloezewiak, M. et al., Biochemistry 1984, 12,
1767; Wayner, E.A., et al., J. Cell. Biol. 1989, 109, 1321.
All publications, patents and other reference materials to which reference is made in the present specification are incorporated herein by reference. SUMMARY OP THE INVENTION
The present invention relates to compounds having activity as cell adhesion modulators. Some of the compounds contain the amino acid sequence arginineglycine-aspartic acid (Arg-Gly-Asp or RGD). Others contain non-RGD sequences, including but not limited to the RCD sequence and "reverse orientation" forms of amino acid residues. The compounds, in one aspect, sufficiently mimic extracellular matrix ligands or other cell adhesion ligands so as to bind to cell surface receptors. Such receptors include integrin receptors, in general, including the fibronectin, collagen, laminin, LFA-1, MAC-1, p150,95, vitronectin and gpIIb/IIIa receptors. The novel compounds have been found to modulate cell adhesion by competing, for example, with ligands containing the appropriate amino acid sequence and by binding to ligand-directed receptors on cell surfaces. The cell adhesive protein, such as (but not limited to) fibronectin, is sufficiently inhibited from binding to the cell's receptor so as to prevent or reduce cell adhesion. Other uses include enhancing cell adhesion by using the compounds to attach cells to a surface, or by other promotion of cell adhesion. The useful compounds herein described function as cell-adhesion modulators.
One object of the present invention is to provide novel compounds which act to modulate cell adhesion. Another object of the present invention is to provide novel RGD-containing compounds which are capable of binding to a cellular receptor. Another object of the present invention is to provide novel non-RGD-containing compounds which contain one or more "reverse orientation" amino acid residues and which are capable of binding to a cellular receptor.
Another object of the present invention is to provide novel non-glycine containing, e.g., RCD-containing, compounds which are capable of binding to a cellular receptor.
Another object of the present invention is to provide new uses for known peptides containing the sequence RGD as cell adhesion modulators.
Another object of the present invention is to provide a novel method for modulating cell adhesion using novel compounds.
Another object of the present invention is to provide compounds having extraordinarily high potencies in modulating cell adhesion to integrin receptors, including specifically inhibition of cell adhesion to the fibronectin receptor. Thus, in one regard, the present invention includes compounds having an IC50 of less than about 500 μM as established in a U937 fibronectin adhesion assay; and in another regard, the invention includes compounds having an IC50 of less than about 100 μM in such assay. The invention also includes methods for obtaining (either in vitro or in vivo) such fibronectin receptor adhesion inhibition, and integrin receptor adhesion inhibition. The compounds of the present invention accomplish strong inhibition, at low concentrations, with an IC50 of less than about 500 μM, or alternatively less than about 100 μM. Another object of the present invention is to provide compounds having high potencies in modulating leukocyte adhesion to endothelial cells. Thus, in one regard, the present invention includes compounds having an IC50, of less than about 200 μM as established in a Jurkat-endothelial cell adhesion assay; and in another regard, the invention includes compounds having an IC50 of less than about 10 μM in such assay. The invention also includes methods for obtaining (either in vitro or in vivo) such leukocyte receptor adhesion inhibition. The compounds of the present invention accomplish strong inhibition using disclosed compounds, at low concentrations, with an IC50 of less than about 200μM, or alternatively less than about 10 μM.
Another object of the present invention is to provide novel compounds, formulations, and methods which may be used in the study, diagnosis, treatment or prevention of diseases and conditions which relate to cell adhesion, including but not limited to rheumatoid arthritis, asthma, allergies, adult respiratory distress syndrome (ARDS), cardiovascular disease, thrombosis or harmful platelet aggregation, reocclusion following thrombolysis, allograft rejection, neoplastic disease including metastasis of neoplastic growth, wound healing, Type I diabetes, inflammatory and immunoinfiammatory conditions including ophthalmic inflammatory conditions and inflammatory bowel disease (e.g., ulcerative colitis and regional enteritis), and autoimmune diseases.
Another object is to provide derivative compounds, such as, but not limited to, antibodies and anti-idiotype antibodies to the compounds disclosed and claimed in order to study, diagnose, treat or prevent diseases and conditions which relate to cell adhesion, including but not limited to rheumatoid arthritis, asthma, allergies, ARDS, cardiovascular disease, thrombosis or harmful platelet aggregation, neoplastic disease including metastasis of neoplastic growth, wound healing, Type I diabetes, inflammatory conditions and autoimmune diseases.
BRIEF DESCRIPTION OF THE DRAWINGS
FIGURES 1a and 1b are diagrams representing chemical reactions for the manufacture of amide-linked cyclic peptides.
FIGURE 2 shows the results of an assay demonstrating cell adhesion inhibition by the representative cyclic polypeptide,
Figure imgf000011_0001
DETAILED DESCRIPTION OF THE INVENTION
The compounds of the present invention are those having the property of modulating cell adhesion.
While cell adhesion is required for certain normal physiological functions, there are situations in which cell adhesion is undesirable, or in which modulated cell adhesion is desirable.
Altered leukocyte-endothelial interactions are implicated in adult respiratory distress syndrome (ARDS). Here, the attachment of inappropriate cells to the lung lining induces an inflammatory response. This results in lung injury, ARDS and in some cases, asthma. Preliminary in vitro results show that such detrimental attachment, in which the leukocyte adheres to endothelial cells or the lung extracellular matrix, is mediated by RGD-containing protein and integrin receptors on the leukocyte. in this situation, peptides or other compounds with a binding affinity to integrin receptors are desirable as competitive antagonists and should be useful in treating ARDS and asthma.
Cell adhesion also contributes to metastasis of cancerous tumors. Metastasis has been called "the major underlying cause of death from cancer." Welch, et al., Intern. J. Cancer 1989, 43, 449. An RGD-containing peptide which would prevent cell adhesion to basement membrane components may be useful to prevent or eliminate metastasis. See, Humphries, M.J. et al., Science 1986, 223, 469; Liotta,
LA., Cancer Res. 1986, 46, 1 ; Roose, E., Biochem. Biophys. Acta. 1986, 738, 263. A peptide or other compound with suitable affinity for RGD receptors should likewise have anti-metastasis utility. Harmful blood clotting is also caused by inappropriate cell adhesion, particularly cell adhesion to the extracellular matrix. The attachment, spreading and aggregation of platelets on extracellular matrices are central events in thrombus formation. These events can be regulated by the family of platelet adhesive glycoproteins, fibrinogen, fibronectin, and von Willebrand factor. Fibrinogen functions as a cofactor for platelet aggregation, while fibronectin supports platelet attachment and spreading reactions. Von Willebrand factor is important in platelet attachment to and spreading on subendothelial matrices. Plow et al., PNAS-USA 1985, 82, 8057. A peptide or other compound which would function as an antagonist and bind to cell receptors which recognize the matrix glycoprotein RGD site would be beneficial as a thrombotic.
Other physiological conditions may be treated by stimulatory modulation of cell adhesion. Wound healing, for example, is undesirably prolonged when insufficient cell adhesion occurs. A peptide or other compound with suitable affinity for integrin receptors attached, for example, to a suitably positioned matrix or surface, may be able to promote beneficial cell adhesion and resultant wound healing by binding cells with the appropriate RGD-recognizing receptor. Also, in prosthetic implantation, such peptides or other compounds coating the prosthesis would provide a means for covering the prosthesis with a surface of cells. This cell surface would provide a surface compatible with the prosthesis, and thus minimize rejection that might otherwise occur due to stimulation of the immune system by the prosthesis itself. The cell adhesion modulation compounds of the present invention are represented in part by amino acid sequence formulas wherein the individual amino acids are represented by their standard three-letter or alternatively one-letter abbreviations as follows:
Three-letter One-letter
Amino Acid symbol symbol
Alanine Ala A
Arginine Arg R
Asparagine Asn N
Aspartic acid Asp D
Cysteine Cys C
Glutamine Gin Q
Glutamic acid Glu E
Giycine Gly G
Histidine His H
Isoleucine He I
Leucine Leu L
Lysine Lys K
Methionine Met M
Phenylalanine Phe F
Proline Pro P
Serine Ser S
Threonine Thr T
Tryptophan Trp w
Tyrosine Tyr Y
Valine Val V
Where abbreviations such as the foregoing are used without an indication of enantiomeric structure, either the l- or d-enantiomers may suitably be utilized, although the l-enantiomer is preferred for amino acids having the normal (non-reversed) peptide bond orientation, and the d-enantiomer is preferred for amino acids having a reversed orientation (see discussion below). Additional abbreviations used herein for analogs of amino acids and amino acid mimetic compounds include: β-Adamantylalanine (Ada)-Ala β-Alanine β-Ala (3-aminopropionic acid) α-Aminoisobutyric acid Aib (2-methylalanine) d-3-(2'-Naphthyl)alanine d-Nal
1-3-(2'-Naphthyl)alanine l-Nal
3,4-Dehydroproline Dhp
Gamma-aminopentane-1,5-dioic acid 3-Glu
Homoarginine homoR
Homocysteine homoC
Homoproline homoP
Homoserine homoS
4-Hydroxyproline Hyp
3-Mercaptopropionic acid Mpr (des-α-amino cysteine)
1 -β-Mercapto-β,β- PMP cyciopentamethylenepropionic acid
Nicotinyl lysine Nic-Lys
Norarginine norArg (H2NC(=NH)NH(CH2)2CH(NH2)CO2H) Norleucine Nile
Ornithine Orn
Penicillamine Pen
(β,β-dimethylcysteine) Pyroglutamic acid pyroGlu
Sarcosine Sar
3-Thioproline or
1-thiazolidine-4-carboxylic acid 3-thioPro
Additional abbreviations used herein include:
(1 ,1 -ACC): 1-Amino-1-cyclohexanecarboxylic acid
(Ada): 1-Adamantaneacetic acid
(Ada-CA): 1-Adamantanecarboxylic acid
(AMBA): 4-(Aminomethyl)benzoic acid
(AnB): 4-Aminobutyric acid
(AnC): 6-Aminocaproic acid
ARDS: Adult respiratory distress syndrome
BOC: tert-butyioxycarbonyl
BS: Bovine serum albumin
Cbz: Benzyloxycarbonyl
(CHA): 3-(Cyclohexyl)-L-Alanine
CHAc: 3-Cyclohexylacetic acid
Chx: Cyclohexyl ester
(CPA): Cyclohexylphenylacetic acid
DCC: dicyclohexylcarbodimide
DCM: Dichloromethane
DMF: Dimethylformamide
DIEA: Diisopropylethylamine
(DTC): L-5,5-dimethylthiazoiine-4-carboxylic acid
(1 -FCA):1-fluorenecarboxylic acid
(9-FCA): 9-fluorenecarboxyiic acid
(9-FA):9-fluoreneacetic acid
(Fm): Fluorenylmethyl ester
(FMOC) : Fluorenylmethyloxycarbonyl
FN: Fibronectin (HCA): Hydrocinnamic acid
ICAM-1 : Intercellular adhesion molecule 1
IC50: Inhibitory concentration, concentration at which adhesion is inhibited to 50% of control level
IPA: isopropyl alcohol
(3-Me-Ada): 3-Methyl-1-adamantaneacetic acid
(MTC): L-2-methylthiazolidine-4-carboxylic acid
(NACA): 3-Noradamantanecarboxylic acid
(Naph-Ac): 1-Naphthylacetic acid
(NB-Ac): 2-Norbornaneacetic acid
(norAda-CA): 3-Noradamantanecarboxylic acid
(PhAc): Phenylacetic acid
PyE: Pyroglutamic acid
(QC): Quinaldic acid
(TA): 3-β-Thienyl-L-Alanine
(TC): DL-thiazolidine-2-carboxylic acid
TEA: Triethylamine
TFA: Trifluoroacetic acid
(TCA): 1,4-thiazene-3-carboxylic acid
(TTC): L-tetrahydrothiazine-4-carboxylic acid
VLA: Very late activation antigens
A. Cyclic Normal Orientation Compounds
The first class of compounds of the invention is represented by the formula:
Figure imgf000017_0001
and pharmaceutically acceptable salts thereof, wherein
L1 and L2 are each, or are together, a residue of an amino acid, an amino acid analog or an amino acid mimetic having a functional group suitable for the formation of a cyclizing bridge between L1 and L2;
Z is a cyclizing moiety or bond between L1 and L2; 1 is optional and, where present, is selected from Leu, Tyr, Phe, Ile, Pro, 3-thioPro, TC, TCA, DTC, MTC, TTC, Gly, Ala, Val, norLeu, norVal, β-Ala, Trp, d-Nal, l-Nal, Sar and (Ada)-Ala;
2 is selected from Arg, homoArg, nitroArg, norArg, p-aminomethyl-Phe, N-alkylArg, N,N-dialkylArg, N,N'-dialkylArg, and N,N,N'-trialkylArg wherein the alkyl has one to four carbons (such as N-methylArg, N,N'-dimethylArg, and N,N-dimethylArg);
3 is selected from Gly, and Sar;
4 is selected from Asp, Glu, and the lower alkyl, aralkyl, aryl esters, OFm esters, O-cyclohexyl esters, O-benzyl esters, of the foregoing two amino acids;
5 is optional and, where present, is selected from Ser, Thr, Tyr, monohalo-Tyr, dihalo-Tyr, Trp, Ala, Val, Phe, o-, m-, and p-halo-Phe, p-nitro-Phe, Leu, and
Figure imgf000018_0001
Figure imgf000018_0002
Figure imgf000018_0003
Figure imgf000018_0004
wherein m is 2, 3 or 4;
6 is optional and, where present, is selected from Pro, 3-thioPro, 1,1-ACC, Dhp, DTC, TCC, TC, MTC, TCA, Hyp, homoPro and Phe, o-, m-, and p-halo-Phe, p-nitro-Phe, TA, d-Nal, l-Nal and isonipecotic acid; X1 and Y1 are each optional and, where present, are independently selected from 1 to 4 d- or l-amino acids and amino acid analogs (such as AMBA, AnC, AnB, and ω-amino-lower alkyl carboxylic acids);
X2 is an optional Nα-substituent selected from R' (including hydrogen) and R'CO-;
Y2 is an optional carboxyl-terminal substituent selected from -OR' (including hydroxyl), -NR'2 (including -NH2 and NHR'), -NHNH2 and -SR'; and wherein each R' is individually a pharmaceutically suitable substituent group, preferably one selected from hydrogen, from linear and branched, unsubstituted and substituted C1-C8 lower alkyIs, C2-C8 alkenyls,
C2-C8 alkynyls, C6-C14 aryls, C7-C14 alkaryls, C7-C14 cycloalkaryls and C3-C14 cycloalkyls, and, in the case of -NR'2, from cyclized groups forming (in an attachment with the nitrogen atom) a 5-8 membered heterocyclic ring optionally containing oxygen, nitrogen or sulfur as a further ring heteroatom. In the above structure I, a bridge is formed via the cyclizing moiety Z between L1 and L2 such that the compound is cyclized. It will be appreciated, both here and in structures depicted below in this disclosure, that the angular corners on connecting lines such as those shown in Structure I as linking Z with L1 and L2 are not intended, at the corners, to represent methylene residues. Therefore, each of L1 and L2 is chosen so as to provide a functional group suitable for the formation of a cyclizing bridge. As is discussed in more detail hereinafter, preferred functional groups include thiol, amino and carboxyl groups and their residues. Such a functional group may be provided by the side-chain, or by the terminal α- amino (in L1) or terminal carboxyl (in L2) group, of a natural amino acid residue or an analog thereof (including a homolog or stereoisomer thereof; see e.g. Table 1 above); or it may be provided by an "amino acid mimetic" moiety, i.e., an organic residue which includes a suitable cyclizing functional group and which is covalently linked through a peptide (i.e., amide) bond to the amino terminus (in the case of
L1) and/or to the carboxyl terminus (in the case of L2) of the residue sequence (NH2-)1 -2-3-4-5-6(-COOH).
The bridging residues L1 and L2 are, in one embodiment, each preferably selected from Cys, Pen, homoC, and, for L1, additionally Mpr and PMP. Each of these residues provides a side chain sulfhydryl group particularly suitable as a reactive precursor functional group for the formation of a cyclizing bridge between L1 and L2. Specifically, in the case of these residues, the cyclic bridge may be formed via oxidative coupling (loss of hydrogens) to form a disulfide bond between the side chain sulfur groups (in which the cyclizing moiety Z is a simple bond between the two sulfur atoms). This may also be depicted generally for compounds wherein, for example, both L1 and L2 are Cys residues as follows:
Figure imgf000020_0001
wherein (as in other similar depictions used herein) the side chain functional group portion (here a sulfur atom in both instances) appears in parentheses above the residue having the side chain.
It is particularly preferred in such embodiments that L1 and L2 be Cys or Mpr. The combination of L1 = Pen and L2 = Cys is, in embodiments containing the sequence Arg-Gly-Asp, not preferred in the practice of the present invention. The cyclizing bridge may also be formed via a hydrocarbon moiety, for example a (poly)methylene bridge moiety of the form -(CH2)n- where n is an integer of from 1 to 8, preferably 1 to about 4. One type of such bridge is represented below, wherein a cyclic compound with three methylene residues (representing Z) between two cysteine side-chain sulfur atoms (representing L1 and L2) is depicted:
Figure imgf000021_0001
See L Fieser and M. Fieser, Reagents for Organic Synthesis; J. Wiley and Sons: 1967; Vol. 1 , pp. 356-357; Fieser, J. Amer. Chem. Soc, 1959, 96, 1945. In other preferred embodiments of the invention, diketo and diamino linking groups
Z such as those of the form
Figure imgf000021_0002
and
Figure imgf000021_0003
wherein n is as defined above, may also conveniently be used to link, for example, side chain amino (as in Lys) or carbonyl (as in Glu or Asp) residues, respectively, on L1 and L2 to yield structures exemplified by
Figure imgf000021_0004
and
Figure imgf000021_0005
(Here, as elsewhere, the side chain functional groups (amino and carbonyl) on L1 and L2 are depicted in parentheses above the residue abbreviation.) The foregoing are but examples of suitable hydrocarbon-containing bridges, and other forms will also be apparent to those skilled in the art. Where the cyclizing moiety Z includes a portion with such a hydrocarbon form, it may be branched and may, where of a size appropriate to form a stable structure (particularly, where Z comprises two or more methylene moieties) also include one or more heteroatom-containing substituents including hydroxyl, amino, nitro, alkoxyl and halo substituents. Such substituents may be used to affect the solubility and/or biodistribution characteristics of the subject compounds. Aromatic or cycloalkyl hydrocarbon-containing bridge groups may also be utilized in the Z position, as for example diketo or diamino structures such as or
Figure imgf000022_0001
Figure imgf000022_0002
Simple hydrocarbon moieties of from 1 to about 4 carbons are preferred for hydrocarbon portions of such Z-moieties. The cyclizing bridge between L1 and L2 may also be formed via a monosulfide
(thioether) linkage, as exemplified below.
Figure imgf000022_0003
In such a case, L1 can be formed from a residue of α,β-dehydroalanine, and L2 from a residue of cysteine, which may be reacted to yield a lanthionine-like thioether linkage. In this regard, see Palmer, et a/., In Peptides-Chemistry, Structure Biology, Rivier & Marshall, Ed., Escom. Leider, 1990; pp. 616-618; and Jung, op. cit., pp. 865-869.
Alternatively, L1 and L2 may be chosen from other amino acids or analogs or amino acid mimetics which provide functional groups suitable for the formation of a side chain or as the amino- or carboxyl-terminus of an amino acid or analog residue. For example, L2 may be selected from Asp, Glu, or other amino acids or analogs which provide a suitable side chain carboxyl group for cyclic linkage, through formation of an amide bond in a condensation reaction, with an amino group (e.g., an Nα-amino group, or a side chain amino group as on, for example, Lys or Orn) on L1, provided, however, that the structure
Figure imgf000023_0001
is not included. The cyclizing moiety Z will in such cases be a simple bond between L1 and L2. Likewise, an amino acid residue L2 may provide a carboxyl group from its carboxyl terminus for amide linkage with either a side chain amino or α-amino group on an amino acid residue or analog L1; or the direction of the amide linkage may be reversed where L1 provides a side chain carboxyl group and
L2 provides a side chain amino group. Such structures may be exemplified as follows:
Figure imgf000023_0002
[wherein the side chain amino and carbonyl groups of L1 (Lys) and L2 (Asp) are directly bonded];
Figure imgf000024_0001
[wherein amide bond direction (from side chains of L1 and L2) is reversed];
Figure imgf000024_0002
[wherein the depicted amino terminus of L1 is directly bonded to the side chain carboxyl group of Glu (L2), or the depicted carboxyl terminus of L2 is directly bonded to the side chain amino group of Orn (L1); here, as elsewhere, the corners of the bent connecting line depicting these bonds do not represent methylene groups];
Figure imgf000024_0003
[wherein the depicted α-amino terminus at L1 is directly bonded to the depicted carboxyl terminus at L2, such that an amide bond is formed in the peptide
"backbone" of the compound.]
Analogs of amino acid residues may also be utilized for L1 and/or L2, as for example homologs (wherein a side chain is lengthened or shortened while still providing a carboxyl, amino or other reactive precursor functional group for cyclization), d-enantiomers of amino acids, analogs having variant side chains with appropriate functional groups (as for example β-cyanoalanine, canavanine, djenkolic acid, l-azaserine or gamma-methyleneglutamic acid), or other amino acid analogs (see for example the table of amino acid analogs and mimetic compounds given above).
Amino acid mimetic structures that are capable of being covalently bonded through an amide bond to a carboxyl and/or amino terminus of the residue sequence 1-2- 3-4-5-6, and which provide a suitable precursor functional group for cyclization
(through Z), may also be employed in positions L1 and/or L2. Such amino acid mimetic structures include organic species containing one or more heteroatoms including at least one functional group (preferably a reactive heteroatom-containing functional group) precursor suitable for cyclization. Examples include residues of the form
Figure imgf000025_0001
wherein n ranges from 1 to about 8, and preferably from 1 to 4, as for example residues of β-alanine and gamma-aminobutyric acid. (Where n is 1 , the amino acid glycine, rather than an α-amino acid mimetic, results.) Such a structure may, similar to the amino acids and amino acid analogs discussed above, be utilized as L1 (wherein the carbonyl group depicted above, formed for example from a carboxyl precursor, conveniently forms an amide (peptide-mimetic) linkage with the amino terminus of residue 2 or, if present, residue 1 , or it may be utilized as L2 (wherein the depicted amino group may engage in an amide linkage with the carboxyl terminus of the terminal residue 4, 5 or 6). If only one such linking residue L is used, it may serve as both L1 and L2 (and thereby include Z) in that cyclization can be achieved through formation of two amide bonds, one at each terminus of the sequence 1 -2-3-4-5-6. Such structures may be exemplified by the form
Figure imgf000026_0001
where the Nα-terminus and the carboxyl terminus of the sequence 1 -2-3-4-5-6 are bonded directly to, respectively, the carbonyl residue and the amino residue of the amino acid mimetic linking group depicted immediately above to form two peptidemimetic amide bonds. Likewise, cyclization can be achieved with such an amino acid mimetic linking moiety wherein a side chain functional group on a second linking moiety appended (as L1 or L2) to one terminus of the numbered sequence
1-2-3-4-5-6 (as for example an amino or carboxyl side chain group) engages in bonding to the mimetic moiety, and the mimetic moiety (as L2 or L1) cyclizes the compound to the remaining terminal residue of the numbered sequence. This may be exemplified by structures of the form
Figure imgf000026_0002
wherein L2 (as for example Asp) provides the side chain carbonyl group depicted in parenthesis, residue 1 provides the depicted Nα-terminal amino group, and the amino acid mimetic linking moiety
Figure imgf000026_0003
serves as L1.
Amino acid mimetic structures containing aromatic, cycloalkyl or other linking portions can also be utilized as L1 and/or L2, such as structures of the form or
Figure imgf000027_0001
Figure imgf000027_0002
Similarly, the heterobifunctional (keto-amino) structures depicted above may also serve as a Z-group in linking complementary side chain functional groups on L1 and L2 (e.g., a side chain amino group on L1 and a side chain carboxyl group on
L2) through two amide bond structures.
As will be discussed in more detail below, homobifunctional structures such as those of the form
Figure imgf000027_0003
and
Figure imgf000027_0004
where t is an integer of from 1 to about 8, and more preferably 1 to 3, may also serve individually as amino acid mimetic structures where a "reverse" amino acid sequence occurs within the structure 1-2-3-4-5-6 (see Structures II and III below).
In such cases, the numbered portion of such a structure will display two carboxyl termini or two amino termini (rather than one of each type ), and L1 and L2 may be selected together to be a homobifunctional linking moiety such as one of those depicted above. Other forms of cyclization include those wherein Z comprises a secondary amino structure (obtained, for example, upon reduction of the carbonyl portion of an amide linkage to a methylene group). For example, a secondary amino linking structure may be formed by reaction of an aldehyde functional group on L1 (e.g., an aldehyde formed by reduction of a side chain carboxyl group on Asp or Glu) or on L2 (e.g., an aldehyde formed from the terminal carboxyl group of L2) with a suitable amino group (on, e.g., the side chain or Nα- terminus of L2 or L1). Methods for the preparation and incorporation of such aldehyde-bearing residues in peptide structures are described by Fehrentz, J-A and Castro, B., Synthesis 1983, 676; and by Sasaki, Y. and Coy, D.H., Peptides 1987, 8, 119. Thus, where the carboxyl terminus of L2 is of the reduced aldehyde form and is bonded to the amino terminus of L1 in a reductive alkylation reaction, a peptide bond isostere structure (-NHCH2-) will result in the cyclic backbone of the product.
Other means of cyclization through appropriate choices of L1, L2 and Z will be recognized by those skilled in the art and are included in the scope of the present invention.
It is also specifically contemplated that the foregoing discussion of cyclizing moieties (Z), bridging residues (L1 and L2), substituents, amino acid analogs, amino acid mimetics, cyclization methods, and the like are applicable, mutatis mutandis, to the other structural formulas discussed hereinafter. Residue 1 in structure I is most preferably Leu; residue 2 is most preferably Arg; residue 3 is most preferably Gly; residue 4 is most preferably Asp; residue 5 is most preferably Ser; and residue 6 is preferably Pro or 3-thioPro. The sequence Leu-Arg-Gly-Asp-Ser-Pro is most preferred for residues 1 -2-3-4-5-6.
Also particularly preferred for residue 4 is Glu where residue 2 is nor Arg. Thus, the sequence Leu-norArg-Gly-Glu-Ser-Pro is also preferred for residues 1 -2-3-4-5-6.
X1 and Y1 are each optional in structure 1. Where present, they are preferably each independently selected so as to enhance the activity of the resultant compound and/or to preserve the compound against metabolism in, for example, the in vivo environment and thereby increase the effective half-life of the compound. In this regard, the use of one or more d-amino acids, most preferably at one or more terminal residue position in the compound (i.e., at the amino-most and/or carboxylmost residue position in X1 or Y1) are believed to stabilize the compound against metabolism by proteolytic or other enzymes in the body. Specific preferred residues for position X1 include Gly-, Phe-, Leu-, Asn-, Val-, Try-, 1- or 2-naphthylalanine, cyclohexylAla-, AMBA, AnC, AnB and ω-amino-lower alkyl carboxylic acids, Aib-, Ser-Tyr-Asn-, Ala-Thr-Val-, and p-chloro-Phe-. Preferred residues for position Y1 include -Ala, -Ala-Ser, -Ala-Ser-Ser, -Ala-Ser-Ser-Lys, -Ala- Ser-Ser-Lys-Pro, -Thr, -Thr-Phe, -Aib, -p-chioro-Phe, AMBA, AnC, AnB, ω-aminolower alkyl carboxylic acids, 1- or 2-naphythlalanine, and -(cyclohexylAla). Such X1 and Y1 groups are preferred also in the corresponding positions given in the structural formulas described hereinafter. Where a substituent X2 or Y2 incorporating R' other than hydrogen is used, e.g., acyl groups R'CO or amino groups of the form R'NH, preferred substituents include those derived from bulky compounds such as adamantaneacetic acid, adamantanecarboxylic acid, 1 - or 2-naphthylacetic acid, 2-norbornaneacetic acid, 3-noradamantanecarboxylic acid, 3-methyladamataneacetic acid, and 1- or 2-adamantylamine. Other suitable R' groups are those derived from acids such as
9-fluoreneacetic acid, 1-fluorenecarboxylic acid, 9-fluorenecarboxylic acid, phenylacetic, hydroxycinnamic acid, quinaldic acid, cyclohexylacetic acid, and 3-mercaptopropionic acid. Structures exemplified by the forms
and
Figure imgf000030_0001
Figure imgf000030_0002
Figure imgf000030_0003
such as those set forth with respect to residue 5 in Structure 1, represent derivatives of amino acid residues wherein the side chain hydroxyl group (shown in parentheses) is optionally substituted with a group of the form R' which can be other than hydrogen as defined above.
Where such substituted residues are employed in position 5 of structure 1, R' is preferably selected from hydrogen and C1 through C8 lower alkyls, particularly methyl and ethyl alkyl moieties.
A particularly preferred compound within the scope of structure I includes:
Figure imgf000030_0004
wherein the shorthand structure -Cys-, consistent with similar usage elsewhere in this description, represents a cysteine residue with its side chain sulfur atom separately depicted, and likewise the structure (S)-(S) represents a disulfide bond.
The compound depicted has been shown to be active in inhibiting cell adhesion to fibronectin.
Other preferred compounds within the scope of structure 1 include:
Figure imgf000030_0005
Figure imgf000031_0001
Figure imgf000032_0001
wherein similar shorthand notation, as elsewhere in this disclosure, has been utilized. B. Cyclic Reversed Orientation Compounds
A "reversed" or "retro" peptide sequence as disclosed herein refers to that part of an overall sequence of covalently-bonded amino acid residues (or analogs or mimetics thereof) wherein the normal carboxyl-to amino direction of peptide bond formation in the amino acid backbone has been reversed such that, reading in the conventional left-to-right direction, the amino portion of the peptide bond (as underlined below) precedes (rather than follows) the carbonyl portion:
Figure imgf000033_0001
wherein "*" represents a side chain group. See, generally, Goodman, M. and M.
Chorev, Accounts of Chem. Res. 1979, 12, 423. Compounds containing such sequences are referred to herein as "reversed" peptides.
The reversed orientation peptides described herein include (a) those wherein one or more amino-terminal residues are converted to a reversed ("rev") orientation (thus yielding a second "carboxyl terminus" at the left-most portion of the molecule), and (b) those wherein one or more carboxyl-terminal residues are converted to a reversed ("rev") orientation (yielding a second "amino terminus" at the right-most portion of the molecule). It will be seen that a normal peptide (amide) bond cannot be formed at the interface between a normal orientation residue and a reverse orientation residue:
Figure imgf000034_0001
Figure imgf000034_0002
(reverse orientation (normal orientation portion [structure a(1)]) portion [structure a(2)] Case (a): N-terminal residue(s) converted to reverse orientation.
Figure imgf000034_0003
Figure imgf000034_0004
(normal orientation (reverse orientation portion [structure b(1)] portion [structure b(2)] Case (b): C-terminal residue (s) converted to reversed orientation.
Therefore, certain reversed peptide compounds of the invention can be formed by utilizing an appropriate amino acid mimetic moiety to link the two adjacent portions of the sequences depicted above utilizing a reversed peptide (reversed amide) bond. In case (a) above, a central residue of a diketo compound, as shown by moiety 3 in Structure II below, may conveniently be utilized to link structures a(1) and a (2) with two amide bonds to achieve a peptidomimetic structure. In case (b) above, a central residue of a diamino compound, as shown by moiety 3 in Structure III below, will likewise be useful to link structures b(1) and b(2) with two amide bonds to form a peptidomimetic structure. With reference also to Structure I above, it will be seen that such central residues are most preferably utilized at residue position 3.
The reversed direction of bonding in such compounds will generally, in addition, require inversion of the enantiomeric configuration of the reversed amino acid residues in order to maintain a spatial orientation of side chains that is similar to that of the non-reversed peptide. The configuration of amino acids in the reversed portion of the peptides is preferably d, and the configuration of the non-reversed portion is preferably I. Opposite or mixed configurations are acceptable when appropriate to optimize a binding activity. 1. Diketo Cyclic Reversed Peptides
Thus, a second class of compounds of the invention is represented by the formula:
Figure imgf000035_0001
and pharmaceutically acceptable salts thereof, wherein:
L1 and L2 are each, or are together, a residue of an amino acid, an amino acid derivative or an amino acid mimetic having a functional group suitable for the formation of a cyclizing bridge between L1 and L2;
Z is a cyclizing moiety or bond between L1 and L2; 1 is optional, and where present, is of reversed orientation and is selected from
Sar, Leu, Tyr, Phe, lie, Pro, 3-thioPro, TC, TCA, DTC, MTC, TTC, Gly, Ala, Val, norLeu, norVal, β-Ala, Trp, l-Nal, d-Nal and (Ada)-Ala;
2 is of reversed orientation and is selected from Arg, nitroArg, homoArg, p-aminomethyl-Phe, norArg N-alkylArg, N,N-dialkylArg, N,N'-dialkylArg, N,N,N'-trialkylArg wherein the alkyl has one to four carbons (such as N-methyl, N,N'-dimethyl, and N,N-dimethyl); 3 is a moiety suitable for linking reversed-orientation residue 2 with residue 4, and is preferably of the form
Figure imgf000036_0001
wherein q and r are independently integers of 0, 1 or 2;
4 is selected from Asp, Glu, the lower alkyl, aralkyl, aryi esters, OFm esters, O-cyclohexyl esters, O-benzyl esters, of the foregoing two amino acids;
5 is optional and, where present, is selected from Ser, Thr, Tyr, monohalo-Tyr, dihalo-Tyr, Trp, Ala, Val, Phe, o-, m-, and p-halo-Phe, p-nitro-Phe, Leu and
Figure imgf000036_0005
Figure imgf000036_0002
Figure imgf000036_0003
Figure imgf000036_0004
wherein m Is 2, 3 or 4;
6 is optional and, where present, is selected from Pro, 3-thioPro, 1,1-ACC, Dhp, DTC, TCC, TC, MTC, TCA, Hyp, homoPro and Phe, o-, m-, and p-haio-Phe, p-nitro- Phe, TA, L-Nal, d-Nal, isonipecotic acid;
X1 and Y1 are each optional and, where present, are independently selected from sequences of from 1 to 4 d- or l-amino acids and amino acid analogs such as AMBA, AnC, AnB, and ω-amino-lower alkyl carboxylic acids; X2 is an optional substituent selected from R'2N- (including R'HN- and H2N-), R'O- (including hydroxyl), H2NNH- and R'S-; Y2 is an optional carboxyl-terminal substituent selected from -OR' (including hydroxyl), -NR'2 (including -NH2 and -NHR"), -NHNH2 and -SR'; and wherein each R; is individually a pharmaceutically suitable substituent group, preferably one selected from hydrogen, from linear and branched, unsubstituted and substituted C1-C8 lower alkyls, C2-C8 alkenyls, C2-C8 alkynyls, C6-C14 aryls, C7- C14 alkaryls, C7-C14 cycloalkaryls and C3-C14 cycloalkyls, and, in the case of -NR'2, from cyclized groups forming (in an attachment with the nitrogen atom) a 5-8 membered heterocyclic ring optionally containing oxygen, nitrogen or sulfur as a further ring heteroatom. In the above Structure II, cyclization may generally be achieved in the manners described above for Structure I. However, it is to be noted that the orientation of peptide bonding in the compounds of Structure II is, in residues to the left of residue number 3, reversed in direction such that a carboxyl "terminus" group is exposed in residue 2 or, if present, residue 1, rather than an amino group. Therefore, linking groups in position L1 may utilize for bonding to this carboxyl terminus an amino moiety, as for example a diamino moiety such as those in preferred structures of the form
-NH-(CH2)t-NH- wherein t is 1 , 2 or 3, which can simultaneously provide as (L2) a second amino moiety for cyclizing bonding to the normal-orientation carboxyl terminus of residue number 4 or, if present, 5 or 6.
Other forms of linking groups, including Z groups, and various combination of bonding between terminal functional groups and side chain function groups on L1 and L2, will be recognized by those skilled in the art in view of the present disclosure. In particular, the discussion above with respect to use of amino acid analogs and amino acid mimetic structures is applicable also here.
Residues L1, 1 , 2 and Y1 are preferably d-amino acids. Residue 1 in Structure II is most preferably absent or Sar, and is secondarily preferred to be d-forms of Leu, Tyr or Gly; residue 2 is more preferably Arg (particularly d-Arg); in residue 3, q and r are most preferably zero and R' is most preferably hydrogen, with lower alkyl also being preferred; residue 4 is most preferably Asp; residue 5 is most preferably Ser; and residue 6 is most preferably 3-thioPro. The sequence
Figure imgf000038_0001
wherein the subscript "rev" indicates a reverse-form residue, is especially preferred for residues 1 -2-3-4-5-6.
As with Structure I, X1 and Y1 are both optional, and are selected from the same constituents as those of X1 and Y1 of Structure I (with appropriate utilization of reversed orientation residues in X1). Optional substituent X2 is of a form suitable for bonding to, typically, a carboxyl terminus on X1 or L1.
For group 3 in Structure II, an especially preferred residue is
Figure imgf000038_0002
wherein s is an integer of from 1 to about 5, preferably 1 to 3, and most preferably
1. A particularly preferred compound class of Structure II is:
Figure imgf000039_0001
wherein R' in X1 and Y1 is preferably hydrogen or lower alkyl.
Specifically preferred compounds include:
Figure imgf000039_0002
Figure imgf000039_0003
wherein "Ada" represents adamantyl notwithstanding the abbreviation used throughout the specification;
Figure imgf000039_0004
Figure imgf000039_0005
Figure imgf000039_0006
As with Structure I, derivatives of the peptides of Structure II may be useful in the generation of antigens which, in turn, may be useful to generate antibodies. These antibodies will in some cases themselves be effective in inhibiting cell adhesion or modulating immune activity by acting as receptors for matrix proteins or other ligands, or, if anti-idiotypic, by acting to block cellular receptors.
2. Diamino Cyclic Reversed Compounds
The compounds of class III of the invention are represented by the formula:
Figure imgf000040_0001
and pharmaceutically acceptable salts thereof, wherein:
L1 and L2 are each, or are together, a residue of an amino acid, an amino acid derivative or an amino acid mimetic having a functional group suitable for the formation of a cyclizing bridge between L1 and L2; Z is a cyclizing moiety between L1 and L2;
1 is optional and, where present, is selected from Leu, Tyr, Phe, He, Pro, 3-thioPro, TC, TCA, DTC, MTC, TTC, Gly, Ala, Val, norLeu, norVal, β-Ala, Trp, l-Nal, d-Nal, (Ada)-Aia and Sar;
2 is selected from Arg, homoArg, nitroArg, norArg, p-aminomethyl-Phe, N-alkylArg, N,N-dialkylArg, N,N'-dialkylArg, and N,N,N'-trialkylArg, wherein the alkyl has one to four carbon atoms (such as N-methyl, N,N'dimethyl, and N,N-dimethyl); 3 is a moiety suitable for linking residue 2 with reversed-orientation residue 4, and is preferably of the form
Figure imgf000041_0001
wherein q and r are independently integers of 0, 1 or 2;
4 is of reversed orientation and is selected from Asp, Glu, and the lower alkyl, aralkyl, aryl esters, OFm esters, O-cyclohexyl esters, O-benzyl esters, of the foregoing two amino acids;
5 is optional and, where present, is of reversed orientation and is selected from Ser, Thr, Tyr, monohalo-Tyr, dihalo-Tyr, Trp, Ala, Val, Phe, o-, m-, and p-halo-Phe, p-nitro-Phe, and
Figure imgf000041_0002
Figure imgf000041_0003
Figure imgf000041_0005
Figure imgf000041_0004
wherein m is 2, 3 or 4;
6 is optional and, where present, is of reversed orientation and is selected from Pro, 3-thioPro, 1,1-ACC, Dhp, Hyp, DTC, TCC, TC, TCA, MTC, homoPro, Phe, o-, m- and p-halo-Phe, p-nitro-Phe, TA, l-Nal, d-Nal, and isonipecotic acid;
X1 and Y1 are each optional and, where present, are independently selected from 1 to 4 d- or l-amino acids and amino acid analogs (such as AMBA, AnC, AnB, and u-amino-lower alkyl carboxylic acids);
X2 is an optional Nα-substituent selected from R' (including hydrogen) and R'CO-; Y2 is an optional substituent selected from -R' (including hydrogen) and -COR'; and wherein each R' is individually a pharmaceutically suitable substituent group, preferably one selected from hydrogen, from linear and branched, unsubstituted and substituted C1-C8 lower alkyls, C2-C8 alkenyls, C2-C8 alkynyls, C6-C14 aryls, C7-C14 alkaryls, C7-C14 cycloalkaryls and C3-C14 cycloalkyls, and, in the case of -NR'2, from cyclized groups forming (in an attachment with the nitrogen atom) a 5-8 membered heterocyclic ring optionally containing oxygen, nitrogen or sulfur as a further ring heteroatom.
In the above Structure III, cyclization may generally be achieved in the manners described above with respect to Structures I and II. Further, it will be seen that the right-most 'terminus" exposed by residue number 4 (or, if present, 5 or 6) is an amino moiety rather than the carboxyl moiety of a non-reverse-orientation sequence, and that a linking group L1 bearing a carboxyl group and suitable for forming an amide bond with this right-most terminus will be appropriate. Such structures include those of the form
Figure imgf000042_0001
where q and r are as defined above; such a structure can, in view of its second carboxyl group, also serve as L1 by bonding to the amino terminus of residue number 2 or, if present, residue 1. Other forms of linking groups L1 and L2, and
Z groups, will be recognized in view, for example, of the discussion above with respect to Structures I and II. L2 may in such a case be selected from Mpr and
PMP. For group 3 in Structure ill, an especially preferred residue is -HN-(CH2),-NH-, wherein s is an integer of from 1 to about 5, preferably 1 to 3, and most preferably 1.
Residues 4, 5, 6, L2 and Y1 in Structure III are preferably d-amino acids. Residue 1 in Structure Hi is most preferably absent or Sar and is secondarily preferred to be Leu, Tyr or Gly; residue 2 is most preferably Arg; in residue 3, q and r are most preferably zero and R' is most preferably hydrogen, with lower alkyl also being preferred; residue 4 is most preferably d-Asp, residue 5 is most preferably d-Ser, residue 6 is most preferably d-Pro. The sequence
Sar-Arg-NH-(CH2)t-NH-d-Asp-d-Ser-d-Pro, where t is 1 , 2 or 3, is most preferred for residues 1-2-3-4-5-6.
As with Structures I and II, X1 and Y1 are both optional, and are selected from the same constituents as those of X1 and Y1 of Structures I and II (with appropriate consideration of reversed orientation residues in Y1). Optional substituent Y2 is of a form suitable for bonding to, typically, an amino terminus of Y1 or L2.
A particularly preferred compound of Structure III is:
Figure imgf000043_0001
More specifically, preferred compounds are:
Figure imgf000043_0002
Figure imgf000044_0001
As with Structures I and II derivatives of the peptides of Structure III may be useful in the generation of antigens which, in turn, may be useful to generate antibodies.
These antibodies will, in some cases, themselves be effective in inhibiting cell adhesion or modulating immune activity by acting as receptors for matrix proteins or other ligands or, if anti-idiotypic, by acting to block cellular receptors.
C. RCD-Containing Cyclic Compounds
Compounds of this class containing, for example, the sequence RCD were synthesized and found to be effective in modulating cell adhesion activity. This demonstrates that the residue glycine is not necessary to adhesion modulation activity and that residues such as cysteine may replace glycine in the peptide while maintaining activity. Moreover, it is an aspect of the invention that cysteine or other cyclizing residues are able in this regard to facilitate cyclization via disulfide or other side chain bridging.
The compounds of Class IV of the invention are represented by the formula:
Figure imgf000045_0001
and pharmaceutically acceptable salts thereof, wherein
L1 and L2 are each, or are together, a residue of an amino acid, an amino acid analog or an amino acid mimetic having a functional group suitable for the formation of a cyclizing bridge between L1 and L2;
X is a cyclizing moiety or bond between L1 and L2;
1 is optional and, where present is selected from Leu, Sar, d-Nal, l-Nal, Tyr, Phe, lie, Pro, 3-thioPro, TTC, TCA, DTC, MTC, TC, Gly, Ala, Val, norLeu, norVal, β-Ala, Trp, and (Ada)-Ala; 2 is selected from Arg, homoArg, nitroArg, norArg, p-aminomethyl-Phe, N-alkylArg, N,N-dialkylArg, N,N'-dialkylArg, and N,N,N'-trialkylArg wherein the alkyl has one to four carbon atoms (such as N-methyl, N,N'-dimethyl, and N,N-dimethyl);
4 is selected from Asp, Glu, the lower alkyl, aralkyl, aryl esters, OFm esters, O-cyclohexyl esters, O-benzyl esters, of the foregoing two amino acids;
5 is optional and, where present, is selected from Ser, Thr, Tyr, monohalo-Tyr, dihalo-Tyr, Trp, Ala, Val, Phe, o-, m-, and p-halo-Phe, p-nitro-Phe, Asn, Asp, Met and
Figure imgf000046_0001
Figure imgf000046_0002
Figure imgf000046_0003
Figure imgf000046_0004
wherein m is 2, 3 or 4;
6 is optional and, where present, is selected from Pro, 3-thioPro, TA, DTC, TTC, TC, MTC, TCA, 1,1 -ACC, Dhp, Hyp, homoPro, Phe, and Thr, Tyr, Val, d-Nal, l-Nal, CHA, Ser, Asn, Glu, o, m, and p-halo-Phe, and isonipecotic acid; 7 is optional and, where present, is Pro, 3-thioPro, TA, DTC, TTC, TC, MTC, TCA,
Ala, Gly, Ser, Phe, and Leu.
X1 and Y1 are each optional and, where present, are independently selected from 1 to 4 d- or l-amino acids or amino acid analogs (such as AMBA, AnC, AnB, and ω-amino-lower alkyl carboxylic acids). X2 is an optional Nα-substituent selected from R'- (including hydrogen) and R'CO-;and Y2 is an optional carboxyl-termlnal substituent selected from -OR' (including hydroxyl), -NR'2 (including -NH2 and -NHR"), -NHNH2 and -SR'; and wherein each R' is individually a pharmaceutically suitable substituent group, preferably one selected from hydrogen, from linear and branched, unsubstituted and substituted C1-C8 lower alkyls, C2-C8 alkenyls, C2-C8 alkynyls, C6-C14 aryls, C7- C14 alkaryls, C7-C14 cycloalkaryls and C3-C14 cycloalkyls, and, in the case of -NR'2, from cyclized groups forming (in an attachment with the nitrogen atom) a 5-8 membered heterocyclic ring optionally containing oxygen, nitrogen or sulfur as a further ring heteroatom. It is particularly preferred that residue number 1 be absent or Leu; that residue 2 be Arg; that residue L1 be Cys; that residue 4 be Asp; that residue 5 be absent or
Ser; that residue 6 be absent, Pro, 3-thioPro; that residue L2 be Cys. Thus, the structures
Leu-Arg-Cys-Asp-Ser-Pro-Cys,
Arg-Cys-Asp-(p-chloro-Phe)-(3-thioPro)-Cys, and
Arg-Cys-Asp-Pro-Cys
are particularly preferred for residues 1-2-L1-4-5-6-7-L2. The compounds
Figure imgf000047_0001
Figure imgf000048_0001
are particularly preferred.
As discussed above in conjunction with Structure I, linking residues L1 and L2 other than Cys, and Z groups other than simple bonds, may also be usefully employed in the context of Structure IV. It will be seen in this regard that the presence of residue numbers 2 and 4 on either side of L1 will typically require cyclization (through Z) to L2 through a side chain or other functional group on L1 that is not engaged in bonding to residues 2 or 4. Residue L2 may more generally be engaged in cyclization through either a terminal (typically, carboxyl) functional group or a side chain functional group. Preferred residues for position X1 include Gly-, Phe-, Leu-, Asn-, Val-, Try, 1 - or 2-naphthylalanine, cyclohexylAla-, AMBA, AnC, AnB, u-amino lower alkylcarboxylic acids, Aib-, Ser-Tyr-Asn-, Ala-Thr-Val-, and p-chloro-Phe-. Preferred residues for position Y1 include -Ala, -Ala-Ser, -Ala-Ser-Ser, -Ala-Ser-Ser-Lys, -Ala-Ser-Ser-Lys- Pro, -Thr, -Thr-Phe, -Aib, -p-chloro-Phe, AMBA, AnC, AnB, w-amino-lower alkyl carboxylic acids, 1- or 2-naphthylalanine, and -(cyclohexylAla).
Where a substituent X2 or Y2 incorporating R' other than hydrogen is used, e.g., acyl groups R'CO or amino groups of the form R'NH, preferred substituents include those derived from bulky compounds such as adamantaneacetic acid, adamantanecarboxylic acid, 1- or 2-naphthylacetic acid, 2-norbornaneacetic acid, 3-noradamantanecarboxylic acid, 3-methyladamataneacetic acid, and 1- or 2-adamantylamine. Other suitable R groups are those derived from acids such as from 9-fluoreneacetic acid, 2-fiuorenecarboxylic acid, 9-fluorenecarboxylic acid, phenylacetic, hydroxycinnamic acid, quinaldic acid, cyclohexyl acetic acid, and 3-mercaptopropionic acid. As with Structures I, II and III, derivatives of the peptides of Structure IV may be useful in the generation of antigens which, in turn, may be useful to generate antibodies. These antibodies will, in some cases, themselves be effective in inhibiting cell adhesion or modulating immune activity by acting as receptors for matrix proteins or other ligands or, if anti-idiotypic, by acting to block cellular receptors.
D. Examples
Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. As set forth above, all publications to which reference is made are incorporated herein by reference.
1. Synthesis and Formulation of Compounds
The "backbones," i.e., the peptide-bond linked portions of the cyclic compounds of the invention were generally synthesized using solid phase peptide synthesis, and then cyclized using a procedure which, where necessary, selectively removed protective groups from only the residues involved in cyclizing. In this way, the peptide sequence in the compound was not changed or lengthened, but the peptide was properly cyclized. Other methods for synthesis and cyclization are known in the art and may be employed in the preparation of the cyclic compounds and formulations disclosed herein.
Thus, peptide sequences in the compounds of this invention may be synthesized by the solid phase peptide synthesis (for example, BOC or FMOC) method, by solution phase synthesis, or by other techniques known in the art including combinations of the foregoing methods. The BOC and FMOC methods, which are established and widely used, are described in the following references:
Merrifield, J. Am.Chem.Soc, 1963, 88, 2149; Meienhofer, Hormonal Proteins and Peptides, CH. U, Ed., Academic Press, 1983, pp. 48-267;
Barany and Merrifield, In The Peptides, E. Gross and J. Meienhofer, Eds., Academic Press, New York, 1980, pp. 3-285. In the preferred solid phase synthesis method, a peptide of a desired length and sequence is produced through the stepwise addition of amino acids to a growing peptide chain which is covalently bound to a solid resin particle. Automated synthesis may be employed in this method.
In the preferred application of this method the C-terminal end of the growing peptide chain is covalently bound to a resin particle and amino acids having protected α-amino groups are added in the stepwise manner indicated above. A preferred α-amino protecting group is the tert-butyloxycarbonyl (BOC) group, which is stable to the condensation conditions and yet is readily removable without destruction of the peptide bonds or racemization of chiral centers in the peptide chain. At the end of the procedure the product peptide is cleaved from the resin, and any remaining protecting groups are removed by treatment under acidic conditions such as, for example, with a mixture of hydrobromic acid and trifluoroacetic acid, with trifluoromethane sulfonic acid or with liquified hydrofluoric acid. For the present cyclic peptides, hydrofluoric acid was typically used. The preferred steps for solid phase peptide synthesis using the symmetric anhydride method are shown in Table 1, below. The preferred steps for solid phase peptide synthesis using the active ester method are shown in Table 2, below. The preferred steps using the DCC method are shown in Table 3, below.
Table 1 : Solid Phase Peptide Synthesis (symmetrical anhydride method)
Step Reagent Vol.* (ml) Time (min)
1 DCM wash (3 times) 15 1 (per wash)
2 TFA-DCM 15 1.5
3 TFA-DCM 15 30
4 DCM wash (6 times) 15 1 (per wash)
5 TEA-DCM 15 1.5
6 DCM wash (6 times) 15 1 (per wash)
7 Symmetrical anhydride 10 120 or until
(0.8 meq) of BOC-amino monitoring shows acid in DCM complete reaction
8 Recouple if necessary
by repeating Steps 4-7
DCM wash (3 times) 15 1 (per wash)
* The volume given is for synthesis using 0.4 meq. of growing peptide chain on 1 gram of resin.
Table 2: Solid Phase Peptide Synthesis (active ester method)
Step Reagent Vol.* (ml) Time (min)
1 DCM wash (3 times) 15 1 (per wash)
2 TFA-DCM 15 1.5
3 TFA-DCM 15 30
4 DCM-wash (6 times) 15 1 (per wash)
5 DIEA-DCM (2 times) 15 1.5 (per wash)
6 DCM wash (6 times) 15 1 (per wash)
7 DMF wash (3 times) 15 1 (per wash)
8 BOC-amino acid active 7 2 hr or until
ester (0.8 meq) in DMF monitoring shows
complete reaction
9 Recouple if necessary by
repeating Steps 4-9
10 DMF wash (6 times) 15 1 (per wash)
11 DCM wash (3 times) 15 1 (per wash)
* The volume given is for the synthesis using 0.4 meq. of growing peptide chain on one gram of resin. Table 3: Solid Phase Peptide Synthesis
(DCC method)
Step Reagent Vol.* (ml) Time (min)
1 DCM wash (3 times) 15 1 (per wash)
2 50% TFA-DCM 15
3 50% TFA-DCM 15 20
4 DCM wash (3 times) 15
5 IPA wash (2 times) 15
6 DCM wash (3 times) 15
7 10% TEA-DCM 15
8 10% TEA-DCM 15 5
9 DCM wash (4 times) 15 1 (per wash)
10 BOC AA (1.2 meq.) 120
in DCM (or DMF)
11 DCC (1.2 meq., 0.5 M) in DCM
12 Recouple if necessary
by repeating Steps 4-11
13 DCM wash (2 times) 15 1 (per wash)
14 50% CH3OH-DCM wash 15 1
15 DCM wash (3 times) 15 1 (per wash)
16 IPA wash (2 times) 15 1 (per wash)
17 DCM wash (3 times) 15 1 (per wash)
* The volume given is for the synthesis using 0.6 meq. of growing peptide chain on one gram of resin.
Alternatively, peptide sequences or portions thereof may be synthesized in solution. See, e.g., M. Mutter and E. Bayer, In "The Liquid Phase Method for Peptide Synthesis"; E. Gross and J. Meienhofer, Eds.; The Peptides; Academic Press: 1980; pp. 285-332, for one example of peptide synthesis in solution. General strategies for preparing cyclic compounds of the invention typically involve selective protection of side chains or termini so that cyclization may be accomplished. Essentially, the peptide bond linked linear backbone of the compound is wholly or partially constructed using one type of protection means on potentially reactive groups (e.g., side groups) on residues not involved in cyclization, with the residues bearing functional groups to be cyclized being protected with another type ("orthogonol protection"). The moieties to be cyclized are then chemically revealed without disturbing the other protective groups. The revealed moieties are then appropriately activated and cyclized. Following this, the remainder of the peptide bond linked portion of the compound is completed (if the partial backbone was cyclized), deprotected, cleaved from the resin (when appropriate) and purified. In this way, functional groups not intended for cyclization are not prematurely exposed and cyclization occurs in the proper location.
For example, a peptide may be synthesized on a resin using FMOC protection on the side chains, or on the terminus or other portion, which will be used for cyclization. Preferred steps for solid phase peptide synthesis using such FMOC orthogonal protection are set forth in Table 4 below. The remainder of the potentially reactive groups of the peptide may be BOC protected. Upon cyclization, the FMOC-protected side chain/termini are deprotected, without deprotection of the BOC-protected moieties. Inappropriate cyclization or other modification is thereby prevented. If cyclization is to be performed prior to completion of the backbone construction, the temporary terminus should be blocked with a protecting group stable to the deprotection and cyclization conditions for the involved cyclized functional groups. Following cyclization, the temporary terminus is then deprotected and the peptide construction is completed.
Table 4: Solid Phase Peptide Synthesis
(FMOC method)
Step Reagent Vol.* (ml) Time (min)
1 DMC wash (2 times) 15 1 (per wash)
2 DMF wash (2 times) 15 1 (per wash)
3 Deprotect: 15 20
DMF: piperidine (4:1)
4 DMF wash (4 times) 15 1 (per wash)
5 DCM wash (3 times) 15 1 (per wash)
6 Symmetrical anhydride of 15 15
FMOC amino acid in DCM
(or DMF:DCM) (with 2-3
fold equivalent excess of
anhydride)
7 Add LO mL of 10% DIEA 1 15 or until
in DCM monitoring shows
coupling complete
8 Recouple if necessary
by repeating Steps 5-7
9 DMF wash (5 times) 15 1 (per wash)
10 IPA wash (5 times) 15 1 (per wash)
11 DCM wash (5 times) 15 1 (per wash)
* The volume given is for synthesis using 0.4 meq. growing peptide chain on one gram of resin. The compounds after cleavage from the resin are isolated and purified by means well known in the art. For example, the cleaved compound/resin mixture is washed in turn with several portions of diethyl ether and then extracted with several portions of aqueous acetic acid. The resin may then be discarded. The aqueous acetic acid extracts are combined, concentrated, resuspended in water and lyophilized. Following this, the crude compound can be purified by reversed phase high pressure liquid chromatography (HPLC), or by size exclusion chromatography, partition chromatography on polysaccharide gel media such as Sephadex G10 or G25, or counter current distribution. The composition of the final compound may be confirmed by amino acid analysis after degradation of the compound by standard means, by amino acid sequencing techniques, or by FAB-MS techniques. For the examples herein, compounds were usually purified by reverse-phase HPLC and subjected to amino acid analysis.
One important aspect in final purification is the removal of fluoride. Even small amounts of fluoride may alter the biological profile of the peptides. Generally, ion exchange chromatography, using AG3-4X acetate for example, to exchange the fluoride salt, is used. The subject compound is dissolved in water and passed over an acetate-form resin. The eluate is collected, and lyophilized to dryness. One skilled in the art will recognize that in some cases, such as, for example, where fluoride is removed through reverse-phase chromatography, or other methods, or where FMOC protection has been utilized without HF cleavage, fluoride removal using ion exchange chromatography is unnecessary.
Salts of carboxyl groups of the product compounds may be prepared in the usual manner by contacting the compound with one or more equivalents of a desired base such as, for example, a metallic hydroxide base such as, for example, sodium hydroxide; a metal carbonate or bicarbonate base such as, for example, sodium carbonate or sodium bicarbonate; or an amine base such as, for example, triethylamine, triethanolamine, and the like. In all such procedures and in other synthetic procedures provided herein, the pH should be kept below approximately
8 in order to avoid complications such as racemization, deamidation, peptide degradation or other undesirable side reactions.
Acid salts of the compounds may be prepared by contacting the polypeptide with one or more equivalents of the desired inorganic or organic acid, such as, for example, hydrochloric acid, acetic acid or citric acid.
Esters of carboxyl groups of the compounds may be prepared by any of the usual means known in the art for converting a carboxylic acid or precursor to an ester. One preferred method for preparing esters of the present compounds, when using the Merrifield synthesis technique described above, is to cleave the completed peptide sequence from the resin in the presence of the desired alcohol either under basic or acidic conditions, depending upon the resin. Thus the C-terminal end of the peptide when freed from the resin is directly esterified without isolation of the free acid. Alternatively, especially where the desired compound contains one or more glutamic acid or aspartic acid residues, C-terminal amino acid esters may be made using solution phase synthesis wherein the C-terminal residue bearing the desired ester functionality is incorporated.
Amides of the compounds of the present invention may also be prepared by techniques well known in the art for converting a carboxylic acid group or precursor to an amide. A preferred method for amide formation at the C-terminal carboxyl group is to synthesize the peptides by solid phase methods on an appropriate resin, for example a 4-methylbenzhydrylamine or a benzhydrylamine resin, and thereafter to cleave the polypeptide from a solid support with an appropriate acid. If the desired amide is to include a secondary or tertiary amino group, then the amide may be synthesized using solution phase techniques wherein an aminated C-terminal residue bearing the desired amide functionality is incorporated.
N-Acyl derivatives of an amino group of the present peptides may be prepared by utilizing an N-acyl protected amino acid for the final condensation, or by acylating a protected or unprotected functional group in the compound. Acylation may be carried out using standard acylating reagents such as acyl halides, anhydrides, acyl imidazoles, and the like prior to deprotection of the residue side chains.
The coupling reaction is generally carried out at 0° - 25º C, deprotection at room temperature, and cleavage at a reduced temperature of -5º to 0° C (especially with HF cleavage). The exact temperature for any particular reaction will, of course, be dependent upon the substrates, reagents, solvents and so forth, all being well within the skill of the practitioner. Illustrative reaction conditions for these processes may be gleaned from the examples.
The compounds of this invention may also be synthesized using any techniques that are known to those in the synthetic arts, for example, those described in
HoubenWeyl, Methoden Der Organischen Chemie; Georg-Thieme-Verlag: Stuttgart,
1974; pp. 1-806, or by recombinant DNA technology when only natural amino acids are used. Presented below are examples wherein cyclization of the present compounds is achieved with a disulfide linkage between side chain sulfur atom. Example 1 relates general procedures as applied to two representative RGD-containing peptides, while Examples 2 and 3 give procedures for preparing disulfide linked compounds according to Structures II and III above.
EXAMPLE 1
General Procedure for Synthesis of
Disulfide Linked Cyclic Compounds
Peptides of this class were synthesized and cyclized as the disulfide. Such peptides include:
Figure imgf000060_0001
and
Figure imgf000060_0002
experimental details for which follow.
All t-butyloxycarbonyl protected amino acids with chiral centers were of the L-configuration. Such protected amino acids included the t-butyloxycarbonyl derivatives of Ser(O-benzyl), Asp(β-cyclohexyl ester), Arg(tosyl), Cys (S-p-methylbenzyl) and Pen (S-p-methoxy benzyl).
Peptide Synthesis. Stepwise build up of the peptides depicted above on the BOC-Cys (S-p-methylbenzyl)-Merrifield resin was done automatically on a Beckman 990C peptide synthesizer (Beckman instrument Company, Palo Alto, California
94304) and using 2 equivalents of protected amino acids for each equivalent of peptide on-resin. Automated synthesis was performed according to the general procedures published with the synthesizer. Trifluoroacetic acid (50% in DCM) was used for deblocking. Triethyl amine (10% in DCM) was used for neutralization. Resin washing was accomplished by application of MeOH-DCM (50:50), isopropyl alcohol and methylene chloride at the other steps. Couplings (usually 120 minutes per coupling) were mediated by N,N'-dicyclohexyl-carbodiimide (DCC) in either DCM, DMF, or mixtures thereof depending on the solubility of the respective amino acid residue being coupled.
The coupled peptides were cleaved from the peptide resin by treatment with distilled anhydrous HF (10 ml/g peptide resin) in the presence of anisole (1 ml/g peptide resin) and dimethyl sulfide (0.5 ml/g) as scavengers. The reaction was carried out at -5ºC for one hour. After removal of the HF under reduced pressure, the resin was washed three times with diethyl ether. The peptide was extracted from the resin with 1 N acetic acid and then lyophilized.
Cyclization to the Disulfide Using Iodine. Approximately 2 grams of the respective cleaved peptides were dissolved in 500 ml 80% acetic acid. While the solution was stirring, a solution of l2, at a 10-fold molar excess over peptide, in glacial acetic acid was added dropwise over 30 minutes. The mixture was stirred for another hour. After this, ascorbic acid was added until the reddish solution turned colorless. The solution was then concentrated by evaporation (Rotavap, Buchi Corporation), and the residue redissolved in water. The aqueous solution was then lyophilized.
Purification. The crude cyclic peptide was purified using preparative RP-HPLC (Waters Delta Prep 3000, Millipore Corporation, Millford, Mass.) according to the manufacturer's general instructions. Such peptides can be generally purified using a linear gradient of increasing acetonitrile concentration in TEAP (1% triethyiamoronium phosphate, pH~2.3) as mobile phase. The collected fractions of pure peptide are reapplied to the HPLC column and then eluted again with 0.5% acetic acid to change the phosphate salt form of the peptide to the desired acetate form. The peptides were then dissolved in water, and fluoride was removed via ion exchange chromatography as described above if necessary. Highly purified fractions were pooled and Iyophilized.
EXAMPLE 2
Synthesis of Disulfide Linked, Diamino
Cyclic Reversed Peptides In this example, the following peptide is synthesized:
Figure imgf000062_0001
Solution phase BOC and FMOC methods are used in this synthesis. The product from each step prior to HF cleavage is purified by silica gel chromatography. The general approach is to synthesize the reversed form of the peptide and attach it to the partially protected diaminopropane moiety, followed with coupling amino acids in the normal orientation to the deprotected diaminopropane coupled to the reversed peptide segment. The peptide is then deprotected with HF, the resulting crude dicysteine containing product cyclized, and the disulfide compound purified. N-BOC-d-aspartic acid is protected with α-9-fluorenylmethyl ester, and the β- cyclohexyl ester is N-deprotected with 1 :1 TFA/DCM. The resulting ammonium trifluoroacetatec is coupled to N-BOC-O-benzyl-d-serine (1.05 eq.) using benzotriazol-1-yloxy-tris(dimethylamino)-phosphonium hexafluorophosphate (BOP reagent, 1.2 meq.), 1 -hydroxybenzotriazole hydrate (HOBt, 0.12 meq.), and diisopropylethylamine (DIEA, 4 meq.) in DMF. This dipeptide product is N-deprotected and coupled as above sequentially to N-BOC-d-proline and N-BOC-S-4-methylbenzyl-d-cystelne. The OFm ester of the aspartic acid residue is deprotected with 20% piperidine/DMF and the free carboxyiate product coupled to 1-(9-fluorenylmethyl-carboxamide)-2-amlnoethane with BOP activation. The product of this reaction is coupled sequentially to N-α-FMOC-N°-tosyl-1-(nor)arginine and N-BOC-S-4-methylbenzyl-1-cysteine, using 20% piperidine/DMF deprotection and activation with BOP. After a final deprotection with HF, the resulting cysteine sulfhydryl are cyclized in an iodine oxidation procedure to produce the final product depicted above.
EXAMPLE 3
Synthesis of Disulfide Linked,
Diketo Cyclic Reversed Peptides
In this example, the following peptide is synthesized:
Figure imgf000063_0001
Solution phase BOC and FMOC methods are used in this synthesis. The product from each step prior to HF cleavage is purified by silica gel chromatography. As can be seen, this peptide contains reversed (rev) forms of d-Cys and d-Arg. The general approach is to synthesize the l-configuration segment of the peptide and then attach, through an amide bond, a residue of malonic acid mono-t-butyl ester. The synthesis is then continued by coupling amino acids in the reversed orientation to the deprotected malonate. The compound is then deprotected with HF, the resulting crude dicysteine-containing product cyclized and the disulfide compound purified.
BOC-Gly (O-benzyl) ester is N-deprotected with 1:1 trifluoroacetic acid/methylene chloride. The resulting ammonium trifluoroacetate is coupled to N-BOC-S-4-methylbenzyl-1-cysteine (1.05 eq.) using benzotriazol-1-yloxy-tris(dimethylamino)-phosphonium hexafluorosphosphate (BOP reagent, 1.2 eq.), 1-hydroxybenzotriazole hydrate (HOBt, 0.12 eq.), and diisopropylethylamine (DIEA, 4 eq.) in dimethylformamide (DMF). This dipeptide product is N-deprotected and coupled as above sequentially to the following compounds: N-BOC-l-proline, N-BOC-O-benzyl-l-serine, N-BOC-(β-cyclohexyl ester)-1-aspartic acid, and malonic acid mono-t-butyl ester.
The t-butyl ester of the malonate is deprotected with 1 :1 TFA/DCM and the freed carboxylate product is activated (using the BOP coupling procedure described above) and coupled to Ng-tosyl-d-arginine, t-butyl ester (free Nα-amine). The t-butyl ester of the resulting arginine-containing product is deprotected with 1 :1 TFA/DCM and the free carboxylate product is again activated and coupled to S-4-methylbenzyl-d-cysteine with BOP reagent.
The product of this reaction is deprotected first with 1 :1 TFA/DMC and then treated with HF, and the resulting cysteine sulfhydryl are cyclized using the iodine oxidation procedure to produce the compound depicted above. Presented below are examples of peptides which were cyclized using an amide bridge. Example 4 is of a side chain-to-side chain amide bridge wherein the δ-carboxyl group of Glu was condensed with the ε-amino group of Lys. Example 5 is of a side chain-to-backbone amide bridge wherein the terminal α-amino group of Gly was condensed with the β-carboxyl group of Asp. In both of these examples, the amino acid backbone was fully assembled, and then cyclized, on a resin.
Example 6 shows cyclization using an amide bridge as an Intermediate step. The amino acid backbone is partially assembled and then cyclized using an amide bridge. After assembly of the amide bridge, the amino acid chain is completed.
EXAMPLE 4
Synthesis of Amide Linked Cyclic
Compounds (Side Chain-Side Chain Linkage)
In this example, the following compound was synthesized:
Figure imgf000065_0001
All amino acids and amino acid derivatives were purchased from BACHEM
(Torrance, California). 9-Fluorenylmethanol and DCC were obtained from Sigma
Chemical Co. (St. Louis, Missouri). Diisopropylethylamine and 4-(dimethylamino)-pyridine were obtained from Aldrich (Milwaukee, Wisconsin). Unless otherwise noted, other reagents were of analytical grade and used without further purification.
All residues were linked by the solid phase method using BOC protection. The side chain carboxyl groups of Asp and Glu were protected as fluorenylmethyl esters and the ε-amino group of Lys and α-amino group of Gly were protected as N-FMOC. The amide bridge between the two side chains (on Glu and Lys) was synthesized while the peptide was bound on the resin. This procedure is represented by Figure 1a. (a) Preparation of N-BOC-O-9-fluorenyimethyl omega-esters of aspartic and glutamic acids.
The N-BOC-O-9-fluorenylmethyl omega-esters of aspartic and glutamic acids were prepared following the procedure as generally described by R. Bolin, C.T. Wang, and A.M. Felix, Organic Preparations and Procedures Intern. 1989, 21, pp. 67-74, with certain modifications.
N-BOC-Oß-9-fluorenylmethyl asparate. 8.31 g (25.7 mmol) of N-BOC-Oα-benzylaspartate and 4.80 g (24.5 mmol) of 9-fluorenylmethanol were dissolved in 150 ml DCM. The solution was chilled in an ice bath. 30 mg (0.24 mmol) of 4-(dimethylamino)pyridine was added to the solution followed by addition of 5.31 g (25.7 mmol) DCC in portions, over 10 minutes. The resulting mixture was stirred for one hour with continued cooling. The precipitated n,n'-dicyclohexylurea was removed by filtration and the filtrate was diluted with 250 ml DCM. This solution was extracted with (in order) 10% citric acid (2 × 50 ml), H2O (1 × 50 ml), 2.5% NaHCO3 (2×50 ml), H2O (1 × 50 ml), brine (1 × 50 ml). The solution was then dried over MgSO4, and concentrated to an oily residue. Recrystallization from methanol/ether/petroleum ether (1 :3:10) yielded 10.85 g (84%) N-BOC-Oα-benzyl-Oβ-fluorenylmethyl-aspartate, with a melting point of 74-77 °C. 5.5 g (10.9 mmol) of the above product was then dissolved in 150 ml warmed methanol, and hydrogenated over 300 mg of 20% Pd(OH)2/C for 1.5 hr at room temperature and a pressure of 35-40 psi. The catalyst was filtered off and the solvent was evaporated in vacua. The residual oil was redissolved in 200 ml diethyl ether and extracted with (in order) 1% NaHCO3 (3 × 50 ml), H2O (1 × 50 ml), 5% citric acid (2 × 50 ml), and brine (1 × 50 ml). The ether layer was dried over MgSO4 and concentrated. Recrystallization from diethyl ether/petroleum ether yielded 3.53 g of N-BOC-Oβ-9-fluorenylmethyl aspartate, with a melting point of 135-137° C. N-BOC-O-fluorenylmethyl-glutamate (gamma ester). N-BOC-Oα-BENZYL¬
GLUTAMATE (4.5 G, 13.3 mol) and 9-fluorenyl-methanol (2.5 g, 12.5 mmol) were dissolved in 100 ml DCM. The solution was stirred and chilled in an ice bath. To the solution, 15.5 mg (0.13 mmol) of 4-(dimethylamino)-pyridine and 2.75 g (13.3 mmol) of DCC were added, and the resulting mixture was stirred for 4 hr with continued cooling. Precipitated N,N'-dicyclohexylurea was filtered off and filtrate was diluted with 200 ml DCM. The solution was extracted and treated in the same manner as was for the aspartate described above. This yielded N-BOC-Oα-benzyl-O-fluorenylmethylglutamate (gamma ester) (4.2 g), with a melting point of 97-99.5°C. 4.0 g (7.75 mmol) of the foregoing product was hydrogenated over 125 mg of 10%
Pd/C in 200 ml mixture of MeOH/EtOH/IPA (2:1 :1) for 2 hr at room temperature at 40 psi. The reaction mixture was filtered to remove the catalyst, and concentrated to an oily residue. The residue was then mixed with 150 ml diethyl ether and combined aqueous layers were back-extracted with diethyl ether (2 × 40 ml). The combined ether layers were dried over MgSO4, filtered, and concentrated to a white form. N-BOC-O-fluorenylmethylglutamate (gamma ester) (2.3 g) was obtained by recrystallizing the crude residue from diethyl ether/petroleum ether (1 :10), melting point 123.5-126°C.
(b) Synthesis of protected EGRGRDSPKSS peptide sequence. Synthesis of the above peptide was performed using, in conjunction, an automated peptide synthesizer (System 990, Beckman Instruments, Inc., Palo Alto, California) and a manual peptide synthesis apparatus (S.C. Glass Tech, Bonica, California).
BOC-Ser(Bzl)OCH2-PAM resin (1.0 g, 0.75 mmol) from Applied Biosystems (Foster City, California) was used as the starting resin. The following amino acids were used in the synthesis: BOC-1-Ser(benzyl), BOC-1-Lys(Nε-FMOC), BOC-1-Pro, BOC-1- Asp(O-benzyl), BOC-Gly, BOC-Arg(Nβ-tos), and BOC-Glu(Fm). Excess amino acid (2-3 fold) was used for each coupling. The peptide chain was constructed on the Beckman peptide synthesizer using BOC chemistry with the stepwise addition of each amino acid following the standardized cycle similar to that presented in Table 3, with adjustments for scale. 50% TFA in DCM, 5% DIEA in DCM, and 0.5 M of
DCC in DCM were used as deprotecting agent, neutralizer, and activating agent, respectively, for each coupling.
(c) Capping of peptide sequence.
Following the removal of the BOC group from the N-terminal Glu with 50% TFA in DCM, and neutralization with 5% DIEA in DCM, the protected peptide on resin was transferred to a manual apparatus for the terminal acetylation, or "capping". The
N-terminal deprotected side chain protected peptide on resin was washed with MeOH (2 × 1 min), DCM (3 x 1 min); neutralized with 5% DIEA again in DCM (1 ×
1 min, 1 × 20 min); washed with DCM (3 × 1 min); and acetylated (capped) with
50% Ac2O in DCM (1 min wash, 20 min acetylation). The peptide then was cyclized by forming an amide linkage between the δ-carboxyl group of Glu and the ε-amino group of Lys by the general procedure below.
(d) General cyclization procedure for formation of the amide bridge.
After the construction of the peptide chain, the amidating cyclization was carried out according to the following protocol. Filtering was performed between each step: (1) MeOH (2 × 1 min); (2) DCM (3 × 1 min); (3) 20% piperidine in DMF, wash for 1 min, and deprotection for 20 min; (4) DMF (2 × 1 min); (5) MeOH (2 × 1 min);
(6) DCM (3 × 1 min); (7) BOP reagent (4 equiv.) in DMF (20 ml/gram of resin), stir for 2 min, and add DIEA (2% of DMF volume), stir for 4 hrs (the completion of the cyclization reaction was monitored by the ninhydrin test; if the reaction was judged incomplete at 4 hrs, the reaction was continued until the ninhydrin test was negative); (8) DMF (2 × 1 min); (9) DCM (2 × 1 min); (10) MeOH (2 × 1 min).
The final cyclic compound was removed from the resin by treatment with HF in the presence of 10% anisole for 1 hr at 0ºC. After evaporation of the HF, the residue was washed with diethyl ether and extracted from the resin with 5% HOAc in H2O. The aqueous extract was lyophilized to yield the crude peptide (730 mg). (e) Purification.
The compound was purified using a Waters Delta Prep 3000 system (Waters, Milford, MA) equipped with a C16 column, using a linear gradient of increasing acetonitrile concentration in TEAP (pH 2.2 to 2.4) as the mobile phase. The collected fractions of the pure compound were pooled and applied again to the C18 column. This time the sample was eluted with 0.5% HOAc to convert the phosphate salt form of the peptide to the desired acetate form. The pure peptide fractions were pooled, concentrated in vacuo, redissolved in water and lyophilized to give 92.9 mg of peptide, 98.7% HPLC purity, white powder.
EXAMPLE 5
Synthesis of Amide-Linked Cyclic Compounds
(Backbone-Side Chain Linkage) In this example, the following compound was synthesized:
Figure imgf000070_0001
The manual synthesis of the above compound began with 4-methyibenzhydryiamine resin (2.0 g, 1.4 mmol) from CBA, Inc. (Boulder, Colorado). The peptide chain was assembled by using the BOC procedure described in the synthesis of the compound of Example 4 above. BOC-1-Asp(Fm), BOC-1-Pro, BOC-1-Ser(Benzyl), BOC-Gly, BOC-1-Arg(Ng-tosyl) and N-FMOC-Gly were used in the synthesis.
The cyclization between the terminal amino group of Gly and the β-carboxyl group of Asp7 was performed according to the general amide cyclization procedure described in the preceding Example 4.
The cyclic compound then was cleaved from the resin by HF and 10% anisole for 1 hr at 0°C. Following evaporation of the HF, the mixture was washed with diethyl ether (ether layer discarded) and extracted with 1 N HOAc. The aqueous extract was lyophilized to yield 1.23 g of the crude compound.
Purification of the compound was achieved using a Waters preparative HPLC system with a C18 column, following the method described in the preceding example. Yield was 678 mg pure product compound, HPLC purity of 99.7%, white powder.
EXAMPLE 6
Synthesis of Amide Linked Cyclic Compounds
(Cyclization Prior to Complete Chain Assembly) In this example, the following compound Is synthesized:
Figure imgf000071_0001
Here, cyclization can be performed when the chain is partially assembled, using orthogonal protection methods as described above. Figure 1b is a diagram representing suitable procedures. The chain is partially assembled using the DCC method (Table 3) with primarily BOC protection until the BOC-Lys(FMOC), representing L1 in the eventual product compound, is added. The BOC-Glu(Fm) and BOC-Lys(FMOC) are substituted for BOC-Glu(Chx) and BOC-Lys(Cl-Cbz). At this time the chain assembly is interrupted and the compound is cyclized while bound to the resin. Cyclization proceeds by treating the compound with 20% piperidine in DCM to deprotect the Glu and Lys residues, followed by filtering and washing, and by then by reaction with BOP in DMF and DIEA until the compound on the resin is ninhydrin negative. The amino-terminal glycine residue is then added to the cyclized compound, and the resulting product cleaved from the resin and worked up as described generally in the foregoing examples.
EXAMPLE 7
Synthesis of Cyclic Disulfide Compounds
Containing RCD
In this example, the following compound was prepared:
Figure imgf000072_0001
All amino acids, amino acid derivatives and amino acid mimetic were purchased from BACHEM (Torrance, California). DCC was from Sigma Chemical Co. (St.
Louis, Missouri). Trifluoroacetic acid was from Halocarbon Co. (New York, New York). Triethyl-amine was from Fisher Scientific (Fair Lawn, New Jersey). Other reagents were obtained from conventional sources and of analytical grade.
Ail peptides were synthesized by the solid phase method with a Beckman automated peptide synthesizer (System 990, Beckman Instruments, Inc., Palo Alto,
California) using BOC chemistry.
Attachment of N-BOC-S-p-methylbenzyl-1-cysteine (BOC-Cys(4-MeBzl)) to the chloromethylpolystyrene resin (Merrifield resin) was done in the presence of potassium fluoride. BOC-Cys(4-MeBzl) (0.9 molar eq.) was reacted with swelled Merrifield resin (Bio-Rad lab., Richmond, California) (1.0 molar eq.) in DMF in presence of KF (1.8 molar eq.) at 80°C for 16 hr. The resin then was filtered, washed, and dried. The molar substitution of the resin was determined by weight. The sequential elaboration of the peptide chain on the BOC-Cys(4-MeBzl) resin was carried out stepwise using the BOC procedure according to the procedure in Table 5, below. At the end of the synthesis the N-terminal BOC protecting group was removed using TFA:DCM (1:1) for 30 min.
TABLE 5:
Solid Phase Peptide Synthesis
For RCD-Containing Compounds
(TFA deprotection/DCC coupling)
Step Reagent Vol*(ml) Time**(min)
1 DMC wash (3x) 20 1
2 TFA-DCM (1 :1) 20 1
3 TFA-DCM (1:1) 20 2
4 DCM wash (3x) 20 1
5 MeOH wash (2x) 20 1
6 DCM wash (3x) 20 1
7 DIEA-DCM (1 :9) 20 1
8 DIEA-DCM (1 :9) 20 5
9 DCM wash (3x) 20 1
10 MeOH wash (3x) 20 1
11 DCM wash (3x) 20 1
12 BOC-AA (3.2 mM, 2-fold excess
in DCM plus DCC in DCM (0.5 M) 1 20
13 DCM wash (2x) 20 1
14 DCM-MeOH (1 :1) (2x) 20 1
15 DIEA-DCM (1 :9) 20 1
16 MeOH wash (2x) 20 1
17 DCM wash (2x) 20 1
18 Ac2O in DCM (1 :3) 20 2
19 DCM wash (3x) 20 1
20 MeOH wash (2x) 20 1
The volume given is for the synthesis using 2 g of resin with the substitution of 0.8 mM/g of resin.
All times given in repeated wash steps are "per wash". Synthesis and Cleavage. For the synthesis of the title compound, the following amino acids were used: N-BOC-1-proline, N-BOC-l-serine(benzyl), N-BOC-1-aspartic acid-β-cyclohexyl ester, N-BOC-1-cysteine-(4-methylbenzyl), and N-BOC-Ng-tosyl-1-arginine. Starting with 2.0 g (1.6 mmol) N-BOC-Cys(4-MeBzl) resin and through the stepwise elaboration of the protected peptide chain, 3.4 g of the peptide resin was obtained. The peptide was removed from the resin by treatment with HF in the presence of 10% anisole and 5% of dimethylsulfide for 1 hr. at 0ºC. Following evaporation of the HF, the peptide resin residue was washed in turn with diethyl ether (discarded ether wash) and extracted with 5% HOAc in H2O (50 ml × 4). The aqueous acetic acid solution was lyophilized to yield 780 mg of the crude, noncyclic peptide (Ellman test positive, Stewart and Young, Solid Phase Peptide Synthesis, 2nd ed. p. 116).
Cyclization. The formation of the intramolecular disulfide bridge was accomplished by using the iodine oxidation method. The crude peptide was dissolved in 300 ml of 80% acetic acid in H2O. The peptide solution was titrated with l2-glacial acetic acid (saturated) until the solution turned light brown in color, and stirred for 1 -2 hr. at room temperature. The excess iodine was removed by adding ascorbic acid-water solution. The peptide solution was then concentrated in vacuo. The residue was redissolved in water and lyophilized to obtain the crude cyclic compound.
Purification. The compound was purified on a 25 × 2.5 cm SP Sephadex c-25 (Pharmacia LKB Biotechnology Inc., Piscataway, NJ) column. The column was first equilibrated with 10 mM NH4OAc buffer (pH 3.5) The compound was eluted with NH4OAc buffer in a linear gradient of increasing NH4OAc concentration with 10-300 mM (pH3.5-6.5). The fractions which contained the pure product were pooled and Iyophilized. The dried residue was redissolved in H2O and Iyophilized thrice to ensure the removal of the NH4OAc salt to yield 106 mg product (HPLC, 95% pure).
Other RCD Peptides. in a similar fashion, the following compounds of the invention are also synthesized:
Figure imgf000076_0001
Figure imgf000077_0001
The peptides containing D-Nal are purified using a Waters Delta Prep 3000 system (Waters, Milford, Massachusetts) equipped with a C18 column, using a linear gradient of increasing acetonitrile concentration in TEAP (pH 2.2 to 2.4) as the mobile phase. The collected fractions of the pure peptide are then eluted again with 0.5% HOAc in the same HPLC system to exchange the phosphate salt form of the peptide to the desired acetate form.
Example 8
Synthesis of Peptide Bond Isostere Compounds
Cell adhesion of modulation compounds containing peptide bond isostere structures of the following formulas were synthesized:
Figure imgf000078_0001
BOC amino acid aldehydes used in this synthesis were prepared by the method of J-A Fehrentz and B. Castro, Synthesis 1983, 676. The introduction of the pseudo CH2NH peptide bond was done by utilizing the reductive alkylation reaction in solid phase (Y. Sasaki and D.H. Coy, Peptides, 1987, 8, 119.
Preparation of BOC-Glycinal. Synthesis of BOC-glycinal from BOC-glycine involved the steps of forming the N-methoxy-N-methyiamide of BOC-protected glycine, followed by reduction to the aldehyde compound. Since the aldehyde was highly reactive it was prepared immediately before use. 8.75 g (50 mmol) of BOC-glycine dissolved in 150 ml DCM and 6.95 ml (50 mmol) of TEA was added to the solution, and stirred. 17.42 g (50 mmol) BOP reagent (Richelieu Biotechnologies, QC, Canada) was added, followed a few minutes later with O,N-dimethyl-hydroxylamine hydrochloride (5.6 g, 55 mmol) and TEA (7.67 g, 55 mmol). The reaction was complete in 60 min, and the result was verified by
TLC monitoring. A small amount of TEA was used to neutralize the mixture (adjust the pH to above 7.0) in order to allow the reaction to go to completion. The mixture was diluted to 500 ml with DCM. The solution was washed in turn with 3N HCI (3 × 100 ml), saturated NaHCO3 (3 × 100 ml), and brine (3 × 100 ml). The DCM layer was dried over MgSO4 and concentrated to obtain the crude product.
Recrystallization from water afforded 5.85 g Nα-(BOC)-glycine N-methoxy-N-methylamide (m.p. 92-95ºC). This product was dried thoroughly in vacuo over P2O5 before use in the following reaction.
To obtain the BOC-glycinal (BOC-NH-CH2-CHO), LiALH4 (569.3 mg, 15 mmol) was added to a stirred solution of the above compound (2.18g, 10 mmol) in 100 ml anhydrous THF (Aldrich). Reduction was completed in 15 min. The mixture was hydrolyzed with a solution of KHSO4 (2.72 g, 20 mmol) in H2O (50 mL). Then, the THF was evaporated, and the aqueous solution was extracted with diethyl ether (1 × 300 ml, 2 × 100 ml). The combined diethyl ether layers were washed in turn with 3N HCI (3 × 70 ml), 5% NaHCO3 (3 × 50 ml), brine (1 × 70 ml), and dried over
MgSO4. The solution was concentrated to leave a light yellow oily residue, which was tested by IR for the presence of the desired aldehyde. The final product was redissolved in anhydrous diethyl ether and stored under N2 gas at -20°C until used. Peptide Synthesis. All residues were incorporated by the solid phase method using the BOC procedure described earlier, except for the reduced bond isosters linkage which was prepared as described below. Following the introduction of the reduced bond isosters to the peptide on-resin, the remainder of the synthesis was continued as before. The peptide fragment preceding the CH2NH bond were assembled in a Beckman Peptide Synthesizer (System 990).
Introduction of the CH2NH bond. The following procedure was next carried out:
(1 ) The peptide-resin was transferred to a manual apparatus after the removal of the BOC group from the partially assembled peptide chain. (2) The resin was washed in turn with DCM (3 x 1 min), MeOH (2 × 1 min), DCM
(3 × 1 min), and DMF (2 × 1 min).
(3) BOC-glycinal (> 3 equiv.) was added in 15 ml DMF containing 1% AcOH.
(4) 10 ml (10 mmol, 4 equiv.) of 1M NaBH3CN in THF (Aldrich) was added portion-wise in 30 min and further stirred for 1 hr for the reductive alkylation. (5) The resin was washed in turn with DMF (2 × 1 min), DCM (3 × 1 min), MeOH
(2 × 1 min), and tested for NH2 content with the ninhydrin assay.
The coupling of the additional amino acids after the CH2NH bond was continued using the standard BOC procedure in a manual apparatus. The peptide was removed from the resin by treatment with HF in presence of 10% anisole and 5% dimethylsulfide for 1 hr at 0°C. The residue was washed with diethyl ether, filtered, and extracted with 1 M HOAc in H2O (50 ml × 4). The solution was Iyophilized to yield the crude noncyclic peptide (780 mg).
Cyclization. With respect to the first title compound, the formation of the intramolecular disulfide bridge was accomplished by using iodine oxidation method. The noncyclic peptide (Ellman positive) was dissolved in 300 ml of 80%
HOAc. The peptide solution was titrated with l2-glacial acetic acid until the solution turned light brown in color, and stirred for 1-2 hr at room temperature. The excess iodine was removed by adding ascorbic acid-water solution. The peptide solution was then concentrated in vacuo. The residue was redissolved in water and Iyophilized to obtain the crude cyclic peptide.
Both peptides were purified using techniques as described in the foregoing examples.
By using the synthetic techniques described above, cyclic compounds of the invention in which linkage (through L1, L2 and Z) includes a secondary amine structure may analogously be prepared. It is most advantageous, from a synthetic standpoint, to incorporate the isostere bond linkage prior to final cyclization of the compound. In such a case, cyclization is completed as a final step (after assembly of the desired residues including the isostere bond) through formation of, typically, a peptide bond at a point within the sequence 1-2-3-4-5-6.
* * * * * 2. Therapeutic Utility
In the practice of the therapeutic methods of the present invention, an effective amount of the active compound, including derivatives or salts thereof, or a pharmaceutical composition containing the same, as described below, is administered via any of the usual and acceptable methods known in the art, either singly or in combination with another compound or compounds of the present invention or other pharmaceutical agents such as immunosuppressants, antihistamines, corticosteroids, and the like. These compounds or compositions can thus be administered orally, sublingually, topically (e.g., on the skin or in the eyes), parenterally (e.g., Intramuscularly, intravenously, subcutaneously or intradermally), or by inhalation, and in the form of either solid, liquid or gaseous dosage including tablets, suspensions, and aerosols, as is discussed in more detail below. The administration can be conducted in single unit dosage form with continuous therapy or in single dose therapy ad libitum. Useful pharmaceutical carriers for the preparation of he pharmaceutical compositions hereof can be solids, liquids or gases; thus, the compositions can take the form of tablets, pills, capsules, powders, enterically coated or other protected formulations (such as binding on ion exchange resins or other carriers, or packaging in lipid protein vesicles or adding additional terminal amino acids), sustained release formulations, solutions (e.g., ophthalmic drops), suspensions, elixirs, aerosols, and the like. Water, saline, aqueous dextrose, and glycols are preferred liquid carriers, particularly (when isotonic) for injectable solutions. The carrier can be selected from various oils including those of petroleum, animal, vegetable or synthetic origin, for example, peanut oil, soybean oil, mineral oil, sesame oil, and the like. Suitable pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, and the like. The compositions may be subjected to conventional pharmaceutical expedients such as sterilization and may contain conventional pharmaceutical additives such as preservatives, stabilizing agents, wetting or emulsifying agents, salts for adjusting osmotic pressure, buffers, and the like. Suitable pharmaceutical carriers and their formulations are described in Martin, Remington's Pharmaceutical Sciences; 15th Ed.; Mack Publishing Co., Easton, 1975, see, e.g., pp. 1405-1412, 1461-1487. Such compositions will, in general, contain an effective amount of the active compound together with a suitable amount of carrier so as to prepare the proper dosage form for proper administration to the host.
In one preferred embodiment, the therapeutic methods of the present invention are practiced when the relief of symptoms is specifically required or perhaps imminent; in another preferred embodiment, the method hereof is effectively practiced as continuous or prophylactic treatment.
In the practice of the therapeutic methods of the invention, the particular dosage of pharmaceutical composition to be administered to the subject will depend on a variety of considerations including the nature of the disease, the severity thereof, the schedule of administration, the age and physical characteristics of the subject, and so forth. Proper dosages may be established using clinical approaches familiar to the medicinal arts. It is presently believed that dosages in the range of 0.1 to 100 mg of compound per kilogram of subject body weight will be useful, and a range of 1 to 100 mg per kg generally preferred, where administration is by injection or ingestion. Topical dosages may utilize formulations containing generally as low as 0.1 mg of compound per ml of liquid carrier or excipient, with multiple daily applications being appropriate.
The compounds and therapeutic or pharmaceutical compositions of the invention are useful in the study or treatment of diseases or other conditions which are mediated by the binding of integrin receptors to ligands, including conditions involving inappropriate (e.g., excessive or insufficient) binding of cells to natural or other ligands. Such diseases and conditions include inflammatory diseases such as rheumatoid arthritis, asthma, allergy conditions, adult respiratory distress syndrome, inflammatory bowel diseases (e.g., ulcerative colitis and regional enteritis) and ophthalmic inflammatory diseases; autoimmune diseases; thrombosis or inappropriate platelet aggregation conditions, and cardiovascular disease; prevention of occlusion following thrombolysis; neoplastic disease including metastasis conditions; as well as conditions wherein increased cell binding is desired, as in wound healing or prosthetic implantation situations as discussed in more detail above. in addition, derivatives of the present compounds may be useful in the generation of antigens which, in turn, may be useful to generate antibodies. These antibodies will, in some cases, themselves be effective in inhibiting cell adhesion or modulating immune activity by acting as receptors for matrix proteins or other cell adhesion ligands, or, if anti-idiotypic, by acting to block cellular receptors. EXAMPLE S
Cell Adhesion Inhibition Assay (I)
The following assay established the activity of the present compounds in inhibiting cell adhesion in a representative in vitro system. The assay was a competition assay in which both fibronectin and a test compound were present. Microtiter plates were first precoated with fibronectin. The test peptide was then added in increasing concentrations with cells known to contain the fibronectin receptor. The plates were then washed and stained for quantitation of attached cells. The present assay directly demonstrates the anti-cell adhesion activity and modulatory activity of the present compounds. Additionally, by immobilizing the peptide on a surface, one could adhere appropriate cells to that surface. Other cell adhesion modulation activity, and utilities pertinent thereto, will be apparent to those skilled in the art.
The cell line U937 was purchased from American Type Tissue Culture Collection. The cells were cultured in RPMI media (J.R. Scientific Company, Woodland Hills,
California 95695) containing 10% fetal calf serum. Fibronectin was purified from human plasma according to the procedure of Engvall, E. and Ruoslahti, E., Int. J. Cancer 1977, 20, 1.
Microtiter plates (96-well, Falcon) were coated overnight at 4*C with 5 μg/mi fibronectin (FN) (for a total volume of 0.1 ml) or, as a control, 5 μg/ml bovine serum albumin (BSA) diluted in phosphate buffered saline (PBS, 0.01 M NaPO4 in 0.9% NaCl at pH 7.2 to 7.4). Unbound proteins were removed from plates by washing with PBS. The plates were then coated with 100 μl of PBS containing 2.5 mg/ml BSA for one hour at 37ºC. This procedure is a modification of a previously published method, Cardarelli, P.M. and M.D. Pierschbacher, PNAS-USA 1986, 83, 2647. The containment in the wells of functional amounts of immobilized protein has been confirmed by independent assay of fibroblast attachment and ELISA (Engvall, E., Methods Enzymol. 1980, 70, 419), although the actual amount of protein bound to the plate in these assays was not determined.
A U937 culture was collected and washed two times with Hanks Balanced Salt Solution. The cells were counted and adjusted to 1.5 × 106 cells per ml in Duibecco's Modified Eagles Medium (DMEM) plus BSA (2.5 mg/ml) for cell attachment assay. Subject compounds were then dissolved in DMEM and BSA, and the pH was adjusted to 7.4 with 7.5% sodium bicarbonate. The compounds
(100 μl) were added to FN-coated wells, at 1.5, 0.75, 0.375, 0.188, 0.094, 0.047, 0.023, 0.012, 0.006 and 0.003 mg/ml final concentration and U937 ceils (100 μl) were added per well. The plates were then incubated at 37ºC for 60 minutes. Following this incubation, the plates were washed once with PBS. Attached ceils were fixed with 3% parformaldehyde in PBS and stained with 0.5% toluidine blue in 3.7% formaldehyde. The cells were stained overnight at room temperature and the optical density at 590 nm of toluidine blue-stained cells was determined using a vertical pathway spectrophotometer to quantitate attachment (VMAX Kinetic Microplate Reader, Molecular Devices, Menlo Park, California 94025). Results. Table 6, below, shows the results of the cell adhesion inhibition assay.
Potency is expressed in μM units. Figure 2 is a diagram representing the curve of cell adhesion inhibition for the compound
Figure imgf000086_0001
TABLE 6
ACTIVITY OF COMPOUNDS IN THE U937 - FIBRONECTIN
ADHESION ASSAY1
Peptide # Sequence IC 50μM
1 C*LRGDSPC* 909
2 GC*LRGDSPC*-NH2 468
3 GC*L(homoA)GDSPC*-NH2 1000-1500
4 C*GRGDSPC* 597
5 C*LRGDSP(Pen)*-NH2 100-1500 6 C*(Nle)RGDSPC*-NH2 383
7 C*(dL)RGDSPC*-NH2 924
8 C*RGDC* 1461
9 C*RGDSC* 1104
10 C*RGDSPC* 140
11 (Mpr*)GRGDSPC* 330
12 (Mpr*)LRGDSPC* 611
13 (Mpr*)LRGDTPC* 870
14 C*YRGDSPC* 198
15 C*GRGDVPC* 494
16 C*GRGDAPC* 829
17 E*GRGDSPK*SS 1059
18 Ac-E*GRGDSPK*SS 171
19 K*RGDSPD*SS 1084
20 (dC*)(dR)G(dD)(dS)(dP)(dC*) 597
21 C*(Sar)RGDSPC* 136
22 G*RGDSPD*-NH2 112
23 (Ada)-C*GRGDSPC* 272
24 VTC*GRGDSPC*A-NH2 50
25 VSC*GRGDSPC*A-NH2 636
26 (dC*)(dP)(dS)(dD)G(dR)(dC*) 1161
27 C*RGDSPC*-NH2 242
1 Asterisk ("*") following residue abbreviation designates linking residue that provides functional group for cyclization. Functional group precursors are as follows: C*, side chain sulfhydryl; Pen*, side chain sulfhydryl; Mpr, 3-mercapto (sulfhydryl) group; K*, side chain amino group D*, side chain carboxyl group; G*, α-amino group; R*, α-amino group, "d" indicates the D-enantiomer. Peptide # Sequence IC50 μM
28 A(norVal)SC*GRGDSPC*A-NH2 632
29 C*GRGD[rhr(OCH3)]PC* 255
30 C*YRGDSPC*-NH2 1024
31 C*GRGDSPC*-NH2 2719
32 (Mpr*)YRGDSPC* 240
33 (Mpr*)RGDSPC* 231
34 (d-Nal)-C*RGDSPC* 236
35 RC*DSPC* 1040
36 C*RGDYPC* 30
37 (Ada)-GGGC*RGDSPC* 85
38 (Ada)-GGC*RGDSPC* 45
39 (Ada)-GC*RGDSPC* 58
40 (d-Nal)-C*RGDSPC* 136
41 (PMP)*-RGDSPC* 227
42 (FMOC)-RC*DPC* 107
43 Sar*RGDSPD* 103
44 C*RGDTPC* 91
45 C*YRGDVPC*-Aib-NH2 106
46 R*GDSPE*-NH2 91
47 G*RGDSPD*-NH2 134
48 R*GDSPD* 60
49 RC*DPC* 32
50 C*RGDFPC* 35
51 (Ada)-GGC*RGDY-(3-thioPro)-C*NH2 7
52 (Ada)-GGC*RGDYPC*-NH2 15
53 (Ada-CA)-GGC*RGDY-(3-thioPro)-C*NH2 25
54 (Ada)-GGC*RGDYPC*-NH2 39
55 (Ada)-GGC*RGDVPC* 30
56 (Ada)-GC*RGDVPC* 54
57 (Ada)-C*RGDVPC* 115
58 (Ada)-GGC*RGDYPC* 42
59 (Ada)-GC*RGDYPC* 81
60 (FMOC)-GGC*RGDSPC* 53
61 (Ada)-GC*RGDSPC*-NH2 86
62 C*RGDS(1 ,1-ACC)C* 148
63 C*RGDWC* 57
64 (Ada)-C*RGDC* 267
65 (Ada)-GGC*RGDWC* 178
66 (Ada)-GGC*RGDPC* 69 Peptide # Sequence IC50 μM
67 (Ada)-GGC*RGDVC* 148
68 (Ada)-C*GRGDS-(3-thioPro)C*-NH2 421
69 (Mpr*)-RGDY-(3-thioPro)C*-NH2 102
70 C*RGD(TA)C* 190
71 C*RGD(CHA)C* 160
72 (AdaCA)C*GRGDS-(3-thioPro)C* 161
73 C*RGD(p-nitro-Phe)PC* 20
74 C*RGDFHypC* 655
75 C*RGD(p-chloro-Phe)PC* 12
76 C*RGDF(d-Nal)C* 428
77 RC*DFPC* 622
78 C*RGD(p-fluoro-Phe)-(3-thioPro)C* 22
79 (1-FCA)RC*D(p-fluoro-Phe)-(3-thio)-ProC* 249
80 (HCA)RC*D-(3-thioPro)C* 69
81 (Ada)-(AMBA)-C*RGDY-(3-thioPro)-C*-NH2 179
82 (Ada)-(AnB)-C*RGDY-(3-thioPro)-C*NH2 68
83 (Ada)-(AnC)-C*RGDY-(3-thioPro)-C*NH2 84
84 (Ada)-GGC*RGDF-(3-thioPro)-C*-NH2 15
85 (QC)GGC*RGDF-(3-thioPro)-C*-NH2 138
86 (HCA)-GGC*RGDF-(3-thioPro)-C*-NH2 107
87 (PhAc)-GGC*RGDF-(3 thioPro)C*-NH2 117
88 (NaphAc)-GGC*RGDF-(3-thioPro)C*-NH2 83
89 C*RGD(p-chloro-Phe)-(3-thioPro)C*-NH2 15
90 (Ada)-GGC*RGD(p-chloro-Phe)- (3-thioPro)C*-NH2 5
91 (1 -FCA)-GGC*RGD(p-chloro-Phe)- (3-thioPro)-C* 37
92 (CPA)-CC*RGDFPC* 55
93 (NACA)GGC*RGDYPC* 116
94 (NBAC)GGC*RGDYPC* 155
95 (Ada)-GGC*RGDY(1 ,1-ACC)C* 301
96 (Ada)-GGC*RGDY(p-OCH3-Tyr)PC*-NH2 9
97 (Ada)-GC*RGDYPC*-NH2 5
98 (FMOC)RC*D-(3-thioPro)C* 16
99 RC*D(Hyp)C* 41
100 RC*DFC* 438
101 RC*D(TA)C* 258
102 RC*D(CHA)C* 182
103 RC*DYC* 318 Peotide # Sequence lC50μM
104 RC*DVC* 35
105 RC*D(L-Nal)C* 463
106 RC*EPC* 23
107 RC*D-(3-thioPro)C* 4
108 (Ada-CA)-RC*D-(3-thioPro)C* 4
109 (NACA)-RC*D-(3-thioPro)C* 16
110 (CPA)-RC*D-(3-thioPro)C* 8
111 (9-FCA)-RC*D-(3-thioPro)C* 14
112 (3-Me-Ada)-RC*D-(3-thioPro)C* 41
113 RC*D-(3-thioPro)C* 66
114 (FMOC)-R(HomoC)*D-(3-thioPro)C* 78
115 HomoRC*D-(3-thioPro)C* 100
116 C*RGDLPC* 210
117 C*RGDY-(3-thioPro)-Pen*-NH2 249
118 Pen*RGDY-(3-thioPro)-Pen*-NH2 121
119 C*VRGDVC* 561
120 (FMOC)-RC*D(DTC)C* 10
121 RC*D(DTC)C* 10
122 RC*D(TTC)C* 6
123 (Ada)-RC*E-(3-thioPro)C* 164
124 (AdaCA)-RC*E-(3-thioPro)C* 47
125 RC*E-(3-thioPro)C* 10
126 (Ada)-GGC*(HomoR)GD(p-chloro-Phe)- (3-thioPro)C* 272
127 (Ada)-GG(HomoC*)RGD(p-chloro-Phe)- (3-thioPro)C* 10
128 HomoC*RGD(p-chloro-Phe)- (3-thioPro)C*-NH2 96
129 K(AnB)-(AnB)-RC*D-(3-thioPro)C* 6
130 K(AnC)RC*D-(3-thioPro)C* 33
131 (FMOC)-R(HomoC)*D-(3-thioPro)-HomoC* 245
132 (1-FCA)RC*D(TTC)C* 92
133 (FMOC)RC*D(MTC)C* 387
134 (1-FCA)C*RGDF-(3-thioPro)C* 106
135 (FMOC)RC*DNAC* 66
136 C*RGD(CH3O-Tyr)PC* 108
137 (Ada)-GGC*RGD-(3-thioPro)C* 4
138 C*RGD-(p-chloro-Phe)(DTC)-C*-NH2 10
139 C*RGD-(p-chloro-Phe)(TTC)-C*-NH2 52 In addition, the following compound was tested and found to have an lC50 of 251 μM.
140
Figure imgf000091_0001
The following compounds of Table 7 have also been synthesized and tested in the cell adhesion inhibition assay described above. Specific activity levels were not established inasmuch as the lC50 of the compounds was determined to be in excess of 1.5 mg/ml. Thus, although such compounds are believed to be active as cell adhesion modulators at higher dosage levels, they are presently not as highly preferred as the compounds exemplified above.
TABLE 7
ADDITIONAL COMPOUNDS2
Sequence
(Pen*)LRGDSPC*
Ac-GC*LRGDSPC*-NH2
(Pen*)LRGDSP(Pen*)-NH2
C*GRGDC*
C*GRGDSC*
C*(norVal)RGDSPC*
C*IRGDSPC*
YC*LRGDSPC*-NH2
LC*LRGDSPC*-NH2
FC*LRGDSPC*-NH2
LC*LRGDSPC*
FC*LRGDSPC* 2 See notes to Table 6. YC*LRGDSPC*
(d-Nal)C*LRGDSPC*
C*GRGD(Sar)PC*
C*GRGDS(Hyp)C*
C*GRGDS(homoP)C*
C*GRGDS(Dhp)C*
C*(dR)G(dD)(dS)(dP)C*
C*TRYRGDQDATMSC*
C*(Nic-Lys)GDSPC*
C*FRGDSPC*
R*GDSPD*-NH2
Ac-D*RGDSPK*-NH2
C*RGD(d-Phe)-PC*
C*RGD(d-p-chloro-Phe)-PC* C*RGEYPC*
RC*DPC*-NH2
(FMOC)-RC*D(1 ,1-ACC)C*
C*PRGDPC*
YIGSRC*DDC*
(FMOC)-RC*DPC*
(Ada)-C*RGDPC*
C*RGD-(p-chloro-Phe)(MTC)-C*-NH2 RC*D(dNal)C*
WRC*DNC*
(FMOC)-RC*DWC*
C*RGD(d-Nal)C*
C*RGD(l-Nal)C*
(Ada)-C*RGESPC*
(Ada)-C*GRESPC*-NH2
C*RGESPC*
C*GRG-SPC*-NH2
RC*D(MTC)C*
RC*D(TC)C*
C*(HomoR)GDF-(3-thioPro)C*-NH2 R(dC)*DP(dC)*
N-Me-ArgC*D-(3-thioPro)C*-NH2 R*GDC-NH-(CH2)3-CO* Thus, an aspect of the present invention is to provide compounds having extraordinarily high potencies in modulating cell adhesion to integrin receptors, including specifically inhibition of cell adhesion to the fibronectin receptor. The invention also includes methods for obtaining (either in vitro or in vivo) such fibronectin receptor adhesion inhibition, and integrin receptor adhesion inhibition.
The disclosed compounds accomplish strong inhibition at desirably low concentrations, with an IC50 of less than about 500 μM, or alternatively less than about 100 μM. Likewise, another aspect of the invention is to provide such compounds, and such methods for obtaining integrin receptors adhesion inhibition, with IC50 potency levels at least as low as about 1 μM, and alternatively at least as low as about 4 μM.
EXAMPLE 10
Cell Adhesion Inhibition Assay II
The following assay established the activity of the present compound in inhibiting cell-cell adhesion in a representative in vitro system. This assay measures the adhesive interactions of T-cells to endothelial cell monolayers in the presence of a test compound. The test compound is added in increasing concentrations with T-cells and this is added to endothelial cell monolayers. The plates are incubated, washed and the percentage of attached cells is quantitated. The assay directly demonstrates the anti-cell adhesion activity and modulatory activity of the present compounds.
Human umbilical vein endothelial cells were purchased from Cionetics (San Diego,
CA) at passage number 2. The cells were grown on 0.5% porcine skin gelatin precoated flasks (Sigma, St. Louis, MO) in EGM-UV media (Clonetics, San Diego, CA) supplemented with 10% fetal bovine serum. Cells were refed every 2-3 days reaching confluence by day 4 to 6. The cells were monitored for factor VIII antigen and our results showed that at passage 12, the cells were positive for this antigen. The endothelial cells were not used following passage 14-15.
The T-cell line Jurkat was obtained from American Type Tissue Culture Collection (Rockville, MD). The cells were cultured in RPMI media containing 10% fetal calf serum. The cells were washed twice with Hank's Balanced Salt Solution (HBSS) and resuspended in Dulbecco's Minimal Eagle's Media (DMEM) containing 2.5 mg/ml Human Serum Albumin (HSA). The Jurkat cells (1×106 cells/ml) were stained with 10 μg/ml fiuorescein diacetate (Sigma, St. Louis, MO) in HSSS containing 5% fetal calf serum. The cells were stained for 15 minutes in the dark at room temperature, washed 2 times, and resuspended in a DMEM-HSA solution.
Confluent endothelial monolayers grown in 96-well tissue culture plates were stimulated for 4 hours at 37ºC with 0.1 ng/ml (~50 U/ml) recombinant IL-1 (Amgen, Thousand Oaks, CA). Following this incubation, the monolayers were washed twice with HBSS and 0.1 ml of DMEM-HSA solution was added. Jurkat cells (5 × 105 cells) were combined with appropriate concentrations of a peptide to be tested and 0.1 mi of the Jurkat-peptide mixture were added to the endothelial cell monolayers. Generally, 200 and 10 μM peptide concentrations were tested. With some representative peptides IC50 was determined by testing the peptides at 200, 40, 8, 1.6, 0.32, and 0.064 μM. The plates were placed on ice for 5 minutes to allow for Jurkat cell settling and then incubated at 37º C for 20 minutes. Following this incubation, the monolayers were washed twice with PBS containing 1 mM calcium chloride and 1 mM magnesium chloride and the plates were read using a Pandex Fluorescence Concentration Analyzer (Baxter, Mundelein, IL). Fluorescence in each well was measured as arbitrary fluorescence units and percent adhesion in the absence of a peptide was adjusted to 100% and the percentage adhesion in the presence of the peptide was calculated. Monolayers were also fixed in 3% paraformaidehyde and evaluated microscopically to verify adhesion.
Results
Table 8 shows the results of the cell adhesion inhibition assay using the JurkatEndothelial cells. Potency is expressed in terms of percentage inhibition at 200 μM and 10 μM concentrations of the tested peptides. Where peptides are determined to be very active, IC50 (expressed as μM units) are also given.
TABLE 8
ACTIVITY OF COMPOUNDS IN THE JURKAT- ENDOTHELIAL CELL ADHESION ASSAY
PEPTIDE # SEQUENCE 200 uM% 10 uM% IC50 μm
14 C*YRGDSPC* 21 31 4
23 (Ada)-C*GRGDSPC* 9 4
42 (FMOC)-RC*DPC* 12 41 17
141 C*LRGESPC* 17 60
142 C*LRGDTPC* 25 98
143 C*VRGDSPC* 16 64
144 (Ada)-C*RGDSPC* 49 95
145 (FMOC)-RC*DSPC* 34 81
146 (FMOC)-RC*D-(3-thioPro)C* 22 24 3
147 RC*D-(3-thioPro)C* 15 57 41
148 (Ada)-RC*DPC* 29 58 22
149 (FMOC)-RC*D(Hyp)C* 16 34 16
150 (Ada-CA)-RC*DPC* 37 44 39
151 (Ada)-RC*DFC* 22 83
152 (Ada)-RC*DNC* 68 72
153 (Ada)-C*GRGDS-(3-thioPro)C* 14 22 1 PEPTIDE # SEQUENCE 200 uM% 10 uM% IC50 μm
154 (FMOC)-RC*EPC* 10 42 4
155 (FMOC)-RC*DNC* 20 96
156 (FMOC)-RC*(DTC)C* 32 90
157 (Ada)-C*GRGES-(3-thioPro)C* 21 30
158 (Ada-CA)-C*GRGES-(3-thioPro)C* 14 57
159 (Ada)-C*GRGESPC* 20 47
160 (Ada)-(HomoR)C*D-(3-thioPro)C* 13 40
161 (FMOC)-RC*D-(3-thioPro)(HomoC*) 35 53
162 (NaphAc)-RC*D-(3-thioPro)C* 37 52
163 (9-FA)-RC*D-(3-thioPro)C* 12 16 0.7
164 (1 -FCA)-RC*D-(3-thioPro)C* 9 16 0.09
165 (FMOC)-RC*E-(3-thioPro)C* 12 30 2
166 (FMOC)-RC*D(TTC)C* 11 18 0.9
Thus, another aspect of the present invention is to provide compounds having high potencies in modulating leukocyte adhesion to endothelial cells.
In one regard, the present invention includes compounds having an IC50 of less than about 200 μM as established in a Jurkat-Endothelial cell adhesion assay; and in another regard, the invention includes compounds having an IC50 of less than about 10 μM in such assay. The invention also includes methods for obtaining (either in vitro or in vivo) such leukocyte receptor adhesion inhibition. The disclosed compounds accomplish strong inhibition at low concentrations, with an IC50 of less than about 200 μM, or alternatively less than about 10 μM. Likewise, a further aspect of the invention is to provide such compounds, and such methods for obtaining leukocyte receptors adhesion inhibition, with IC50 potency levels at least as low as about 0.1 μM, and alternately at least as low as about 50 μM. PREPARATION 1
(d,1)-Thiozolidine-2-carboxylic Acid
(TC)
A solution consisting of cysteamine hydrochioride (56.8 g, 0.5 mole), triethylamine (50.6 g, 0.5 mole), glyoxylic acid (37 g, 0.4 mole), and 150 ml ethanol was refluxed for 2.5 hrs. Upon completion of reaction, the reaction mixture was cooled to collect solids. The solids were washed with ethanol and recrystallized from boiling water ( ~ 100 ml) to afford the title product which was washed with water and dried in vacua at 40* C. The yield of pure product amounted to 25 g (47%): mp 195*C (dec); Anal. Calcd. for C4H7N151O2: C,
36.07; H. 5.29; N, 10.52. Found: C, 36.16; H, 5.34; N, 10.53.
PREPARATION 2
1-2-Methylthiazolldlne-4-carboxylic Acid
(MTC)
To l-cysteine (hydrochioride monohydrate; 10 g, 63.45 mmole) dissolved in 35 ml water was added acetaldehyde (4 ml, 71.5 m mole) at ice-bath temperature. After stirring in the cold for 2 days, pyridine (10 ml) and ethanol 950 ml) were added to the reaction mixture. The resultant mixture was further allowed to stand at room temperature for two days. The mixture was diluted with ethanol (100 ml) and upon standing overnight, the title compound (3.6 g) was obtained as a gelatinous product. The material was dried in vacua at 40°; m.p. 145152°C. PREPARATION 3
N-BOC-(d,1)-thlazolidine-2-carboxylic acid
To a solution consisting of thiazolidine-2-carboxylic acid of preparation 1 (5 g, 37.5 m mole), 70 ml water, 37 ml INNaOH, and 70 ml dioxane, was added di-tbutyl-dicarbonate (BOC)2O(8.2 g, 37.5 mmole) diluted with 30 ml dioxane. The mixture was stirred at ambient temperature for 4 hrs, with the pH being maintained between 8 and 9. Additional (BOC)2O (3.75 mmole) was added to the mixture. Stirring continued for 16 hr. at pH 9. The reaction mixture was concentrated to Vz volume and extracted with hexane (x2). The organic extract was discarded and the aqueous phase (chilled with ice) was acidified to pH 3 with I N NaHSO4. The acidified solution was then extracted with ethyl acetate (x3). The ethyl acetate extract was washed with water (x3), dried over anhydrous MgSO4 and filtered. After concentration of the solvent, there was obtained the title compound as a white powder. The yield of product amounted to 6.9 g (79%). m.p. 84-86ºC. Anal. Calcd for C9H15N1O4Si; C, 46.39; H, 6.43;
N, 6.00. Found: C, 46.46; H, 6.53; N, 6.03.
PREPARATION 4
N-BOC-(1)-5,5-dimethylthiazolidine-4-carboxylic Acid
(N-BOC-DTC)
The method of Preparation 3 was repeated, except that 1-5,5-dimethylthiazoldine-4-carboxylic acid (available from Sigma Chemicals) was used as the starting material in lieu of (d,1)-thiazolidine-2-carboxylic acid. The title compound was thus prepared, m.p. 104-108ºC. Anal. Calcd for C^H^N^S,: C, 50.54; H, 7.27; N, 5.35. Found: C, 50.69; H, 7.35; N, 5.38. PREPARATION 5
N-BOC-(l)-2-methylthiazolidlne-4-carboxylic Acid
The method of preparation 3 was repeated, except that l-2-methylthiazolidine -4-carboxylic acid (Preparation 2) was used as the starting material in lieu of (d,l)-thiazolidine-2-carboxylic acid. The title compound was thus prepared, m.p. 93- 96ºC. Anal. Calcd for C10H17N1O4S1; C, 48.55; H, 6.93; N, 5.66. Found: C, 48.68; H, 6.96; N, 5.74.
PREPARATIONS 6-9
N,N (or N')-Dialkyl-1-arginines
l-Ornithine HCI (1 eq.), 1 eq. S-methylisothiouronium salts (Schenck, M., Archiv. der Pharmazie, 1911 , 249, 478) or 1 eq. of (alkyl- or dialkyl amino)-(alkylimino)methanesulfonic acid (Arzeno, H.B. et al., Syn. Com., 1990, 20, 3433; Maryanoff, C.A. ef al., J. Org. Chem., 1986, 51 , 1882), 2 eq. 1 N NaOH were combined and, after dissolution, the mixture was allowed to stand at room temperature for 5-10 days. The reaction progress was monitored by tlc
(methanol/ammonium hydroxide 1 :1) and leveled off at approximately 90% reaction. The reaction mixture was diluted with 1 vol. water, adjusted to pH 5 with aq HCI and applied to a column of Amberlite IR-120 H+ resin (5 eq.). The column was washed with water until neutral or negative to chloride and sulfate test. The amino acids were eluted following the sequential treatment with 2 column volumes each of 0.15 N and 0.25 N ammonium hydroxide, then with 3 column volumes of 0.3 N ammonium hydroxide. Fractions were taken starting when the ammonia front exits the column. Early fractions were a mixture of both Ornithine and the product. Later fractions contained pure products. The purification was followed by tlc. The fractions containing pure product were combined, concentrated in vacuo at 40ºC and freeze dried. This hygroscopic material was crystallized as follows: The amino acid was dissolved in the minimum amount of HCI or acetic acid and diluted with 1 volume of ethanol. Acetone was then added slowly to turbidity (2-3 vol.). The solution was cooled and the product was collected, washed with acetone and dried under vacuum.
The title compounds were thus prepared.
N-BOC Protection:
The method of preparation 3 was repeated, except that the various alkylated arginines were used as the starting materials. BOC-protected amino acids corresponding to the title compounds were obtained. These were N,N-dimethyl-l-arginine, N,N'-dimethyl-l-arginine, and N,N'-diethyl-l-arginine.
The foregoing examples are given to enable those skilled in the art to more fully understand and practice the present invention. They should not be construed as a limitation upon the scope of the invention, which is set forth in the appended claims, but merely as being illustrative and representative thereof.

Claims

1. A compound of the formula
Figure imgf000101_0001
and pharmaceutically acceptable salts thereof, wherein
L1 and L2 are each, or are together, a residue of an amino acid, an amino acid analog or an amino acid mimetic having a functional group suitable for the formation of a cyclizing bridge between L1 and L2;
Z is a cyclizing moiety or bond between L1 and L2;
1 is optional and, where present, is selected from Leu, Tyr, Phe, He, Pro, 3-thioPro, TTC, TCA, DTC, MTC, TC, Gly, Ala, Val, norLeu, norVal, β- Ala, Trp, d-Nal, l-Nal, Sar and (Ada)-Ala;
2 is selected from Arg, homoArg, nitroArg, norArg, p-aminomethylPhe, N-alkylArg, N,N-dialkylArg, N,N'-dialkylArg, N,N,N'-trialkylArg, wherein the alkyl has from one to four carbon atoms;
3 is selected from Gly, and Sar;
4 is selected from Asp, Glu, and the alkyl, aralkyl, aryl esters of the foregoing two amino acids;
5 is optional and, where present, is selected from Ser, Thr, Tyr, monohalo-Tyr, dihalo-Tyr, Trp, Ala, Val, Phe, o-, m- and p-halo-Phe, p-nitroPhe, Leu
Figure imgf000101_0002
wherein m is 2, 3 or 4; 6 is optional and, where present, is selected from Pro, 3-thioPro,
1,1 -ACC, Dhp, DTC, TTC, TC, MTC, TCA, Hyp, homoPro and Phe, p-haloPhe, p-nitro-Phe, TA, d-Nal, l-Nal, isonipecotic acid;
X1 and Y1 are each optional and, where present, are independently selected from 1 to 4 d- or l-amino acids and amino acid analogs;
X2 is an optional Nα-substituent selected from R' (including hydrogen) and R'CO-;
Y2 is an optional carboxyl-terminal substituent selected from -OR' (including hydroxyl), -NR'2 (including -NH2 and -NHR'), 'NHNH2 and -SR'; and wherein each R' is individually a member selected from hydrogen, from linear and branched, unsubstituted and substituted C1-C8 lower alkyls, C2-C8 alkenyls, C2-C8 alkynyls, C6-C14 aryls, C7-C14 alkaryls, C7-C14 cycloalkaryls and C3-C14 cycloalkyls, and, in the case of -NR'2, from cyclized groups forming (in an attachment with the nitrogen atom) a 5-8 membered heterocyclic ring optionally containing oxygen, nitrogen or sulfur as a further ring heteroatom.
2. A compound of claim 1 wherein L1 and L2 are each Cys or homoCys, and cyclization is achieved through a disulfide bond.
3. A compound of claim 1 wherein L1 and L2 each provide sulfur-containing functional groups, and Z is a hydrocarbon bridge between said sulfur groups.
4. A compound of claim 1 wherein Z is a diketo, a diamino or a keto-amino moiety.
5. A compound of claim 4 wherein Z is of the form
Figure imgf000103_0001
wherein n is from 1 to 8.
6. A compound of claim 4 wherein Z is of the form
-NH-(CH2)n-NH- wherein n is an integer of from 1 to 8.
7. A compound of claim 1 wherein the linkage between L1 and L2 is a
monosulfide linkage.
8. A compound of claim 1 wherein L1 is directly bonded to L2 via an amide bond.
9. A compound of claim 1 wherein one or both of L1 and L2 is an amino acid mimetic structure.
10. A compound of claim 9 wherein said amino acid mimetic structure is
Figure imgf000103_0002
and n is an integer of from 1 to about 8.
11. A compound of claim 1 wherein the sequence 1-2-3-4-5-6 is of the
structure:
Leu-Arg-Gly-Asp-Ser-Pro or Arg-Gly-Asp-Phe-3-thioPro
12. A compound of claim 1 wherein X2 is selected from the group consisting of 1 -adamantaneacetyl, 1-admantanecarbonyl, 9-fluoreneacetyl, 9- fluorenecarbonyl, 1-fluorenocarbonyl, fluorenylmethyloxycarbonyl, 3- noradamantanecarbonyl, 3-methyladmantane acetyl, 2-norbornaneacetyl, phenylacetyl, 1-naphthylacetyl, hydrocinnamyl, quinaldyl, cyclohexylacetyl, and 3-mercaptopropionyl.
13. A compound of claim 1 wherein X1 and Y1 are each selected from the group consisting of l-3-(2'-naphthyl)-alanine, l-3-(2'-naphthyl-)alanine., AMBA, AnC, AnB and ω-amino-lower alkyl carboxylic acids.
14. A compound of claim 1 selected from the group consisting of
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
15. A compound of the formula
Figure imgf000106_0002
and pharmaceutically acceptable salts thereof, wherein: L1 and L2 are each, or are together, a residue of an amino acid, an amino acid derivative or an amino acid mimetic having a functional group suitable for the formation of a cyclizing bridge between L1 and L2;
Z is a cyclizing moiety or bond between L1 and L2;
1 is optional, and where present, is of reversed orientation and is selected from Sar, Leu, Tyr, Phe, He, Pro, 3-thioPro, TC, TCA, DTC, MTC, TTC, Gly, Ala, Val, norLeu, norVal, β-Ala, Trp, L-Nal, D-Nal and (Ada)-Ala;
2 is of reversed orientation and is selected from Arg, homoArg, p- amino-methyl-Phe, nitroArg, norArg, p-aminomethyl-Phe, N-alkylArg, N,N- dialkylArg, N,N,N'-dialkylArg, N,N'-trialkylArg wherein the alkyl has one to four carbon atoms;
3 is a moiety suitable for linking reversed-orientation residue 2 with residue 4;
4 is selected from Asp, Glu, and the lower alkyl, aralkyl, aryl esters, O-Fm esters, O-cyclohexyl esters, O-benzyl esters of the foregoing two amino acids;
5 is optional and, where present, is selected from Ser, Thr, Tyr, monohalo-Tyr, dihalo-Tyr, Trp, Ala, Val, Phe, o-, m-, and p-halo-Phe, p- nitro-Phe, Leu and
Figure imgf000107_0003
Figure imgf000107_0001
Figure imgf000107_0002
Figure imgf000107_0004
wherein m is 2, 3 or 4;
6 is optional and, where present, is selected from Pro, 3-thioPro, DTC, TCC, TC, MTC, TCA, 1 ,1-ACC, Dhp, Hyp, homoP, Phe, o-, m-, and p- halo-Phe, p-nitro-Phe, TA, d-Nal, isonipecotic acid; X1 and Y1 are each optional and, where present, are independently selected from 1 to 4 d- or l-amino acids and amino acid analogs;
X2 is an optional substituent selected from R'2N- (including R'HN- and H2N-), R'O- (including hydrnoxyl), H2NNH- and R'S-;
Y2 is an optional carboxyl-terminal substituent selected from -OR' (including hydroxyl), -NR'2 (including -NH2 and 'NHR'), "NHNH2 and 'SR'; and wherein each R' is individually a member selected from hydrogen, from linear and branched, unsubstituted and substituted C1-C8 lower alkyls, C2-C8 alkenyls, C2-C8 alkynyls, C6-C14 aryls, C7-C14 alkaryls, C7-C14 cycloalkaryls and C3-C14 cycloalkyls, and, in the case of -NR'2, from cyclized groups forming (in an attachment with the nitrogen atom) a 5-8 membered heterocyclic ring optionally containing oxygen, nitrogen or sulfur as a further ring heteroatom.
16. A compound of claim 15 wherein residue 3 is a diketo moiety of the form
Figure imgf000108_0001
wherein q and r are independently integers of 0, 1 or 2;
17. A compound of claim 16 wherein R' is hydrogen.
18. A compound of claim 15 wherein residue 2 and, if present, residue 1 are of the d-form.
19. A compound of claim 15 wherein one or both of L1 and L2 comprises a diamino moiety.
20. A compound of claim 19 wherein L1 and L2 together comprise a diamino moiety of the form
-NH-(CH)t-NH- wherein t is 1, 2 or 3.
21. A compound of claim 15 wherein the sequence 2-3-4-5-6 is of the
structure
Figure imgf000109_0001
wherein s is an integer of from 1 to about 5.
22. A compound of claim 15 wherein the cyclizing linkage between L1 and L2 comprises a structure selected from the group consisting of disulfide bonds, monosulfide bonds, amide bonds, and structures of the form
-S-(CH2)n-S- wherein n is an integer of from 1 to about 8.
23. A compound of claim 15 selected from the group consisting of
Figure imgf000109_0002
Figure imgf000109_0003
Figure imgf000110_0001
Figure imgf000110_0002
and
Figure imgf000110_0003
24. A compound of the formula
Figure imgf000111_0001
and pharmaceutically acceptable salts thereof, wherein:
L1 and L2 are each, or are together, a residue of an amino acid, an amino acid derivative or an amino acid mimetic having a functional group suitable for the formation of a cyclizing bridge between L1 and L2;
Z is a cyclizing moiety between L1 and L2;
1 is optional and, where present, is selected from Leu, Tyr, Phe, He, Pro, 3-thioPro, TC, TCA, DTC, MTC, TTC, Gly, Ala, Val, norLeu, norVal, β- Ala, Trp, l-Nal, d-Nal, (Ada)-Ala and Sar;
2 is selected from Arg, homoArg, nitroArg, norArg, p-aminomethyl- Phe, N-alkylArg, N,N'-dialkylArg, N,N,N'-trialkylArg wherein the alkyl has one to four carbons;
3 is a moiety suitable for linking residue 2 with reversed-orientation residue 4;
4 is of reversed orientation and is selected from Asp, Glu, the lower alkyl, aralkyl, aryi esters O-Fm esters, O-cyclohexyl esters, O-benzyl esters of the foregoing two amino acids;
5 is optional and, where present, is of reversed orientation and is selected from Ser, Thr, Tyr, monohalo-Tyr, dihalo-Tyr, Trp, Ala, Val, Phe, o-, m-, and p-halo-Phe, p-nitro-Phe, Leu and
Figure imgf000111_0002
Figure imgf000111_0003
Figure imgf000111_0004
Figure imgf000111_0005
wherein m is 2, 3 or 4; 6 is optional and, where present, is of reversed orientation and is selected from Pro, 3-thioPro, DTC, TCC, TC, MTC, TCA, 1 ,1-ACC, Dhp,
Hyp, homoPro, Phe, p-halo-Phe, p-nitro-Phe, TA, d-Nal, l-Nal, and isonipecotic acid;
X1 and Y1 are each optional and, where present, are independently selected from 1 to 4 d- or l-amino acids and amino acid analogs;
X2 is an optional Nα-substituent selected from R' (including hydrogen) and R'CO-;
Y2 is an optional substituent selected from -R' (including hydrogen) and -COR';
and wherein each R' is individually a member selected from hydrogen, from linear and branched, unsubstituted and substituted C1-C8 lower alkyls, C2-C8 alkenyls, C2-C8 alkynyls, C6-C14 aryls, C7-C14 alkaryls, C7-C14 cycloalkaryls and C3-C14 cycloalkyls, and, in the case of -NR'2, from cyclized groups forming (in an attachment with the nitrogen atom) a 5-8 membered heterocyclic ring optionally containing oxygen, nitrogen or sulfur as a further ring heteroatom.
25. A compound of claim 24 wherein residue 3 is a diamino moiety of form
Figure imgf000112_0001
wherein q and r are independently integers of 0, 1 or 2.
26. A compound of claim 25 wherein R' is hydrogen.
27. A compound of claim 24 wherein residues 4 and, if present, residues 5 and 6 are of the d-form.
28. A compound of claim 24 wherein one or both of L1 and L2 comprises a diketo moiety.
29. A compound of claim 28 wherein L1 and L2 together comprise a diketo moiety of the form
Figure imgf000113_0001
wherein t is 1, 2 or 3.
30. A compound of claim 24 wherein the sequence 2-3-4-5-6 is of the
structure
Arg-NH-(CH2),-NH-d-Asprev-d-Serrev-d-Prorev
wherein s is an integer of from 1 to about 5.
31. A compound of claim 24 wherein the cyclizing linkage between L1 and L2 comprises a structure selected from the group consisting of disulfide bonds, monosulfide bonds, amide bonds, and structures of the form
-S-(CH2)n-S- wherein n is an integer of from 1 to about 8.
32. A compound of claim 24 selected from the group consisting of
Figure imgf000114_0001
33. A compound of the formula
Figure imgf000114_0002
and pharmaceutically acceptable salts thereof, wherein
L1 and L2 are each, or are together, a residue of an amino acid, an amino acid analog or an amino acid mimetic having a functional group suitable for the formation of a cyclizing bridge between L1 and L2; Z is a cyclizing moiety or bond between L1 and L2;
1 is optional and, where present, is selected from Leu, Sar, d-Nal, l-Nal, Tyr, Phe, lIe, Pro, 3-thioPro, TTC, TCA, DTC, MTC, TC, Gly, Ala, Val, norLeu, norVal, β-Ala, Trp, and (Ada)-Ala; 2 is selected from Arg, homoArg, nitroArg, norArg, p-aminomethyl- Phe, N-alkylArg, N,N-dialkylArg, N-N'-dialkylArg, and N,N,N'-trialkylArg wherein the alkyl has one to four carbon atoms;
4 is selected from Asp, Glu, and the lower alkyl, aralkyl, aryi esters, O-Fm esters, O-cyclohexyl esters, O-benzyl esters, of the foregoing two amino acids;
5 is optional and, where present, is selected from Ser, Thr, Tyr, p- methoxy-Tyr, monohalo-Tyr, dihalo-Tyr, Trp, Ala, Val, Phe, o-, m-, and p- halo-Phe, p-nitro-Phe, Asn, Asp, Met and
Figure imgf000115_0002
Figure imgf000115_0003
Figure imgf000115_0004
Figure imgf000115_0001
wherein m is 2, 3 or 4;
6 is optional and, where present, is selected from Pro, 3-thioPro, TA, DTC, TTC, TC, MTC, TCA, 1,1-ACC, Dhp, Hyp, homoPro, Phe, p-halo- Phe, p-nitro-Phe, Tyr, Val, d-Nal, l-Nal, CHA, Ser, Asn, Glu and Thr, o-, m-, p-halo-Phe, isonipecotic acid;
7 is optional and, where present, is Pro, 3-thioPro, TA, DTC, TTC, TC, MTC, TCA, Ala, Gly, Ser, Phe, and Leu.
X1 and Y1 are each optional and, where present, are independently selected from 1 to 4 d- or l-amino acids or amino acid analogs;
X2 is an optional Nα-substituent selected from R'- (including hydrogen) and R'CO-; and
Y2 is an optional carboxyl terminal substituent selected from -OR' (including hydroxyl), -NR'2 (including -NH2 and -NHR'), -NHNH2 and -SR'; and wherein each R' is individually a member selected from hydrogen, from linear and branched, unsubstituted and substituted C1-C8 lower alkyls, C2-C8 alkenyls, C2-C8 alkynyls, C6-C14 aryls, C7-C14 alkaryls, C7-C14 cycloalkaryls, and C3-C14 cycloalkyls, and, in the case of -NR'2, from cyclized groups forming (in an attachment with the nitrogen atom) a 5-8 membered heterocyclic ring optionally containing oxygen, nitrogen or sulfur as a further ring heteroatom.
34. A compound of claim 33 wherein L1 and L2 each provide a sulfurcontaining functional group, and cyclization is achieved through a disulfide bond.
35. A compound of claim 33 wherein L1 is Cys or homoC.
36. A compound of claim 33 wherein L1 and L2 each provide sulfur-containing functional groups, and Z is a hydrocarbon bridge between said sulfur groups.
37. A compound of claim 33 wherein the linkage between L1 and L2 is a
monosulfidθ linkage.
38. A compound of claim 33 wherein Z is a diketo, a diamino or a keto-amino moiety.
39. A compound of claim 38 wherein Z is a diketo moiety of the form
Figure imgf000117_0001
wherein n is from 1 to 8.
40. A compound of claim 38 wherein Z is a diamino moiety of the form
-NH-(CH2)n-NH- wherein n is an integer of from 1 to 8.
41. A compound of claim 33 wherein L1 is directly bonded to L2 via an amide bond.
42. A compound of claim 33 wherein the sequence 1-2-L1-4-5-6-L2 is selected from structures of the form
Leu-Arg-Cys-Asp-Ser-Pro-Cys,
Arg-Cys-Asp-Ser-Pro-Cys,
Arg-Cys-Asp-Pro-Cys, and
Arg-Cys-Asp-(3-thioPro)-Cys.
43. A compound of claim 33 wherein X2 is selected from the group consisting of 1 -adamantoneacetyl, 1 -admantanecarbonyl, 9-fluoreneacetyl, 9- fluorenecarbonyl, 1-fluorenecarbonyl, fiuorenylmethyloxycarbonyl, 3- noradamantanecarbonyl, 3-methyladmantaneacetyl, 2-norbornaneacetyl, phenylacetyl, 1-naphthylacetyl, hydrocinnamyl, quinaldyl, cyclohexylacetyl, and 3-mercaptopropionyl.
44. A compound of claim 33 wherein X1 is selected from the group consistin of l-3-(2'-naphthyl)-alanine, and l-3-(2'-naphthyl)alanine, AMBA, AnC, AnB, and ω-amino-lower alkyl carboxylic acids.
45. A compound of claim 33 selected from the group consisting of
Figure imgf000118_0001
Figure imgf000118_0002
Figure imgf000118_0003
Figure imgf000118_0004
Figure imgf000118_0005
Figure imgf000118_0006
and
Figure imgf000118_0007
46. A compound of claim 1 useful in modulating adhesion of a cell expressing a fibronectin receptor.
47. A compound of claim 15 useful in modulating adhesion of a cell
expressing a fibronectin receptor.
48. A compound of claim 24 useful in modulating adhesion of a cell
expressing a fibronectin receptor.
49. A compound of claim 33 useful in modulating adhesion of a cell
expressing a fibronectin receptor.
50. A method of modulating cell adhesion comprising administering, in a
system including cells expressing a receptor protein, an amount effective to modulate the adhesion of said cells of a compound of claim 1.
51. The method of claim 50 wherein said cells express an integrin receptor.
52. The method of claim 50 wherein said cells express a receptor for
fibronectin.
53. The method of claim 50 wherein said system is a mammalian system
characterized by an excessive or inadequate level of cell adhesion.
54. A method of treating a mammalian condition comprising administering a therapeutically effective amount of a compound of claim 1 , wherein said condition is selected from rheumatoid arthritis, asthma, allergy conditions, adult respiratory distress syndrome, inflammatory bowel diseases, ophthalmic inflammatory diseases, autoimmune diseases, thrombosis, platelet aggregation conditions, cardiovascular diseases, neoplastic diseases, wound healing conditions, and prosthetic implantation conditions, reocclusion following thrombolysis, and allograft rejection.
55. A method of modulating cell adhesion comprising administering, in a system including cells expressing a receptor protein, an amount effective to modulate the adhesion of said cells of a compound of claim 15.
56. The method of claim 55 wherein said cells express an integrin receptor.
57. The method of claim 55 wherein said cells express a receptor for
fibronectin.
58. The method of claim 55 wherein said system is a mammalian system characterized by an excessive or inadequate level of cell adhesion.
59. A method of treating a mammalian condition comprising administering a therapeutically effective amount of a compound of claim 15, wherein said condition is selected from rheumatoid arthritis, asthma, allergy conditions, adult respiratory distress syndrome, inflammatory bowel diseases, ophthalmic inflammatory diseases, autoimmune diseases, thrombosis, platelet aggregation conditions, cardiovascular diseases, neoplastic diseases, wound healing conditions, and prosthetic implantation conditions, reocclusion following thrombolysis, and allograft rejection.
60. A method of modulating cell adhesion comprising administering, in a system including cells expressing a receptor protein, an amount effective to modulate the adhesion of said cells of a compound of claim 24.
61. The method of claim 60 wherein said cells express an integrin receptor.
62. The method of claim 60 wherein said cells express a receptor for
fibronectin.
63. The method of claim 60 wherein said system is a mammalian system characterized by an excessive or inadequate level of cell adhesion.
64. A method of treating a mammalian condition comprising administering a therapeutically effective amount of a compound of claim 24, wherein said condition is selected from rheumatoid arthritis, asthma, allergy conditions, adult respiratory distress syndrome, Inflammatory bowel diseases, ophthalmic inflammatory diseases, autoimmune diseases, thrombosis, platelet aggregation conditions, cardiovascular diseases, neoplastic diseases, wound healing conditions, and prosthetic implantation conditions, reocclusion following thrombolysis, and allograft rejection.
65. A method of modulating cell adhesion comprising administering, in a system including cells expressing a receptor protein, an amount effective to modulate the adhesion of said cells of a compound of claim 33.
66. The method of claim 65 wherein said ceils express an integrin receptor.
67. The method of claim 65 wherein said cells express a receptor for fibronectin.
68. The method of claim 65 wherein said system is an animal system
characterized by an excessive or inadequate level of cell adhesion.
69. A method of treating a mammalian condition comprising administering a therapeutically effective amount of a compound of claim 33, wherein said condition is selected from rheumatoid arthritis, asthma, allergy conditions, adult respiratory distress syndrome, inflammatory bowel diseases, ophthalmic inflammatory diseases, autoimmune diseases, thrombosis, platelet aggregation conditions, cardiovascular diseases, neoplastic diseases, wound healing conditions, and prosthetic implantation conditions, reocclusion following thrombolysis, and allograft rejection.
70. A compound of claim 1 having an IC50 in a U937 fibronectin adhesion assay of less than about 500 μM.
71. A compound of claim 70 having an IC50 in a U937 fibronectin adhesion assay of less than about 100 μM.
72. A compound of claim 15 having an IC50 in a U937 fibronectin adhesion assay of less than about 500 μM.
73. A compound of claim 72 having an lC50 In a U937 fibronectin adhesion assay of less than about 100 μM.
74. A compound of claim 24 having an IC50 in a U937 fibronectin adhesion assay of less than about 500 μM.
75. A compound of claim 74 having an IC50 in a U937 fibronectin adhesion assay of less than about 100 μM.
76. A compound of claim 33 having an IC50 in a U937 fibronectin adhesion assay of less than about 500 μM.
77. A compound of claim 76 having an IC50 in a U937 fibronectin adhesion assay of less than about 100 μM.
PCT/US1991/004862 1990-07-09 1991-07-09 Cyclic cell adhesion modulation compounds WO1992000995A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP91513631A JPH05508860A (en) 1990-07-09 1991-07-09 Cell adhesion regulating cyclic compound

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US550,330 1990-07-09
US07/550,330 US5192746A (en) 1990-07-09 1990-07-09 Cyclic cell adhesion modulation compounds

Publications (1)

Publication Number Publication Date
WO1992000995A1 true WO1992000995A1 (en) 1992-01-23

Family

ID=24196720

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/004862 WO1992000995A1 (en) 1990-07-09 1991-07-09 Cyclic cell adhesion modulation compounds

Country Status (6)

Country Link
US (1) US5192746A (en)
EP (1) EP0538399A1 (en)
JP (1) JPH05508860A (en)
CA (1) CA2087021A1 (en)
SG (1) SG72615A1 (en)
WO (1) WO1992000995A1 (en)

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024520A1 (en) * 1992-06-04 1993-12-09 Merrell Dow Pharmaceuticals Inc. Conformationally restrained peptide analogs as antiplatelet agents
WO1995000544A1 (en) * 1993-06-18 1995-01-05 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
WO1995028426A2 (en) * 1994-04-13 1995-10-26 La Jolla Cancer Research Foundation Peptides for reducing or inhibiting bone resorption, angiogenesis and restenosis
WO1996006108A2 (en) * 1994-08-25 1996-02-29 Cytel Corporation Cyclic cs-1 peptidomimetics, compositions and methods of using the same
WO1996040781A1 (en) * 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
US5591719A (en) * 1992-12-10 1997-01-07 Regents Of The University Of Minnesota Method for treating acute and chronic inflammatory disorders using polypeptides with fibronectin activity
US5635477A (en) * 1991-09-30 1997-06-03 The Dupont Merck Pharmaceutical Company Cyclic compounds useful as inhibitors of platelet glycoprotein IIB/IIIA
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5643872A (en) * 1989-10-23 1997-07-01 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
AU682036B2 (en) * 1994-07-07 1997-09-18 Tanabe Seiyaku Co., Ltd. Peptide inhibitors of cell adhesion
US5672585A (en) * 1990-04-06 1997-09-30 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5773411A (en) * 1992-11-18 1998-06-30 The Dupont Merck Pharmaceutical Company Cyclic compounds linked by a heterocyclic ring useful as inhibitors of platelet glycoprotein IIB/IIIA
US5780426A (en) * 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
US5821329A (en) * 1996-06-06 1998-10-13 Tanabe Seiyaku Co., Ltd. Cyclic peptide inhibitors of β1 and β2 integrin-mediated adhesion
EP0425212B1 (en) * 1989-10-23 1999-04-07 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US6034057A (en) * 1995-07-06 2000-03-07 Zeneca Limited Peptide inhibitors of fibronectine
US6034056A (en) * 1994-12-24 2000-03-07 Zeneca Limited Fibronectin adhesion inhibitors
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US6056958A (en) * 1994-12-09 2000-05-02 Dupont Pharmaceuticals Method of treatment of arterial and venous thromboembolic disorders
US6235711B1 (en) 1996-06-21 2001-05-22 Zeneca Limited Cell adhesion ihibiting compounds
US6239108B1 (en) 1996-07-11 2001-05-29 Biogen, Inc. Cell adhesion inhibitors
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
US6265572B1 (en) 1999-04-20 2001-07-24 Hoffmann-La Roche Inc. Pyrrolidincarbonylamino cyclic disulfide anti-inflammatory agents
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
US6329344B1 (en) 1998-10-22 2001-12-11 Ranbaxy Laboratories Limited Derivatives of monosaccharides as cell adhesion inhibitors
US6495525B1 (en) 1998-05-28 2002-12-17 Biogen, Inc. VLA-4 inhibitor: oMePUPA-V
US6511961B1 (en) 1997-11-13 2003-01-28 Toray Industries, Inc. Cyclic peptides and medicinal use thereof
US6521594B1 (en) 1990-04-06 2003-02-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US6552216B1 (en) 1996-07-25 2003-04-22 Biogen, Inc. Molecular model for VLA-4 inhibitors
US6590085B1 (en) 1999-01-15 2003-07-08 Ranbaxy Laboratories Limited Derivatives of monosaccharides as cell adhesion inhibitors
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6630503B1 (en) 1999-08-13 2003-10-07 Biogen, Inc. Cell adhesion inhibitors
US6667331B2 (en) 1999-12-28 2003-12-23 Pfizer Inc Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
US6686350B1 (en) 1996-07-25 2004-02-03 Biogen, Inc. Cell adhesion inhibitors
US6875743B1 (en) 2000-11-28 2005-04-05 Biogen, Inc. Cell adhesion inhibitors
US7001921B1 (en) 1995-01-23 2006-02-21 Biogen Idec Ma Inc. Cell adhesion inhibitors
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
EP2065050A1 (en) 1998-09-14 2009-06-03 Board of Regents, The University of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
US7642235B2 (en) 2003-09-22 2010-01-05 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
EP2140881A1 (en) 1999-12-16 2010-01-06 Biogen Idec MA Inc. Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
US7749961B2 (en) 2004-01-21 2010-07-06 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
WO2011123652A1 (en) 2010-04-02 2011-10-06 The Regents Of The University Of Michigan Rfamide-related peptides and methods thereof
US8187883B2 (en) * 2005-10-21 2012-05-29 Wisconsin Alumni Research Foundation Method and system for delivering nucleic acid into a target cell
US8455618B2 (en) 2009-06-08 2013-06-04 Astrazeneca Ab Melanocortin receptor-specific peptides
US20130172270A1 (en) * 2009-12-21 2013-07-04 The Regents Of The University Of California Rgd-containing cyclic peptides
US8487073B2 (en) 2008-06-09 2013-07-16 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
US8492517B2 (en) 2009-11-23 2013-07-23 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
US8808698B2 (en) 2006-02-03 2014-08-19 The Regents Of The University Of California Methods for inhibition of lymphangiogenesis and tumor metastasis
US8933194B2 (en) 2009-11-23 2015-01-13 Palatin Technologies, Inc. Melanocortin-1 receptor-specific linear peptides
US9403908B2 (en) 2003-09-29 2016-08-02 The Regents Of The University Of California Method for altering hematopoietic progenitor cell adhesion, differentiation, and migration
WO2018140510A1 (en) 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
US10335485B2 (en) 2010-04-16 2019-07-02 Biogen Ma Inc. Anti-VLA-4 antibodies

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0391928B1 (en) * 1987-09-28 1993-12-01 La Jolla Cancer Research Foundation Selection for cells having increased cell adhesion properties
US5721210A (en) * 1990-07-09 1998-02-24 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
WO1992013958A1 (en) * 1991-02-06 1992-08-20 Georgetown University Receptor blocking peptides of fibroblast growth factor receptor
US5747447A (en) * 1992-04-30 1998-05-05 Cor Therapeutics Stable polypeptide composition
UA43823C2 (en) * 1992-07-06 2002-01-15 Мерк Патент Геселлшафт Міт Бесшренктер Хафтунг PHARMACEUTICAL COMPOSITION FOR INTEGRIN INHIBITION <font face = "Symbol"> a </font> <sub> V </sub> <font face = "Symbol"> b </font> <sub> 3 </sub> cell adhesion mammal WAY treatment and prevention of diseases associated with cell adhesion DISORDERS, METHOD FOR BINDING LOCK integrin fibrinogen, a composition for wound healing
WO1994005314A1 (en) * 1992-09-08 1994-03-17 Centocor, Inc. Peptide inhibitors of leukocyte adhesion
WO1994014836A1 (en) * 1992-12-18 1994-07-07 Centocor, Inc. Peptide inhibitors of selectin binding
US6380163B1 (en) 1992-12-22 2002-04-30 Baxter International Inc. Peritoneal dialysis solutions with polypeptides
WO1994022909A1 (en) * 1993-03-29 1994-10-13 The Du Pont Merck Pharmaceutical Company NOVEL PROCESSES AND INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF PLATELET CLYCOPROTEIN IIb/IIIa INHIBITORS
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
DE4310643A1 (en) * 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclic adhesion inhibitors
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
DE4415310A1 (en) * 1994-04-30 1995-11-02 Merck Patent Gmbh Cyclopeptides
AU2958195A (en) * 1994-06-29 1996-01-25 Texas Biotechnology Corporation Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
US5817750A (en) * 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
NZ321304A (en) * 1995-10-18 2000-08-25 Cor Therapeutics Inc Methods of identifying signalling partners in phosphorylation of cytoplasmic tyrosine residues in the beta subunit of integrins
US6060588A (en) * 1996-11-18 2000-05-09 Cor Therapeutics, Inc. Bap-1 proteins
US6194557B1 (en) 1996-11-18 2001-02-27 Cor Therapeutics, Inc. Nucleic acid molecules encoding Bap-1 proteins
US6025150A (en) * 1996-11-21 2000-02-15 The Regents Of The University Of Michigan Methods and compositions for wound healing
US6001965A (en) * 1996-11-21 1999-12-14 The Regents Of The University Of Michigan Anticancer compounds and methods
US5840514A (en) * 1996-11-21 1998-11-24 The Regents Of The University Of Michigan Methods of testing cancer and anticancer drugs
US6331409B1 (en) 1996-11-21 2001-12-18 The Regents Of The University Of Michigan Methods and compositions for wound healing
US6274305B1 (en) 1996-12-19 2001-08-14 Tufts University Inhibiting proliferation of cancer cells
US6127520A (en) * 1997-04-15 2000-10-03 Regents Of The University Of Michigan Compositions and methods for the inhibition of neurotransmitter uptake of synaptic vesicles
IL133467A0 (en) * 1997-06-12 2001-04-30 Applied Research Systems Peptidomimetic compounds inhibiting cd28/ctl-a4 and their use
GB9714276D0 (en) 1997-07-08 1997-09-10 Univ Dundee Peptides and related compounds
KR20010087125A (en) 1998-04-16 2001-09-15 데이비드 비. 맥윌리암스 Compounds that inhibit the binding of integrins to their receptors
AUPP616498A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Synthesis of cyclic peptides
US6599506B1 (en) 1999-04-21 2003-07-29 The University Of Kansas D-form polypeptide that inhibits the interaction between LFA-1 and ICAM-1
US6972296B2 (en) * 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6673346B1 (en) * 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
US20020146684A1 (en) * 2001-04-09 2002-10-10 Meldal Morten Peter One dimensional unichemo protection (UCP) in organic synthesis
US20030096748A1 (en) * 2001-06-04 2003-05-22 The Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
CA2494870A1 (en) * 2001-08-06 2003-03-06 The Regents Of The University Of California Methods for inhibiting angiogenesis
WO2003070892A2 (en) * 2002-02-15 2003-08-28 The Regents Of The University Of Michigan Inhibitors of rgs proteins
US7074893B2 (en) * 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US8557957B2 (en) 2003-01-03 2013-10-15 Elizabeth Kornecki Methods of treating disorders by administration of F11 receptor antagonists
US20050265992A1 (en) * 2003-01-03 2005-12-01 The Research Foundation Of State University Of New York F11 receptor (F11R) antagonists as therapeutic agents
JPWO2004101610A1 (en) * 2003-05-16 2006-10-26 住友電気工業株式会社 Oligopeptide
WO2005090570A1 (en) * 2004-03-24 2005-09-29 Supratek Pharma Inc. Therapeutic compositions and methods for treating diseases that involve angiogenesis
US20060078535A1 (en) * 2004-10-13 2006-04-13 The Regents Of The University Of Michigan Anticancer compounds and methods
JP5274253B2 (en) 2005-08-05 2013-08-28 アライム ファーマシューティカルズ，インコーポレーテッド Tissue protective peptides and uses thereof
EP2360473A1 (en) 2005-08-22 2011-08-24 Cornell Research Foundation Compositions and methods for analyzing protein interactions
CA2624900A1 (en) * 2005-10-04 2007-04-19 The Research Foundation Of State University Of New York Fibronectin polypeptides and methods of use
US20100136537A1 (en) * 2006-10-10 2010-06-03 The Regents Of The University Of Michigan Photoreceptor precursor cells
CA2690734A1 (en) * 2007-06-14 2008-12-24 Richard A. Clark Polypeptides and methods of use
KR20100074177A (en) * 2007-09-10 2010-07-01 유니버시티 오브 매사추세츠 Mitochondria-targeted anti-tumour agents
US8198406B2 (en) * 2007-11-07 2012-06-12 Northwestern University Methods and compositions for inhibiting angiogenesis
US9096689B2 (en) 2007-11-07 2015-08-04 Northwestern University Methods and compositions for inhibiting angiogenesis
KR20180041269A (en) 2008-01-22 2018-04-23 아라임 파마슈티칼즈, 인크. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
EP2862871A1 (en) 2008-04-14 2015-04-22 The General Hospital Corporation Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
CA2756760A1 (en) 2009-03-27 2010-11-04 Gojo Industries, Inc. Compositions and methods for screening and using compounds antagonizing spore-surface interactions
US8940701B2 (en) 2009-05-13 2015-01-27 The Regents Of The University Of Michigan Compounds for, and methods of, treating cancer and inhibiting invasion and metastases
US9352039B2 (en) 2012-02-09 2016-05-31 The Regents Of The University Of Michigan Method of reducing the number of EMT and MET type breast cancer stem cells
SG11201507226YA (en) 2013-03-15 2015-10-29 Protagonist Therapeutics Inc Hepcidin analogues and uses therof
RS62392B1 (en) * 2014-05-16 2021-10-29 Protagonist Therapeutics Inc Alpha4beta7 integrin thioether peptide antagonists
SG11201700327WA (en) 2014-07-17 2017-02-27 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
AU2015328002A1 (en) 2014-10-01 2017-04-27 Protagonist Therapeutics, Inc. Novel alpha4beta7 peptide monomer and dimer antagonists
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2017189988A1 (en) 2016-04-29 2017-11-02 Araim Pharmaceuticals, Inc. Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage
US11548935B2 (en) 2016-10-14 2023-01-10 Neomatrix Therapeutics Inc. Peptides derived from fibronectin with improved bioactivity and reduced susceptibility to neutrophil elastase degradation
US10729741B2 (en) 2017-03-27 2020-08-04 Neomatrix Therapeutics Inc. Methods of treating burns with i.v. cP12 in a window from 2 to 6 hours after injury
US10875875B2 (en) 2017-04-26 2020-12-29 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
US10278957B2 (en) 2017-09-11 2019-05-07 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
EP3849605A4 (en) 2018-09-10 2022-06-15 Cold Spring Harbor Laboratory Methods for treating pancreatitis
AU2020311395A1 (en) 2019-07-10 2022-02-03 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
BR112022013957A2 (en) 2020-01-15 2022-10-11 Janssen Biotech Inc PEPTIDE INTERLEUKIN-23 RECEPTOR INHIBITORS AND THEIR USE TO TREAT INFLAMMATORY DISEASES
JP7397239B2 (en) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ．ベー． Compositions of peptide inhibitors of interleukin-23 receptors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792525A (en) * 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0731110A1 (en) * 1987-12-10 1996-09-11 La Jolla Cancer Research Foundation Methods for the production of conformationally stabilized cell adhesion peptides
ZW6189A1 (en) * 1988-05-09 1990-05-09 Smithkline Beckman Corp Anti-aggregatory peptides
JP2945680B2 (en) * 1988-09-09 1999-09-06 旭硝子株式会社 Peptide derivatives and their uses
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors
US5384309A (en) * 1989-07-17 1995-01-24 Genentech, Inc. Cyclized peptides and their use as platelet aggregation inhibitors
CA2021951A1 (en) * 1989-07-28 1991-01-29 Ruth F. Nutt Fibrinogen receptor antagonists
CA2021952A1 (en) * 1989-07-28 1991-01-29 Ruth F. Nutt Fibrinogen receptor antagonists
EP0410541A1 (en) * 1989-07-28 1991-01-30 Merck & Co. Inc. Fibrinogen receptor antagonists
EP0410537A1 (en) * 1989-07-28 1991-01-30 Merck & Co. Inc. Fibrinogen receptor antagonists
AU6470590A (en) * 1989-10-23 1991-04-26 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
CA2073696A1 (en) * 1990-02-02 1991-08-03 Peter L. Barker Cyclic peptides containing arg-gly-asp flanked by proline
DE69126871T2 (en) * 1990-04-06 1998-03-12 Jolla Cancer Res Found METHOD AND CONNECTION FOR TREATING THROMBOSE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792525A (en) * 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Journal of Biological Chemistry, Vol. 262, No. 3, issued 25 January 1987, LAM et al., "Evidence that Arginyl-Glycyl-Aspartate Peptides and Fibrinogen Chain Peptides Share a common Binding site on Platelets", pages 947-950, see entire document. *
Journal of Biological Chemistry, Vol. 262, No. 36, issued 25 December 1987, PIERSCHBACHER et al., "Influence of Stereochemistry of the Sequence Arg-Gly-Asp-Xaa on binding specificity in Cell Adhesion", pages 17294-17298, see Abstract. *
See also references of EP0538399A4 *

Cited By (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0425212B1 (en) * 1989-10-23 1999-04-07 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US5643872A (en) * 1989-10-23 1997-07-01 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US6521594B1 (en) 1990-04-06 2003-02-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5672585A (en) * 1990-04-06 1997-09-30 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5635477A (en) * 1991-09-30 1997-06-03 The Dupont Merck Pharmaceutical Company Cyclic compounds useful as inhibitors of platelet glycoprotein IIB/IIIA
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5786322A (en) * 1992-05-06 1998-07-28 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US6107275A (en) * 1992-06-04 2000-08-22 Merrell Pharmaceuticals Inc. Cyclic Antiplatelet peptides with pseudo-bond
WO1993024520A1 (en) * 1992-06-04 1993-12-09 Merrell Dow Pharmaceuticals Inc. Conformationally restrained peptide analogs as antiplatelet agents
US5849693A (en) * 1992-11-18 1998-12-15 The Dupont Merck Pharmaceutical Company Cyclic compounds linked by a heterocyclic ring useful as inhibitors of platelet glycoprotein IIb/IIIa
US5773411A (en) * 1992-11-18 1998-06-30 The Dupont Merck Pharmaceutical Company Cyclic compounds linked by a heterocyclic ring useful as inhibitors of platelet glycoprotein IIB/IIIA
US5591719A (en) * 1992-12-10 1997-01-07 Regents Of The University Of Minnesota Method for treating acute and chronic inflammatory disorders using polypeptides with fibronectin activity
WO1995000544A1 (en) * 1993-06-18 1995-01-05 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5807819A (en) * 1994-04-13 1998-09-15 La Jolla Cancer Research Center Peptides useful for altering bone resorption
US5849865A (en) * 1994-04-13 1998-12-15 La Jolla Cancer Research Foundation Peptides for altering bone resorption, angiogenesis and restenosis
US5773412A (en) * 1994-04-13 1998-06-30 La Jolla Cancer Research Center Use of peptides for altering αV β3 -mediated binding
US5759996A (en) * 1994-04-13 1998-06-02 La Jolla Cancer Research Center Peptides useful for altering αv β3 -mediated binding
WO1995028426A3 (en) * 1994-04-13 1995-12-14 Jolla Cancer Res Found Peptides for reducing or inhibiting bone resorption, angiogenesis and restenosis
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US5792745A (en) * 1994-04-13 1998-08-11 La Jolla Cancer Research Center Use of peptides for altering bone resorption
EP0896003A1 (en) * 1994-04-13 1999-02-10 La Jolla Cancer Research Foundation Peptides for reducing or inhibiting bone resorption, angiogenesis and restenosis
WO1995028426A2 (en) * 1994-04-13 1995-10-26 La Jolla Cancer Research Foundation Peptides for reducing or inhibiting bone resorption, angiogenesis and restenosis
AU682036B2 (en) * 1994-07-07 1997-09-18 Tanabe Seiyaku Co., Ltd. Peptide inhibitors of cell adhesion
US5869448A (en) * 1994-08-25 1999-02-09 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
US5811391A (en) * 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
WO1996006108A2 (en) * 1994-08-25 1996-02-29 Cytel Corporation Cyclic cs-1 peptidomimetics, compositions and methods of using the same
WO1996006108A3 (en) * 1994-08-25 1996-03-21 Cytel Corp Cyclic cs-1 peptidomimetics, compositions and methods of using the same
US6056958A (en) * 1994-12-09 2000-05-02 Dupont Pharmaceuticals Method of treatment of arterial and venous thromboembolic disorders
US6034056A (en) * 1994-12-24 2000-03-07 Zeneca Limited Fibronectin adhesion inhibitors
US7001921B1 (en) 1995-01-23 2006-02-21 Biogen Idec Ma Inc. Cell adhesion inhibitors
US6624152B2 (en) 1995-01-23 2003-09-23 Biogen, Inc. Cell adhesion inhibitors
US6376538B1 (en) 1995-01-23 2002-04-23 Biogen, Inc. Cell adhesion inhibitors
US6630512B2 (en) 1995-01-23 2003-10-07 Biogen, Inc. Cell adhesion inhibitors
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
WO1996040781A1 (en) * 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
US5780426A (en) * 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
US6034057A (en) * 1995-07-06 2000-03-07 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
US6596687B1 (en) 1995-07-11 2003-07-22 Biogen, Inc. Cell adhesion inhibitors
US6274556B1 (en) 1996-01-04 2001-08-14 Millennium Pharmaceuticals, Inc. Inhibitors of MadCAM-1-mediated interactions and methods of use therefor
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US5821329A (en) * 1996-06-06 1998-10-13 Tanabe Seiyaku Co., Ltd. Cyclic peptide inhibitors of β1 and β2 integrin-mediated adhesion
US6235711B1 (en) 1996-06-21 2001-05-22 Zeneca Limited Cell adhesion ihibiting compounds
US6239108B1 (en) 1996-07-11 2001-05-29 Biogen, Inc. Cell adhesion inhibitors
US6552216B1 (en) 1996-07-25 2003-04-22 Biogen, Inc. Molecular model for VLA-4 inhibitors
US6949534B2 (en) 1996-07-25 2005-09-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
US6686350B1 (en) 1996-07-25 2004-02-03 Biogen, Inc. Cell adhesion inhibitors
US6511961B1 (en) 1997-11-13 2003-01-28 Toray Industries, Inc. Cyclic peptides and medicinal use thereof
US6495525B1 (en) 1998-05-28 2002-12-17 Biogen, Inc. VLA-4 inhibitor: oMePUPA-V
EP2065050A1 (en) 1998-09-14 2009-06-03 Board of Regents, The University of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
US6329344B1 (en) 1998-10-22 2001-12-11 Ranbaxy Laboratories Limited Derivatives of monosaccharides as cell adhesion inhibitors
US7037899B2 (en) 1999-01-15 2006-05-02 Sudershan K Arora Derivatives of monosaccharides as cell adhesion inhibitors
US7005516B2 (en) 1999-01-15 2006-02-28 Ranbaxy Laboratories Limited Derivatives of monosaccharides as cell adhesion inhibitors
US7005422B2 (en) 1999-01-15 2006-02-28 Ranbaxy Laboratories Limited Derivatives of monosaccharides as cell adhesion inhibitors
US6590085B1 (en) 1999-01-15 2003-07-08 Ranbaxy Laboratories Limited Derivatives of monosaccharides as cell adhesion inhibitors
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6265572B1 (en) 1999-04-20 2001-07-24 Hoffmann-La Roche Inc. Pyrrolidincarbonylamino cyclic disulfide anti-inflammatory agents
US7034043B2 (en) 1999-08-13 2006-04-25 Biogen Idec Ma Inc. Cell adhesion inhibitors
US6630503B1 (en) 1999-08-13 2003-10-07 Biogen, Inc. Cell adhesion inhibitors
EP2140881A1 (en) 1999-12-16 2010-01-06 Biogen Idec MA Inc. Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
EP2332578A1 (en) 1999-12-16 2011-06-15 Biogen Idec MA Inc. Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
US6903128B2 (en) 1999-12-28 2005-06-07 Pfizer Inc Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
US6668527B2 (en) 1999-12-28 2003-12-30 Pfizer Inc. Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
US6667331B2 (en) 1999-12-28 2003-12-23 Pfizer Inc Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
US6875743B1 (en) 2000-11-28 2005-04-05 Biogen, Inc. Cell adhesion inhibitors
US7642235B2 (en) 2003-09-22 2010-01-05 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US9403908B2 (en) 2003-09-29 2016-08-02 The Regents Of The University Of California Method for altering hematopoietic progenitor cell adhesion, differentiation, and migration
US7749961B2 (en) 2004-01-21 2010-07-06 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
US8187883B2 (en) * 2005-10-21 2012-05-29 Wisconsin Alumni Research Foundation Method and system for delivering nucleic acid into a target cell
US8808698B2 (en) 2006-02-03 2014-08-19 The Regents Of The University Of California Methods for inhibition of lymphangiogenesis and tumor metastasis
US8729224B2 (en) 2008-06-09 2014-05-20 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of female sexual dysfunction
US8487073B2 (en) 2008-06-09 2013-07-16 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
US8455617B2 (en) 2009-06-08 2013-06-04 Astrazeneca Ab Melanocortin receptor-specific peptides
US8455618B2 (en) 2009-06-08 2013-06-04 Astrazeneca Ab Melanocortin receptor-specific peptides
US9040663B2 (en) 2009-06-08 2015-05-26 Astrazeneca Ab Melanocortin receptor-specific peptides
US9580466B2 (en) 2009-11-23 2017-02-28 Palatin Technologies, Inc. Melanocortin-1 receptor-specific linear peptides
US10017539B2 (en) 2009-11-23 2018-07-10 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic hexapeptides
US8877890B2 (en) 2009-11-23 2014-11-04 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
US8933194B2 (en) 2009-11-23 2015-01-13 Palatin Technologies, Inc. Melanocortin-1 receptor-specific linear peptides
US8492517B2 (en) 2009-11-23 2013-07-23 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
US10711039B2 (en) 2009-11-23 2020-07-14 Palatin Technologies, Inc. Melanocortin receptor-specific peptide with C-terminal naphthylalanine
US10106578B2 (en) 2009-11-23 2018-10-23 Palatin Technologies, Inc. Melanocortin-1 receptor-specific linear peptides
US9447148B2 (en) 2009-11-23 2016-09-20 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
US20130172270A1 (en) * 2009-12-21 2013-07-04 The Regents Of The University Of California Rgd-containing cyclic peptides
US9073974B2 (en) * 2009-12-21 2015-07-07 The Regents Of The University Of California RGD-containing cyclic peptides
EP2671889A2 (en) 2010-04-02 2013-12-11 The Regents Of The University Of Michigan RF amide-related peptides and methods thereof
US9527889B2 (en) 2010-04-02 2016-12-27 The Regents Of The University Of Michigan RFamide-related peptides and methods thereof
WO2011123652A1 (en) 2010-04-02 2011-10-06 The Regents Of The University Of Michigan Rfamide-related peptides and methods thereof
US10335485B2 (en) 2010-04-16 2019-07-02 Biogen Ma Inc. Anti-VLA-4 antibodies
US11083791B2 (en) 2010-04-16 2021-08-10 Biogen Ma Inc. Anti-VLA-4 antibodies
US11571477B2 (en) 2010-04-16 2023-02-07 Biogen Ma Inc. Anti-VLA-4 antibodies
WO2018140510A1 (en) 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders

Also Published As

Publication number Publication date
EP0538399A1 (en) 1993-04-28
EP0538399A4 (en) 1994-05-04
US5192746A (en) 1993-03-09
JPH05508860A (en) 1993-12-09
CA2087021A1 (en) 1992-01-10
SG72615A1 (en) 2000-05-23

Similar Documents

Publication Publication Date Title
US5192746A (en) Cyclic cell adhesion modulation compounds
AU705717B2 (en) Fibronectin adhesion inhibitors
EP0677060A1 (en) Peptide inhibitors of cell adhesion
US5849690A (en) Anti-aggregatory peptides
US5770565A (en) Peptides for reducing or inhibiting bone resorption
Barker et al. Cyclic RGD peptide analogs as antiplatelet antithrombotics
EP0656008B1 (en) Thrombin receptor antagonists
US5260277A (en) Guanidinyl and related cell adhesion modulation compounds
EP0422937B1 (en) Fibrinogen receptor antagonists
AU618118B2 (en) Neuropeptide agonists
JPH03118330A (en) Fibrinogen receptor antagonist
WO1993008823A1 (en) Guanidinyl and related cell adhesion modulation compounds
BG65065B1 (en) Peptide antiangiogenic drugs
KR20000022075A (en) Cell adhesion inhibiting compounds
EP0410767A1 (en) Fibrinogen receptor antagonists
JPH03118331A (en) Cyclic fibrinogen receptor antagonist
AU664855B2 (en) Lanthionine bridged peptides
FI92209C (en) A process for the preparation of therapeutically useful peptide compounds
US5721210A (en) Cyclic cell adhesion modulation compounds
EP0514721B1 (en) Peptides having thrombospondin-like activity and their therapeutic use
EP0421367B1 (en) Anticoagulant peptides
JP3621099B2 (en) Osteogenic growth oligopeptide and pharmaceutical composition containing the same
US5192747A (en) Anticoagulant peptides
US6673769B2 (en) Lanthionine bridged peptides
WO1993000108A1 (en) Novel inhibitors of platelet aggregation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2087021

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991914755

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991914755

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1991914755

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991914755

Country of ref document: EP